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The synthesis and pharmacology of novel excitatory amino acid miTnetics
M. Joseph 1984
Glutamic and aspartic acids are considered to be potent excitatory amino 
acid neurotransmitters of vertebrates. Receptors for these amino acids 
may be sub-divided into three types: (i) Quisqualate/glutamate, (ii) N— 
methyl-D-aspartate (NMDA) and (iii) ICainate type. The aim of this 
project has been to develop specific mimetics which act only at one 
defined site. In particular, attention has been focused on the two 
former sub-groups.
It has been shown that 2-amino-5-phosphonopentanoic (APP) and 2-amino- 
7-phosphonoheptanoic (APH) acids are very potent NMDA antagonists and 
anticonvulsants and in order to further the pharmacological study of this 
class of compound, efficient synthetic routes have been developed which 
afford the compounds in high overall yields. APB(2—amino—4—phosphono— 
butanoic acid), APP and APH can now be obtained in 10—50 g quantities which 
has permitted the evaluation of these compounds in a variety of animal 
models of epilepsy closely related to those in man. A study focused on 
photically stimulated seizures in the baboon has shown APP and APH to be 
particularly effective. This model is thought to be one of the closest 
to human seizures.
Quinolinic acid (Quin), an endogenous excitant and neurotoxin, may be 
classified as an NMDA type compound. The aim of this project has been 
to develop analogues of Quin, some of which may well be specific antag­
onists of NMDA. The higher homologue (1) of Quin has been s3rnthesised 
and has very recently been shown to be at least twelve times more potent 
than Quin as a neurotoxin. A series of homologues are to be S3nxthesised, 
the S3mthesis of homologue (2) is now being completed. The peptide 
derivative (3) and its phosphonate analogue (4) have recently been 
synthesised and experiments are now in progress to determine their 
potency.
Tricholomic acid (TA)(5), an amino acid extracted from Tricholoma 
muscarium, has been suggested to be a very potent neuroexcitant "o^f the 
quisqualate/glutamate sub-division by some Japanese workers. However, 
studies on this compound and the development of putative mimetics have 
been hindered by the lack of any reasonable synthetic route to TA. Such 
a route has now been devised and TA has been synthesised.
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CHAPTER ONE
INTRODUCTION
1.1 Introduction
1.1.1_ Historical
In the 1960s several criteria were put forward as necessary for 
the identification of a neurotransmitter^^* ;
Firstly, the substance must be synthesised and/or stored pre~ 
synaptically in the nerve endings from which it is released. The 
substance must be released upon presynaptic stimulation and appear in 
the extracellular fluid in the vicinity. Thirdly, postsynaptic appli­
cations of the substance must mimic the action seen when the presynaptic 
system is stimulated. A mechanism must exist for the removal of the 
transmitter from the postsynaptic region. Finally, specific antagon­
ists should he able to block both natural transmission and the action 
of exogenously applied transmitter.
Neurochemical studies aimed at outlining a possible transmitter 
role for glutamate Cl) have been fraught with difficulties because of 
the multitude of roles this amino acid must perform, e.g. it is 
incorporated into proteins and peptides; it contributes (along with 
glutamine (2) to the regulation of ammonia levels and the control of 
osmotic or anionic balance; it is involved in fatty acid synthesis; 
it serves as a precursor for y-aminobutyric acid (GABA) (3) and for 
various Krebs cycle intermediates and it is a constituent of at least 
two important cofactors (glutathione and folic acid).
The excitatory effect of glutamate on the cerebral cortex was
78first reported by Hayashi in 1952 . Eight years later Curtis et
43 44al ’ demonstrated the excitation of single neurones in the Central 
Nervous System (CNS) by L-glutamate (1), L-aspartate (4) and 
structurally related acidic amino acids.
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For the next ten years or so much of the evidence to support a
transmitter role for glutamate and aspartate came mainly from ionto-
90phoretic studies . One of the main difficulties has been the lack 
of specific antagonists which could be used to compare the actions of 
excitatory amino acids with those of a natural transmitter released 
synaptically at discrete populations of neurones.
1.1.2 Blood-btain barrier and general entry of 
amino acids into the brain
The blood-brain barrier (BBB) is formed by the brain capillary 
endothelial cells being fused together by tight functions, which con­
vert the brain capillary wall into an epithelial barrier. The BBB 
segregates the cerebral and systematic extracellular fluids and is 
effectively a plasma membrane for the entire brain; due to the 
presence of the BBB, circulating compounds entering the brain are
either lipid soluble, such as drugs, or are water soluble, such as
133metabolic substrates . Transport systems for neutral and basic
132amino acids have been known for some r - j e  , but only more recently
13 Afor acidic amino acids . Systemic administration of glutamate
• • flifails to raise brain levels of this amino acid , Carrier
systems for amino acids are bidirectional and the net influx for
neutral and basic amino acids, is approximately zero^^, with the
exception of leucine and isoleucine, which have positive net uptakes 
of up to 40Z of the rate of influx. The rate of glutamate influx 
into brain is 1.0 nmoles/min/g, the rate of net flux is 5.9 moles/ 
min/g from brain to plasma^^. Thus the rate of unidirectional efflux 
of glutamate is seven times greater than the rate of influx. If the 
glutamate carrier were symmetric, on both sides of the BBB, then the 
glutamate concentration in the brain interstitial space would have 
to be greater than 1 mM. Since this seems unlikely, it is probable 
that the carrier system is asymmetrical, and that the brain actively 
transports glutamate from the interstitium to the blood against a con­
centration gradient.
The rate of influx of a substrate into the brain is proportional
to the rate of cerebral blood flow as long as the BBB permeability
constant CPS in ml/min/g) is within an order of magnitude of the rate
of flow ( J  in ml/min/g). The relationship between PS and F is given
by the fractional extraction (E) of the unidirectional influiw of the
substrate into brain. When E is greater than about 15Z, the influx
18changes with flow ; the E value for glutamate or aspartate is never 
generally higher than 2 or 3Z , therefore cerebral blood flow does 
not normally influence the brain uptake of glutamate or aspartate. 
However, there are several circumventricular organs (CVOs) of the 
brain which lack a BBB, where the regional E value for glutamate may 
exceed 15Z. Any condition, such as a seizure, which is induced by a 
high glutamate level, increasing F, may accelerate the uptake of 
glutamate into the CVOs.
The rate of brain uptake of amino acid is proportional to the 
plasma concentration as long as the Km (half-saturation constant) of 
BBB amino acid tranaport is greater than or equal to the plasma level. 
Postprandial plasma amino acid levels are a function of dietary amino 
acid conq>osition and transport across splanchnic (gut and liver)
3
barriers. Physiological doses of glutamate and aspartate are meta~ 
bolised to alanine via transamination by gut epithelial cells^^^. 
Larger, pharmacological doses exceed the capacity of the gut trans­
amination sites and the acidic amino acids enter the portal 
circulation; from the portal system they must clear the hepatocyte 
bed before entering the systemic circulation. In the case of neutral
amino acids a specific high capacity and low affinity uptake system 
143operates ; thus the liver is rarely, if ever, saturated by neutral 
amino acids.
The Km of aspartate and glutamate transport is 1.9 mM and 2.7 mM, 
respectively. Normal portal plasma level of glutamate is 0.3 
and thus no saturation occurs; however, levels may reach 2.5 mM 
following oral doses of 2 gAcg of glutamate and the system may well 
become saturated. Since the capacity of the splanchnic barriers to 
clear high doses of glutamate is limited, the major factor protecting 
the brain from toxic levels of glutamate is the BBB.
1.1.3 Metabolism of Glutamate
Glutamate's intracellular concentration could be as high as 
20 mM in view of its low concentration in blood and cerebral spinal 
fluid (CSF), and therefore presumably in the extracellular fluid^^^*^^^. 
It readily replaces glucose as an energy source, in vitro, and, though 
less effective, in vivo, due to limitations on entry (see 1.1.2), 
systemically-administered glutamate enhances recovery from insulin- 
induced coma. Endogenous glutamate may be rapidly and efficiently 
utiliseu for energy production when glucose supplies are limited^^^*^^^ 
Under normal conditions, in vivo, there is a rapid conversion of 
glucose to glutamate; within minutes of systemic administration of 
labelled glucose (intraperitoneally or subcutaneously), over 80Z of 
the carbon is found in the non-essential amino acid fraction in which
glutamate predominates^^^* .  Conq>arison of the specific radio­
activities of glutamate and of o-ketoglutarate (5) showed that the 
labelling of the glutamate had occurred via the normal reactions of 
transamination and dehydrogenation.
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Glutamate also plays a key role in ammonia removal; in the 
absence of a fully functional urea cycle in^the brain^^^, major 
routes of amnonia detoxication involve glutamate formation, through 
amination of a-ketoglutarate via glutamate dehydrogenas^ , and 
glutamine formation via the glutmoine synthetase reaction, both of 
which utilise the ammonium ion directly . Glutamate shows both 
high and low affinity uptake tu syuaptosomes and glial cells (Km •
10 pM and 300-700 pM, respectively), whereas glutamine transport seems 
to be solely low affinity (Km » 250-600 pM). While no significant 
differences are observed for the transport of these two amino acids 
into nerve endings or glial cells, relevant differences in the acti­
vities of related enzymes have emerged. Cerebral synaptosomes and 
separated cerebellar Purkinje neurons, appear to be very enriched in 
glutaminase but low in glutamine synthetase whereas the reverse occurs 
in glial cells: these showed high synthesising ability but were 
almost devoid of glutaminase * * . These observations fit in well
with earlier studies on compartmentation of glutamate and glutamine 
metabolism®»^
Thus, two separate metabolic pools or compartments exist: one 
(presiimably neuronal) where glutamate is preferentially fed into the 
Krebs cycle and the GABA shunt (Scheme 1) , the other (presumably glial)^
5
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where glutamate is preferentially converted to glutamate (Fig. 1) 
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The synthesis of glutamate derived from glucose or glutamine 
increases when the nerve terminals release glutamate in response to 
depolarisation and Ca influx. Glutamate release from this conq>art~ 
ment is reduced by a unilateral entorhinal lesion so that it appears 
related to perforant path efferents to the dentate gyrus. Nearly 
all of the releasable glutamate is newly synthesised (70Z is derived 
frOTi glutamine and the rest from glucose) .
Fig. 1 Metabolic relationships at a glutamatergic bouton
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Depolarisation and Ca influx triggers a substantial glutamate 
release which lowe.s the pool of glutamate. This relieves pre- 
synaptic glutaminase from end product inhibition and results in an 
activation of the enzyme. Ca dependent release of glutamate also 
stimulates glutamine influx from the extracellular space. The 
glutamate released is recaptured from the presynaptic ending via
7
high affinity transport systems and made available again for release. 
In addition glutamate probably enters glial cells where it is con­
verted into glutamine which is released into the extracellular space
and made available .to the boutons to serve again as a glutamate 
73precursor
1*1.4 Action of L—Glut^«te
Glutamatergic fibres may constitute the major central afferent 
and descending pathways in the mammalian CNS. lontophoretic appli­
cation of L-glutamate causes a fast onset excitation of most neurones 
tested in the CNS . Dorsal root ganglion cell bodies, fibres and 
glia cells are insensitive to glutamate. However, afferent terminals
in the spinal cord of cat seem to be depolarised by excitatory amino 
42acids . Very little data have been recorded where L—glutamate or 
agonists caused inhibitory actions. During the application the de­
polarisation reaches a plateau (dose—dependent) where neuronal 
®3ccitability is increased. Due to the decrease in the input resis­
tance, associated with this depolarisation, excitatory and inhibitory 
postsynaptic transients are reduced in amplitude. Spike initiation 
which increases at lower levels of depolarisation decreases when 
higher concentrations of glutamate are applied which are sufficient
to induce conductance changes detectable with electrodes lodged in
192the soma of the neuron . This depolarisation block is presumably 
due to an inactivation of the voltage—dependent sodium channels.
Small phoretic currents applied to dendritic regions of spinal 
neurons caused rapid onset depolarisations suggesting a de^^aritic 
localisation of glutamate receptors.
Recent studies suggest that the L-glutamate-operated ionophore 
in the mammalian CNS regulates the permeability of the postsynaptic 
membrane preferentially for Na^ ions (and ions). Tetrodotoxin
8
does not block the depolarising response of L-glutamate, indicating 
that glutamate does not interfere with the voltage'^sensitive Na^ 
channel that is blocked by tetrodotoxin^^*^^^. Additional Ca^^ 
influx triggered by this depolarisation might activate a conduc­
tance and could be involved in the hyperpolarisations observed after 
L-glutamate application. However, there are complicating factors to 
be considered, such as, ion movements, linked with amino acid uptake 
and alterations of intra— and extracellular ion concentrations 
induced by prolonged activation of receptors and the possibility of 
an electrical consonant contained in some excitatory postsynaptic 
potentials CEPSPs)^®^.
Most depolarising responses to L-glutamate in the vertebrate CNS 
do not desensitise. After termination of application there is a 
rapid repolarisation which usually exceeds the control values for 
some 5-10 mV and lasts for several minutes. The decay rate of the 
amino acid action is most likely not regulated by mere diffusion^^^.
The other contributing factors may be low and high affinity, Na^- 
dependent active uptake; activation of pump mechanisms; activation 
of K conductance following Ca influx; desensitisation; actions 
as neighbouring (inhibitory) neurones and peripheral receptors which 
mediate inhibitory responses.
L-glutamate is a flexible molecule existing in aqueous solution 
in a variety of low-energy conformations, ranging from partially folded 
to fully extended states^®. There is evidence that different L- 
glutamate receptors as found in invertebrates, also exist in neürones 
of the mammalian CNS and that these receptors are not homogeneously 
distributed over the surface of the neurone.
Thus, the use of various analogues, especially conformâtionally 
restricted analogues e.g. kainic acid, can yield information as to 
the distribution of these receptor types, whereas the natural ligand
9
would be expected to interact equally well with the different sub­
classes of receptors.
1.2 Elucidation of receptors for excitatory amino acids
To date the various approaches to the- identification of the receptor 
or receptors involved in synaptic excitation involve four methods: 
electrophysiological studies^ binding studies and the determination of 
neurotoxic and convulsant activity. (Convulsant action is discussed in
1.3 and 2.3.)
1.2.1 Electrophysiological studies
Recent electrophysiological studies^^’^®*^^^^*^^^^ indicate the 
existence of three groups of. receptors for excitatory amino acidsi in the 
vertebrate CNS based on the effects of a range of selective antagonists 
which block the actions of some excitants but not others^^*^^*^^*^^*^^*^^^* 
The actions of these antagonists suggest that the excitants N-methyl-D- 
aspartic (NMDA) (6) , kainic (7) and quisqualic (8) 
acids preferentially act as separate receptors. ^
H
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Several agents exist which are able to antagonise responses to*
NMDA in the absence of marked depressant effects on quisqualate or
183kainate-induced responses CTable 1) : 2—amino-5-phosphonopentanoic
acid (AFP) (11) has marked depi^essant action on NMDA-induced responses 
in low micromolar concentration while 0.5-1 mM has little or no
effect on quisqualate or kainate-induced responses. APP has no
^ , ^ 5 0action on non-amino acid receptors
A group of conq>ounds, D-o-aminoadipic (D-oAA) (14), D-a-amino-
pimelic (D-oAP) (15), D-a-aminosuberic (D-oAS) (16) and D,D-o-e”dia-
10



sites; the binding should be readily reversible with a time course 
consistent with the rate of termination of the physiological action, 
and the subcellular distribution of binding sites should be compatible 
with that for neurotransmitter receptors, i.e. a preferential local­
isation in the synaptic membrane fraction.
The most important criterion for receptor identification is
pharmacological specificity. Thus, drugs which from 'indirect*
studies have been found to mimic or to antagonise the effects of the
natural ligands, should also be effective displacers of the binding of 
the ligand.
91The early proposals of Johnson stated that at least four pop­
ulations of excitant amino acid agonist binding sites are associated 
with rat brain membrane.
L-glutamic acid preferring (extended) binding sites which show 
a preference for kainic acid over L-glutamic acid and interact poorly 
with L-aspartic acid, D-aspartic acid and NMDA; these sites are 
studied using kainic acid as the binding ligand. L-glutamic acid 
preferring (partially folded) binding sites which prefer L-glutamic 
acid to either kainic acid or L-aspartic acid; these are the bulk of
the sites studied using L-glutamic acid as the binding ligand.
33L-aspartic acid preferring binding sites show a strong pref­
erence for L-aspartic acid over L-glutamic acid and show little inter­
action with kainic acid or D-aspartic acid; these sites are studied 
using L-aspartic acid as the binding ligand.
NMDA interacts very strongly and kainic acid interacts only 
poorly with the fourth class of binding site, L-glutamic acid and L- 
aspartic acid binding sites; these sites show little selectivity 
between L-glutamic, or D- or L-aspartic acids and are studied using 
D-aspartic acid as the binding ligand.
Many in vitro studies have been directed towards the physio­
logical receptor of L-glutamic acid. One approach has been to study
14
the binding of labelled kainic acid to whole membrane or crude 
synaptic membrane preparations, where saturable, h i ^  affinity sites
have been detected.
164Simon et al were the first to describe the specific, rever­
sible, high affinity binding of [^]—kainic acid to rat brain mendbranes. 
They defined a binding site with an apparent Kj^  of 50 nM in the rat 
forebrain, using a relatively low specific activity ligand CO.4 Ci/mnol). 
The use of a more highly radioactive [ H]-kainic acid, although the 
specific activity is still low (2.1 - 5.7 Ci/mmoD , has revealed the 
presence of at least two sites: one with a Kjj of approximately 50 nM, 
similar to that reported b y »Simón et al^^^, and a second higher affinity 
site with a Kjj of approximately 3-5 Other investigators have
described either the higher or lower affinity binding site^*^^^.
The binding sites for kainic acid appear to have a predominantly 
neuronal localisation since specific binding could not be demonstrated 
in non-neuronal tissues such as liver and muscle. The higher and 
lower affinity sites had an uneven and independent distribution in rat 
brain with high affinity sites contributing up to 30% of total binding 
in the frontal cortex and striatum but representing 10% or less of 
total binding in the cerebellum, brain-stem regions and the retina^^^.
At a subcellular level, synaptic functions contribute the majority of 
the 'synaptic population* of kainic acid binding sites and in the 
hippocanq>u8 these sites are present in high density in close oppo­
sition to the mossy fibres - GA3 pyramidal cell synapse. Neither 
glutamate nor aspartate seem to be transmitters at this synapse^^.
Kainic acid lesion to the striatimi, which caused a virtually 
confíete degeneration of striatal intrinsic neurones, resulted in a 
50% reduction in both the higher and lower affinity binding sites 
within the lesioned striatum. In contrast, decortication, \diich
15
ablated a major excitatory, presumably glutamatergic, input from 
the overlying cerebral cortex, did not significantly reduce the 
specific binding of kainic acid in the underlying striatum^^.
Extensive structural activity studies of the neurophysiological
effects of kainic acid, kainic acid derivatives and other confor-
mationally restricted analogues of glutamate have been carried out
12 158in the vertebrate CNS * ' The results of these studies can be
used to identify critical features of the kainate molecule responsible 
for binding to and activation of its recognition site; the results 
of competition studies can be used in the same way (Table 2).
From Table 2, kainic acid (7) itself, was seen to be the most 
effective inhibitor of specific binding. Dihydrokainic acid (23), 
which has the double bond in the isopropylene side—chain reduced, and 
a-allo kainic acid (24), which has the isopropylene side chain in the 
opposite plane had at least a 400-fold lower affinity for the binding 
site.
If the conformational rigidity of the kainic acid molecule, in 
particular the two carboxyl groups, confer its potent action at 
glutamate receptors, it is surprising that alteration of the 
isopropylene side chain, which has no homology iii the glutamate 
molecule, so dramatically affects its affinity for the receptor 
sites.
Both agents are virtually inactive as neuroexcitants and
. • 12,92neurotoxins *
a-Keto-kainic acid (25), which has a keto grr-*# in the place 
of the methylene group, exhibited an affinity approximating that of 
quisqualic acid.
16
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L-glutamic acid showed a 20-£old lower affinity for the site 
than kainic acid. D-glutamic acid was 100-fold less effective than 
L-glutamic acid.
The distance between the carboxyl groups on the cosqpounds also 
played a major role since the dicarboxylic acids, D- and L-aspartic 
acids^^^ and NMDLA were virtually inactive at the receptor site.
The importance of the dicarboxylic nature of the molecule was 
further emphasised by the rather poor results of substitution with 
the electrophilic sulphur or phosphate moiety for the ycarboxyl group 
i.e. D,L-homocysteic acid (22) and APB (10), respectively,
Ibotenic acid (2^ "^  and cis-l-amino-1,3-dicarboxycyclopentane 
(ACDP) (27) a conformationally restricted analogue of glutamic acid 
had very poor affinity for the site.
18
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Reputed glutamate antagonists (19) and DoAA (14)^^*^^^ did
not exert any inhibition o£ specific binding at concentrations 200- 
fold greater than that of the radioligand.
The Hill coefficients of approximately 1.0 for kainic acid, quis- 
qualic acid and a-keto-kainic acid and of approximately 0.5 for dihydro- 
kainic acid, L- and D-glutamic acid, suggested that the double bond in 
the isopropylene side—chain or a keto group as occurs in o-keto-kainic 
acid and quisqualic acid served as essential moieties in the binding 
to the recognition site for [^]—kainic acid. Reduction or orien­
tation in the opposite plane of the isopropylene side-chain or the 
absence of a pi-electron group at the appropriate site resulted in 
compounds which lacked an essential conq>onent for interaction with the 
recognition site for [^]—kainic acid.
Thus, the recognition site mediating kainate's action on neurones
appears to be highly selective and is also unlikely to be a recognition
site for the excitatory effects of glutamic acid. Â view which is
reinforced by the marked stereoselectivity for the L-form of glutamic
acid in contrast to the nearly equipotent excitatory efficacy of the
12D- and L-isomers in the mammalian Œ S  . Also, although qui<T;ualic
12acid (8), a potent nexiroexcitant , e^ibits a relatively high 
affinity for the kainate receptor binding sites, ibotenic acid is 
nearly inactive as a competitor.
19
Ân alternative approach to the elucidation of the L-glutamic acid 
receptor has been to use labelled glutamic acid itself as the receptor 
probe.
The binding of [^]-L-glutamic acid to brain synaptic membranes
152was first described by Roberts . Further studies indicated a family
of sodium independent binding sites for L-glutamic acid with multiple
KjjS of approximately 10,000 and 70 (The existence of a 2-
amino~’4~phosphonobutyric (APB)-sensitive L-glutamic acid binding site
153has recently been reported •)
Â neuronal localisation is supported by the observations that 
peripheral tissues e^dhibit negligible specific binding of [^]-L- 
glutamate and that prior kainate lesion of the striatal intrinsic 
reduced specific binding in this region by 45Z^. Cortical regions, 
including frontal and parietal cortex, and hippocançus have high 
levels of specific binding, whereas, hypothalamus, medulla-pons and 
cerebellum have considerably lower levels.
Competitive inhibition studies have provided correlations which 
suggest that the binding site is a recognition site mediating the 
excitatory effects of glutamate. There is a significant stereo­
selectivity for the L-form of glutamate. L-aspartate exhibits 
activity at the binding site, whilst, RMDLA, an agonist at aspartate 
preferring receptors, has a negligible affinity for the site^^.
From Table 3 it is observed that quisqualic acid exhibits a two­
fold greater affinity, and cis-l,3-ADCP an eight-fold lower affinity, 
than L-glutamate. Ibotenic acid, with a Hill coefficient of nearly 
1.0, is surprisingly weak (Foster^^ found quisqualic acid and ibotenic 
acid to be equipotent) . DoAA and DoAF exhibited significant activity
for the binding site. Neither kainic acid nor dihydrokainic acid
3inhibited the specific binding of [ H]-L-glutamic acid at concentrations 
of 0.1 mmol. However, a-keto-kainic acid did show some activity which
20
indicates that the isopropylene side-chain, with or without a double 
bond, offers severe steric hindrance that interferes with the binding 
at the recognition site for [^]-glutamic acid. However, the iso­
propylene side-chain is a major determinant for binding to the kainic 
acid receptor, as was seen above. The keto groiq> of quisqualic acid 
does not hinder binding to the recognition site for L-glutamic acid 
and it also partially satisfied the pi-electron requirement of the
kainate site . Ibotenic acid and cis-l,3-ADCP were both relatively
3effective competitors for the [ H]-L-glutamic acid recognition site
3with neither showing any effective affinity for the [ H] kainic acid 
site.
Studies of [^]-L-glutamic acid and [^] -kainic acid binding have
revealed two distinct receptor sites. NMDA has virtually no affinity
for either of these sites^^*^^*^^^, but it is a potent neuroexcitant
158with neurotoxic effects , which suggests the presence of at least a 
third receptor.
The study of L-aspartate binding is not very advanced and so far
none of the binding sites identified satisfy the requirements of an
14aspartate receptor. Using [ C]-aspartate three distinct sites (Kjj ■
640.2, 10 and 50 ym) have been detected . Recently, Sharif and
133 163 3.Roberts * , investigating the binding of -L-aspartate to
cerebellar synaptic membranes, have identified a single binding site 
with a of 874 nM. Quisqualic acid, a good inhibitor of glutamate 
binding, was only weakly active on the aspartate system. Kainic acid 
was devoid of any inhibitory activity, showing the same minimal 
affinity for the L-aspartate site as it did for the L-glutamate site. 
Binding was inhibited by DoAA (14), D a A S (16) and HA-996 (18) but not 
by NMDA. The surprising lack of inhibitory effects of NMDA, a prop­
osed aspartate-preferring agonist^^^ and of the D- and L-isomers of 
homosysteic acid (22), means that many more results will have to be21

Illspinal neurones . Unfortunately the binding of [ H]-NMDA to 
cerebellar membranes has not yet been shown.
1.2.3 Neurotoxicity of amino acids
41A3 44 135 139 141Glutamate has excitatory * and neurotoxic * ' properties.
Circxuoventricular organs (CVOs) are selectively damaged by systemic 
administration of glutamate^^^’^^^. Glutamate lesions cause rapid 
swelling of neuronal dendrites and cell bodies followed by acute 
degenerative changes in intracellular organelles and coarse clumping
of nuclear chromatin.
138 137Olney * used the term 'excitotoxic* amino acids to refer to 
those structixral analogues of glutamate which esdiibit both neuro- 
excitatory and neurotoxic activity and have the same order of potency 
for their excitatory and toxic activities. An excitotoxic hypothesis 
of neuronal death was proposed * * which stated that glutamate, when
present in unphysiological concentrations in the vicinity of dendritic 
or somal surfaces of the neuron, effects a state of continuous depolar­
isation and sustained increased in plasma membrane permeability,
possibly resulting in cell death.
91 137 138It was established * ’ that when systemically administered
to immature rats, excitatory amino acids act as convulsants that vary 
in potency in direct proportion to their known excitatory and toxic 
activities. However, more recent s t u d i e s ^ s h o w  a poor correlation 
between excitatory potency and neurotoxLc action as well as little 
correspondence between neurotoxic effects and epileptogenic action in 
«.he hippocampal formation.
Con^>ounds interacting with the kainate receptor determined by the 
specific binding of [^]-kainic acid^^^, exhibited neurotoxic effects 
in the striatum which correlated reasonably well with their affinities 
for the receptor site.
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Domoic acid C28X reputed to be 2 to 3-£old more potent than 
12kainic acid (7) , has a 3-£old higher a££inity £or the kainate
receptor binding site. In the striatum, domoate has a neurotoxic 
action comparable to that o£ kainate, making the two compounds the 
most potent excitotoxins studied.
(28) (7)
The neurotoxic activity o f o-keto-kainate (25) was in good agree­
ment with its excitatory activity\^ Schwarcz^® has shown that di- 
hydrokainic acid C23) which has weak excitatory e££ects and a 300-£old 
lower a££inity £or the kainate receptor, is devoid o£ neurotoxic 
activity at doses £i£ty times greater than the threshold dose o£ 
kainate. Unlike dihydrokainic acid, a-allo-kainic acid (24) was 
neurotoxic although with only 2% o£ the potency o£ kainate. The 
excitatory amino acids thought to act at receptors di££erent £rom that 
o£ kainate (£or example, ibotenic acid, cis—1,3—ADCP, quisqualic acid 
and NMDA) were substantially less potent as neurotoxins.
A more compelling pattern o£ results emerged when rabher than 
using striatal neuronal markers, intrahippocampal injection was used?"^ ,^ 
to study neurotoxic and convulsant properties.
Kainate, domoate and a-allo-kainate caused intermittent episodes
o£ seizures, predominantly o£ Stage I, totalling 3Q-40Z o£ the recording
24
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period. The duration of seizure activity for a~keto-‘kainate was 
nearly twice that occurring with kainate. The pattern of seizure 
activity with quisqualate resembled that observed with kainate-like 
substances; quisqualate has shown some affinity for the kainate 
receptor^^^, NMDA was the most effective convulsant, causing EE6 
seizures for 95Z of the recording period. The NMDA-treated animals 
exhibited the greatest percentage of time in Stag^ 1 and Stage II 
seizures and e^erienced the greatest nuniber of generalised tonic-clonic 
convulsions, which occurred only rarely with kainate. Ibotenic acid 
and cis-1,3-ADCP were virtxially devoid of epileptogenic effects.
Thus, stibstantial differences in the neurotoxlc and epileptogenic 
effects of the potent excitatory amino acid analogizes exist. Kainic 
acid and its structurally related analogues possessing a double bond in 
the isopropylene side chain appear to be disproportionately more potent
as neurotoxins than is suggested by their neurophyaiologically—defined
12excitatory effects . One notable exception is o—alio—kainic acid 
which has a low affinity for the kainic receptor site but substantial 
neurotoxic properties CTable 4).
The receptor that mediates the effects of NMDA has been well 
characterised by neurophysiological and neuropharmacological techniques 
. The convulsant and neurotoxic effects of NMDA diverge consider­
ably from those observed with the other agents. NMDA appears to be 
disproportionately more potent as a convulsant at doses that produce 
limited lesions. Quisqualic acid, which does not interact at the NMDA 
site, also possesses weak neurotoxic effects in comparison to its 
neurophysiologically defined excitatory actions and to its epilepto­
genic effects in the hippocanq>al formation. Ibotenate and cis—1,3— 
ADCP ezdiibited negligible convulsant effects at doses that produced 
substantial and relatively uniform lesions. Neurophysiological 
experiments indicate that ibotenic acid activates an excitatory
25

Decortication, which causes degeneration of the reputed cortico- 
striate excitatory glutamate pathwa^^^, prevents the neurotoxic effects 
of kainic acid in the striatum^^*^^^ without altering the excitatory 
effects^^. The disparities between thé nexirotoxic and convulsant 
properties of these agents would therefore be more likely to be present 
at the level of specific receptors, which differentially alter neuronal 
membrane conductance.
1.2.4 Three-point attachment site?
The actions of many of the compounds discussed in this chapter 
sxiggest that receptors are not completely rigid templates to which 
agonist molecules must conform but rather that some degree of flexi­
bility in the chemical structure of the receptors themselves is possible.
Curtis and Watkins^^ put forward a fundamental requirement for the 
variotis receptor types: a three—point attachment site involving both 
of the acidic and the single cationic groups which all of the agonists 
possess.
Investigations have been made of the structural features of 
agonists acting on NMDA receptors in attempts to elucidate the nature 
of the transmitter postulated to activate synaptic receptors that are 
sensitive to blockade by NMDA antagonists.
a-Aminomalonate* (30) is an NMDA agonist; the fact that a sub­
stance with as short a molecule as this con^>ound is such an agonist
-2 + 182(susceptible to blockade by I>-a-amino-adipic acid (D-oA^ and Mg ) 
suggests that if the postulated transmitter is L—glutamate or L— 
aspartate it probably acts in a * folded* conformation.
Some idea of this active conformation has been gained by the study 
of the cyclic aspartate and glutamate analogues, 2,3— and 2,4—piperidine 
dicarboxylates (PDA), respectively. The trans forms of these
* H2NCH(COO )^
>1
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substances are both NMDA agonists of quite high potency* Cis-2,3-PDA 
(21) is an NMDA antagonist with partial agonist activity, while cis- 
2,4-PDA C32) appears to be relatively inactive either as an agonist 
or antagonist . Since cis-2,4-PDA is an 'extended* glutamate analogue 
(with reference to the relative disposition of the two carboxylate 
groups) and trans-2,4-PDA (33) is a 'folded* glutamate analogue, it 
seems that glutamate and glutamate analogues might need to possess or 
be able to assume a 'folded* conformation (carboxyl groups less than 
maximally separated) in order to interact effectively with NMDA receptors.
H H
O O C
e
O O C
( 21) (32)
Trans—2,3-PDA (31) and trans—2,4-PDA (33) could both act on the NMDA
44receptor by way of a 3—point ionic binding , if the distal carboxylate 
groups in the two compounds could each provide an anionic oxygen atom 
in a similar position in space to allow binding to the same membrane
cationic group CFig* 3) 182
I) t
Fig. 3 shows that an oxygen atom from either an equatorial C-3 
or an axial C-4 carboxylate group could occixpy a similar position in 
space and thus could interact equally with an appropriately positioned 
membrane cationic group. An equatorial C-4 carboxylate group, as in 
the inactive isomer cis-2,4-PDA could not interact effectively with
.182
this mendbrane group.
It has been suggested“^ t h a t  such an anionic oxygen would be 
separated by approximately 3.8-4.2 % from the centre of the o-car- 
boxylate carbon atom and approximately 4.2 — 4.8 % from the centre of 
the N atom, and this may well be a feature conducive to NMDA agonist 
activity.
Cia-l-amlno-1,3-di^carhoxyclopentane Ccis-1.3-ADCP) (27) has a
similar arrangement of amino and carboxyl groups to trans—2,4—PDA (33)
69and can be regarded in the same light. Cis-1,3-ADCP is a DoAA and 
Mg^^-susceptible^®^ agonist and interestingly trans-l,3-ADCP (29) (with 
intercharge relationships more similar to cis-2,4PDA) is considerably
less potent69
H 2 N ^ 0 2 H
^ C 0 2 H
H2N  ^ CO2H
C02H
(27) (29)
McLennan using observed differences between glutamic acid diethyl ester 
(GDEE) and D-a-aminoadipate (DoAA)-sensitive receptors, attempted to 
define the likely conriguration of the three-point site. Glutamate, 
quisqualate and o-amino-3-hydroxy-5-methyl-4-isoxazole-propionate (34) 
are examples of molecules which are most sensitive to GDEE block­
ade but are little affected by DoAA, they possess one common feature, 
a considerable flexibility in the permissible distance between the
29
HO. X O 2 H
N H 2
(34)
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acid groups as well as between the distal acid function and the amino 
nitrogen.
Ibotenic and 1,3-ADCP are examples of molecules with inflexible 
structures, the three active substitutes form part of or are closely 
attached to planar rings such that interatomic mobilities are 
restricted, they are DoAA-sensitive but are little affected by 6DEE"
In these molecules the spacing between the carbon atoms of the acidic 
groups is relatively fixed at ca. 0.4 nm, while in molecules such as 
glutamate the analogous distance can vary from ca. 0.2 nm to 0.4 nm or 
more. Th.ua, it appears that the GDEE-sensitiva receptor accepts its 
ligands in a folded configuration in which the inter—carboxylate 
spacing optimally is ca. 0.2 nm. In DaAA—antagonised receptors that 
distance is greater, approximately 0.4 nm.
D- and L-glutamate can exist in both folded and extended config­
urations. D—glutamate has an excitatory potency about one half that
of the L-isomer^^ and unlike L-glutamate its effects are preferentially 
blocked by DoAA. It is likely therefore that the excitatory effect 
of D-glutamate is due to reactionuwith the extended receptor, while L- 
glutamate reacts preferentially with the folded form.
Consideration of the carbon—nitrogen distance which is ve..y 
similar to the carbon-carbon bond length suggests that the carbon- 
nitrogen spacing may in fact be the distinguishing factor for GEEE— 
sensitive from DoAA-sensitive receptors (Table 5) .
h I
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TABI£ 3 Maximal and minimal distances (nm) between carboxyl 
carbon atoms (C^ and and the amino nitrogen atom 
in three amino acids.
3-aminoglutarate (3 5) is a symmetrical molecule and a neuronal 
excitant^^. From the table it is evident that if the carbon-carbon 
distances are critical 3-aminoglutarate should resemble glutamate 
pharmacologically. The carbon-nitrogen distances are identical to 
those for the distal-carbon-nitrogen spacing in aspartate.
© ooc cooe
Experimental testing has indicated that 3—aminoglutarate is in­
distinguishable from aspartate but differs from glutamate in terms of 
its pattern of blockade by GDE£ and DuAA and therefore as stated above 
the carbon—nitrogen spacing appears to be the one distinguishing GDEE—
sensitive from DoAA-sensitive receptors.
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1.3 Clinical Considerations 
Epilepsy
In reflex epilepsy, in focal epilepsy and in primary generalised 
epilepsy with clonic or tonic motor signs, the development of clinically 
evident convulsive activity is associated with the excessively syn­
chronous or sustained discharge of a group of neurones. Since this 
process depends on excitatory neurotransmission it can be prevented by 
antagonists of excitatory neurotransmitters. If applied iontophoret- 
ically glutamic and aspartic acids are each excitatory on most central 
neurones^^ but precise evidence of physiological role is still lacking. 
Similarly, an exact role for these acids is epileptogenesis, or anti­
convulsant drug action has yet to be defined. In an effort to define 
this role, Croucher and Meldrum have since carried out extensive studies 
examining the effects of the phosphono derivatives of aliphatic amino
acids on seizures in baboons and mice.
37In an early study Croucher investigated the role of excitatory
amino acids in the development of seizure responses by administering
selective antagonists of these excitants to DBA/2 mice, an inbred
strain in which, within a critical age range, a fixed sequence of
28seizure responses can be induced by a loud sound . It was found that 
the amino phosphono acids that antagonise NMDA-induced excitation 
blocked all stages of the audiogenic seizure response. APH was the 
most potent of the series. The relative anti-convulsant potencies of 
these compounds matched their relative potencies as antagonists of 
NMDA to the rat cortex'*®’^ *’ . The greater activity of the D-(-)- 
isomer of APH compared with the (+)-isomer also corresponded to the 
relative activities of the two isomers after iontophoretic application. 
This correlation suggests that excitatory neurotransmission mediated 
by the NMDA receptor plays an important role in the spread of epileptic
neuronal hyperactivity.
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The recent findings of Meldrvm and Croucher^^^*^^^^ have 
indicated that selective antagonists of amino acid-induced excitation 
provide an anticonvulsant action comparable both in terms of efficacy 
and acute toxicity to that of some drugs in clinical use. The testing 
of such antagonists in man for their efficacy against reflex epilepsy 
and focal or generalised seizures must await further study of their 
selectivity of action and short- and long-term toxicity.
Huntington*s Chorea
35Huntington's Chorea is a heriditary condition, confined to
humans, characterised by severe mental deterioration and bizarre motor
abnormalities. Although nothing is known about what induces neuronal
changes in the disease it is thought that neuronal cell loss may occur
... 34,137through a mechanistn analogous to the mechanism of neurotoxicity 
involving kainate and glutamate systems of brain (interaction between
kainater and glutamate-induced depolarisation has been well
 ^  ^ ,14,15,62a.documented ;.
Although Huntington's Chorea is a rare disease (occurring in
355 in 100,000 in the United States and United Kingdom ), an 
elucidation of its pathophysiology could lead to fundamental advances 
in our understanding of brain mechanisms underlying other behavioural
and motor disorders.
- f,
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1,4 Aima of Project
The concept of at least three types of excitatory amino acid 
receptor has been developed throughout this chapter; the receptors 
being NMDÁ (antagonised by DaAA, DoAS and Mg ) ; kainate (antagonised 
by yDGG and cis-2,3-PDA) and quisqualate (antagonised by GDEE) . It 
still remains uncertain whether any or all of these receptors are in­
volved in the actions of endogenous synaptic transmitters, e.g. 
glutamic acid and it has therefore become increasingly important to 
try to define the precise molecular requirements necessary for 
activating the different receptors and to develop specific mimetics 
which act only at one defined site (focusing attention on NMDÂ and 
quisqualate type receptors).
To date only a few conq>ounds, antagonists or agonists, have been 
found which exhibit a marked degree of selectivity. One approach to 
this problem is to examine structure-activity relationships e.g. the 
limits of chain length of the straight chain amino acids; the effects 
of altering groups within a conq>ound or of conformâtxonally restricted 
analogues.
A series of long chain alkyl o-amino acids with substitution
which terminates in a phosphonic acid residue have been synthesised38
H 2 O 3 PS C O 2 H
Su\«equent pharmacological testing showed that 2-amino-5-phosphonopen- 
tane acid (APP) (11), n» 2, and 2-amino-7-phosphonoheptanoic acid (APH) 
(13), n «  4, were highly potent and selective antagonists of NMDA. Thus,
replacement of the distal carboxylic acid groups by a phosphonic acid
. . ^38,140,148,169.group had an obviously significant effect
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It was decided, therefore, to enq>loy the amino phosphonic acids 
in further biological tests. Many of the experiments previously 
carried out would be repeated to examine the reproducibility of their 
results. Also, studies would be carried out on different systems 
e.g. seizure in baboons.
AFP Cll) and APH C13) would be synthesised based on the tried and
38tested method outlined by Curry . The lower homologue, 2-amino~4-
phosphonobutyric acid CAFB) (10), n« 1, which exhibited weak and un-
182specific antagonism , would also be synthesised, in order that its 
action on different regions of the CNS could be studied.
Quinolinic acid (44), a rigid aspartic acid (4) analogue and an
endogenous metabolite^^^*^^, is a potent excitant at amino acid
80,168 receptors ’
t 0 2 H
(44)
H O o C
.C0 2 H
NH*
(4)
However, except for the recent cursory work of Perkins and 
Stone^^^*^^^, the role of quinolinic acid in the study of excitatory 
amino acids has remained virtually unexplained. It was decided that 
the action of quinolinic acid would be further investigated utilising
various quinolinic acid derivatives.
The higher homologues, (45) and (46), of quinolinic acid (44)
(45) (47)

CHAPTER TWO
AMINO FHOSFHONO ACIDS
2.1 Introduction
2.1.1 Straight chain acidic amino acids
A range o£ straight chain acidic amino acids, and derivatives, 
have been tested iontophoretically to assess their excitatory and 
inhibitory tendencies^®(Table 1).
For the carboxylic, acidic amino acids, L-glutamic and L-aspartic 
acids were the most potent, followed by their respective D-isomers, 
showing about half the potency. D-a-aminoadipate had little or no 
activity as an excitant. This pattern was followed by cysteic acid 
(48), in which the difference between L and D activity was slightly 
more pronounced. However, for the sulphono containing glutamic acid 
analogue, homocysteic acid (22), the L-form was a good agonist whilst 
the D isomer was the most potent straight chain analogue to be tested.
Generally, N-alkylation produced an increase in activity for 
aspartic acid and a decrease for glutamic acid and the sulphur- 
containing amino acids. In the case of aspartic acid, N—méthylation,
increased the activity of the D-isomer, whilst decreasing it for the
 ^ . 180 L-isomer
The longer chain analogues, far from being excitants, seemed to
antagonise tfhe excitatory effects of other acidic amino acids, par-
58ticularly N-methyl-D-aspartic acid (NMDA) and homocysteic acid . The 
L-isomers of these analogues retained a modicum of excitatory potency 
whilst the D-forms of a-aminoadipic, pimelic and suberic acids were 
all relatively powerful antagonists of a specific nature, in that they 
diminished responses due to NMDA and homocysteic acid, whilst having 
no effect on excitations produced by glutamic and aspartic acids
(Table 1) .
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CHAPTER TWO
AMINO PHOSPHONO ACIDS
2.1 Introduction
2.1.1 Straight chain acidic amino acids
A range of straight chain acidic amino acids, and derivatives, 
have been tested iontophoretically to assess their excitatory and 
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For the carboxylic, acidic amino acids, L-glutamic and L-aspartic 
acids were the most potent, followed by their respective D-isomers, 
showing about half the potency. D-a-aminoadipate had little or no 
activity as an excitant. This pattern was followed by cysteic acid 
(48), in which the difference between L and D activity was slightly 
more pronounced. However, for the sulphono containing glutamic acid 
analogue, homocysteic acid (22), the L~form was a good agonist whilst 
the D isomer was the most potent straight chain analogue to be tested.
Generally, N-alkylation produced an increase in activity for 
aspartic acid and a decrease for glutamic acid and the sulphur- 
containing amino acids. In the case of aspartic acid, N—méthylation,
increased the activity of the D-isomer, whilst decreasing it for the
 ^ . 180 L-isomer
The longer chain analogues, far from being excitants, seemed to
antagonise Îhe excitatory effects of other acidic amino acids, par-
58ticularly N-methyl-D-aspartic acid (NMDA) and homocysteic acid . The 
L-isomers of these analogues retained a modicum of excitatory potency 
whilst the D-forms of a-aminoadipic, pimelic and suberic acids were 
all relatively powerful antagonists of a specific nature, in that they 
diminished responses due to NMDA and homocysteic acid, whilst having 
no effect on excitations produced by glutamic and aspartic acids
(Table 1) .
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Thus, it appears that excitatory potency falls as chain length 
of the D-isotners is increased. The relationship between chain length 
and antagonist activity was not so well defined; adipic and suberic 
acids were both antagonists of similar potency, whilst pimelic acid 
was considerably less potent.
2.1.2 Structure of amino phosphono acids
Replacement of the terminal y-carboxyl group of straight chain 
carboxylic amino acids, with an isoteric phosphonic acid group, 
a-amino*‘a>-phosphono acid (36) .
H j O s P C O 2 H
NH.
(36)
1, 2-amino-4-phosphonobutyric acid (APB) (10)
2, 2-amino-5-phosphonopentanoic acid (APP) (11)
3, 2-amino-6-phosphonohexanoic acid (APHex)(12)
4, 2-amino-7-phosphonoheptanoic acid (APR) (13)
2.1.3 Previous pharmacological evaluation
Stone^^^ and Perkins^^® tested the effects of the microionto-
phoretic application of several amino phosphono acids on rat cerebral
cortex. The results of their experiments showed that APH and APP were
more potent and selective antagonists of NMDA than compounds tested
p r e v i o u s a n d  also suggested that a distinct population of
receptors exists in the vertebrate CNS for NMDA on which glutamate,
kainate and quisqualate have little activity; (±)APH (13) was found to
be the most potent member of the phosphonic acid series, requiring
currents of only 10 nA or less for 30-60 seconds to greatly reduce NMDA 
responses. The lower homologue (i)APP (11) needed ejection currents 
of 30-50 nA to reduce NMDA responses. (±)APHex (12) had poor antagonistic
effect (Table 2) .
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TABLE 4 Mean ratios of agonist response38
-
% reduction 
(+)-APH/(- 
Mean
ratio
)-APH
SEM
Cells
tested
NMDA 0 . 6 6 ±0 . 1 2 6
c i s-cyclopenty1 glutamate 0.75 ±0.07 6
4-fluoroglutamate 0.49 ±0.07 11
D-homocysteate 0.63 ±0.13 7
Also, it has been reported, that in cortex, (-)-APP is much more
powerful than D-oAA in antagonising either excitatory or neurotoxic
activities of NMDA. (-)-APP (7.5 mg/Kg) afforded protection (98%)
140against the neurone—necrotising activity of NMDA (Table 5) •
TABLE 5 Relative antagonist potencies of D-aAA and (-)-APP
Agents Pose (mg/Kg) Lesion severity
NMDA
NMDA + D-aAA 
NMDA + D-aAA 
NMDA + D-aAA 
NMDA + (-)-APP 
NMDA + (-)-APP 
NMDA + (-)-APP 
NMDA + (-)-APP
23.8 ± 1.2 
13.3 ± 2.1
1.5 ± 0.7 
0.7 ± 0.6
17.0 ± 3t0
5.5 ± 2.1 
0.5 ± 0.2 
0.0 ± 0.0
Interestingly, Davies and co-workers^°, using spinal cord prep­
arations, also found APP to be considerably more potent than DaAA.
40
169However, unlike the results of Stone , Davies found AFP and not AFH
59to be the most potent substance of the amino phosphono acid series ,
in isolated spinal cord preparations of immature rat or frog. This
anomaly can probably be explained in terms of methodological differences
184combined with regional CNS differences or species differences
Measurement of the stimulation of cyclic GMP (guanosine mono­
phosphate) formation in cerebellar slices by excitatory amino acids
has shown that APP is more potent than APH against NMDA, whilst APH is
. . 154more potent against aspartate .
Generally, the long chain amino phosphono acids showed the pre­
dicted trend of antagonism to straight chain amino acid excitants. The 
antagonist activity was directed toward NMDA type agonists and resided 
in the D-isomers.
APB (10), a glutamic acid analogue, exhibited little excitatory 
action and weak and unspecific antagonism. APP (11) and APH (13) 
showed much more powerful and specific antagonist action, with the 
anomalous, APHex being rather weaker and less specific in its action.
As these preliminary s t u d i e s ^ * ® h a d  shown that it was possible 
to improve the potency and selectivity of amino acid antagonists by 
using phosphonate analogues it was decided that APB, APP and APH would 
be synthesised and used in more rigorous pharmacological tests.
!
2.2 Synthesis of Amino Phosphono Acids
2.1.1 Introduction
.n the 1940s, Kosolopoff’® ’’® published several syntheses of alkyl
phosphonates from phosphite esters.
Alkyl phosphonates, prepared from diethyl and triethyl phosphites,
25 38
have been used in syntheses of amino phosphono acids
Although a synthetic route could be designed based on earlier
41
L.-'
25 39reports * , several refinements were necessary if more efficient
yields were to be obtained. Reactions were carried out on larger 
scales and under milder conditions.
2.2.2 General synthesis
Scheme 1
Nq®P®0.(0C2Hs)2
E tjO .O 'C  
cr, 0) -  dibromoalkane
n = 2,3.5
(H5C20)2“ ^ ^ ^ B r
diethyl-n-bromoalkane
phosphonate
Nq®
V
à  ^
NH2
a-amino-iû'^phosphono 
alkyl carboxylic acid
" Vo
alkyl-co-diethylphosphono 
substituted acetamido 
malonate
2.2.3 Preparation of alkyl phosphonates
Diethyl-3—bromopropane phosphonate (38), n ■ 3, and diethyl-5“ 
bromopentane phosphonate (39), n - 5, were prepared by the reaction 
of 1 ,3-dibromopropane and 1 ,5 -dibromopentane, respectively, with 
sodium diethyl phosphite, in dry diethyl ether at 0*C (Michaelis 
Becker reaction) (Scheme 1).
Theprogress of the reaction was followed by thin-layer chroma-
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tography (TLC) . Sodium bromide formed was filtered and the pure
phosphonates were isolated after column chromatography. There was no
38need for the additional distillation step as described by Curry 
13The C spectra were complex due to the coupling of phosphorus to 
31carbon. P resonances for phosphonates (38) and (39) were at 6 29.888 
and 6 30.698 respectively,
(Diethyl-2-bromoethane phosphonate (37), n ■ 2, was supplied by 
Aldrich.)
2.2.4 Preparation of alkyl~b)~diethylphosphono substituted 
acetamido malonate
The acetamido malonate adducts (40), n ■ 2; (41), n ■ 3 and (42),
n - 5 , were synthesised by straightforward malonic ester syntheses.
Thé reaction of sodiimi acetamidomalonate and a bromophosphonate 
(Scheme 1) was followed by TLC. The adducts (40), (41), (42) were 
obtained, after column chromatography, in 51, 50 and 52Z yields, res­
pectively. (Unreacted starting materials were recovered.)
2.2.5 Synthesis of (±)-a-amino-a)-phosphono acids
The acetamido malonate adducts (40), (41) and (42) were hydrolysed 
in 6M HCl within 12 hours. The reactions were clean and the amino 
acids isolated as the chlorides were dissolved in methanol. The slow 
addition of propylene oxide afforded the precipitation of the free
amino acids•
The racemic amino acids were recrystalUsed from water-ethanol and
were obtained in high yield: (±)APB (10) 6 8 X; (±)APP (11) 90Z and
13(±)APH (13) 70Z. The purity of these acids was determined by C and 
^^P NMR; analysis; melting-point and optical rotation (Table 6 ).
Generally, purer and more easily purified products were isolated
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than in previous reports hy Curry^^ and Chambers et al^^ who 
treated products of the acid hydrolyses with decolourising charcoal. 
Also, the amino acids had to be treated with ion-exchange resin before 
recrystallisation.
2.2.6 Resolution of (±)-a-flinTno-u)-phosphono acids (10) , (11) , (13)
The racemic amino phosphono acids, (±)APB, (±)APP and (±)APH were
58resolved using a modification of the method described by Evans et al 
The L-lysine salts of the acids were easily formed in aqueous 
solution. However, siibsequent precipitation of these salts required 
much care and methanol and diethyl ether were cautiously added. 
Increasing the scale of the resolution did not pose any problems.
Degradation of these salts was achieved on ion-exchange resin 
(Dowex5(^pyridinium form), which tigihtly bound lysine (H2N(CH2 )^CH 
(NH2)C0 2H) (4 9 ) and allowed the elution of the acidic acids with 
aqueous pyridine. (TLC of the eluant showed that lysine was not
eluted.)
The optical rotations of the isomers C"*") C~) were measured
on an automatic polarimeter at the mercury line. The rotation values 
obtained for (+) and (-) amino phosphono acids showed that the reso­
lutions had been successful (Table 6 ). (Slightly higher values have been 
reported by Evans et al^^, where rotations were determined in 6M HCl 
rather than in water.)
Circular dichroism (CD) spectra (supplied by Dr. P.M. Scopes of 
Westfield College) of the (+) and (-) amino phosphono acids showed 
that the (-) isomer and (+) isomer have D- and L-configurations,
respectively.
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Table 6
Amino
phosphono
acid
mpt °C 
(with
Analysis found/required 
decomposition)
25
®546 (i)
APB (10) 225 C, 26.08; H, 5.48; N, 7.37; P, 16.87 
C, 26.23; H, 5.50; N, 7.65; P, 16.92
(D)-14.^
(L)+ll.f
26.65
APP (11) 230 C, 30.09; H, 6.14; N, 6.81; P, 15.62 
C, 30.46; H, 6.14; N, 7.10; P, 15.71
(D)-lO^
(L)*8°
29.95
APH (13) 213 C, 37.13; H, 7.29; N, 6.11; P, 13.76 
C, 37.33; H, 7.16; N, 6.22; P, 13.76
(D)-7°
(L)+7.S“
31.77
13C See experimental
2,3 Methods and Results of Pharmacological Tests
2.3.1 Introduction
The antagonist actions of APP (11) and APH (13) were compared on
the excitatory activity of NMDA or aspartate on rat cortical neurones
• .N-n 1 trt * 37.121aand also against seizures induced by sotmd in DBA/2 mice or
seizure induced by NMDA or by 3-mercaptopropionic acid (3MPA) (43) in
„  . c  • 1 2 1 aSwiss S mice
The effects of APP and APH (and other excitatory amino acid
antagonists) on photically-induced epileptic responses in baboons,
• ^ 1 2 1Papio papio> were also examined. .
The above-mentioned tests were carried out by B.S. Meldrum of the
Institute of Psychiatry, London.
APB (10), APP (11) and APH (13) were also tested on retina of
albino rabbits^^^, by M. Neal of the School of Pharmacy, University of 
London. Experiments were designed to investigate the relative 
importance of ON- and OFF-channels as inputs to the cholinergic
amacrine cells.
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2.3.2 Microiontophoretic studies in rat cortex
Male Wistar rats were anaesthetised and secured in a stereotaxic 
frame. The cerebral cortex was exposed and the dura nater removed; 
the exposed surface was covered with warm saline throughout the 
experiment.
All compounds (MMDA, glutamate, aspartate, APP, APH) were applied
QC
by microiontophoresis” from seven-barrelled micropipettes, the tips i 
of which were broken back to 4-8 pm under microscopic observation. A 
separate single glass microelectrode was glued alongside the multi­
barrel for recording unit activity.
The ratios of the potency of APH to that of APP were determined 
against NMDA, L-glutamate and L-aspartate (Table 6 ). Whereas APH and 
APP were essentially equipotent against L—glutamate, APH showed greater 
activity than APP against NMDA and aspartate.
TABLE 6 Ratios of the antagonist potency of AP:APP against 
amino acid excitants on cortical neurones
Method* NMDA
Potency ratios APH:APP 
Glutamate Aspartate
1.52 ± 0.35 (1 1) 1.14 ± 0.40 (6 ) 1.80 ± 0.38 (1 0)
Plateau 0.94 ± 0.14 (7) 0.90 ± 0.21 (8 ) 1.31 ± 0.29 (6 )
4 1.39 ± 0.18 (2 2) not tested
1.21 ± 0.32 (8 )
* For explanation of method see Meldrum et al1 2 1 a
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2.3.3 Protection against sound-induced seizures 
The investigation o f the protection afforded by AFP and APH 
against sound-induced seizures used 21-28 days old DBA/2 mice. DBA/2 
mice are an inbred strain in which, within a critical age range, a
28fixed sequence of seizure responses can be induced by a loud sound 
Animals recived drugs either intraperitoneally Cip) or intra- 
cerebroventricularly Cicv) and were placed individually under a hemi­
spheric perspex dome for behavioural and postural assessment. Auditory 
stimulation, an electric bell generating 109 dB at moxise level, was 
subsequently applied for one minute or untxl tonic extension occurred. 
Responses were graded according to the severity of the seizure.
Control seizure responses consisted of an initial wild running phase 
(WR; score 1) followed by fore- and hind-limb myoclonus (score 2), 
tonic flexion and extension (score 3) and occasionally respiratory 
arrest (RA; score 4). Absence of any abnormal motor response was 
scored as zero and only the maximal score for each animal was recorded.
The relative anticonvulsant activities of APP and APH against the 
principal phases of the audiogenic seizure response are shown in Table 
7. Figure 1, shows the log dose response curves for APH are to the 
left of those for APP, suggesting that APH is approximately one order 
of magnitude more active than APP against all phases by the response, 
following either ip or icv administration. The (-)-isomer of each 
antagonist showed greater anticonvulsant activity than the (+)-isomer.
»y
r
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TAB1£ 7 Relative anticonvixlsant potencies of AFP and AFH in
DBA/2 mice following central or systemic administration
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Fig. 1 Log dose-response curves for (±)APP(A) and (±)APH(A) against 
the individiial phases of the audiogenic seizure response in 
DBA/2 mice
lOOr
0.0001 0.001 0.01 
moles
0.01 1.0
mmoles/kg
10
A. Intracerebroventricular injection. B. Intraperitoneal injection. 
Siezure responses were assessed following administration of progressive 
doses of antagonist and ED3 Q values for each phase of the seizure 
response were estimated.
( ---- wild running: — clonus; -----  tonus) .
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2.3.5 Suppression of photically-induced epilepsy
Baboons, Papio papio, from the Casamance region of Senegal show
a genetically-determined syndrome of photosensitive epilepsy that is
manifest as myoclonic responses; and sometimes tonic-clonic seizures,
126during stroboscopic stimulation
Adolescent baboons were tested whilst seated in a primate chair 
by exposure to stroboscopic stimulation for up to five minutes, in a 
standardised fashion. Compounds APP(ll), APH (13), GDEE (19) and 
cis-2,3-PDA (21) were administered intravenously and the animals were 
observed for the following five hours with testing of myoclonus 
responses to stroboscopic stimulation at hourly intervals.
Administration of APH (0.1-1.0 nmol/Kg) resulted in a dose 
dependent suppression of photically—induced myoclonus. (Fig. 2).
Control animals showed diffuse myoclonus of the limbs and trunk in 
response to intermittent light stimulation (ILS). Ten minutes after 
APH, 1.0 mmol/Kg, stimulation-induced only intermittent eyelid 
flickering in all animals. The myoclonic response was maintained at 
this level, or was totally abolished, for the following five hours.
APH action produced no marked neurological impairment. At the 
highest dose, one baboon showed some retching and excess salivation, 
but all animals appeared alert during photic stimulation.
APP showed a shorter time-course of action than APH; myoclonic 
responses were suppressed within ten minutes of the administration of 
APP, 1.0 mmol/Kg, but returned to control levéis after 1-2 hours. 
Following APP (3.3 mmol/Kg) responses to ILS were markedly reduced or 
absent for 2 - 4 hours, but diffuse myoclonic re.-,/onses returned on sub­
sequent stimulation.
At the lower dose levels no behavioural or postural impairment was 
evident. At 3.3 mmol/Kg, however, signs of sedation appeared 
immediately after injection with drooping eyelids, a loss of muscle
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FIG. 2 The suppression of photically-induced myoclonic responses 
in the baboon, Papio papio, by APP(A) and APH(B)
The mean myoclonic response to photic stimulation is 
plotted aginst time (hours) relative to drug administration
at time zero.
Groups of n animals were tested at each dose level
(n - 3 at all doses except APP control group where n - 5)
The following dose levels (mmol/Kg) are shown.
A: O  saline; 
B: O  saline;
0.1; i 0.33;
0.1; A  1.0;
i!'
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tone in all four limbs and a lack of responsiveness to aggressive 
stimuli. Excessive salivation was noted in two out of three drug- 
treated animals. Normal responsiveness returned within one hour 
although mild sedation persisted for the duration of the experiments.
Cis-2,3-PDA (21) resulted in a similar but weaker protection 
against photically-induced myoclonus as APH. Few signs of toxicity 
were noted, with only three of nine drug administrations inducing 
periods of yawning and transient drowsiness.
6DEE (19) administration caused very little suppression of photo­
sensitivity. A transient reduction in the severity of the myoclonic 
response was observed after GDEE, 1.0— 3.3 mmol/Kg, which was preceded 
by a period of respiratory distress and cardiac arrhythmias.
2.3,6 APR-effect on acetylcholine release from rabbit retina
Adult albino rabbits were anaesthetised and a stainless steel ring
was sutured to the episclera to prevent collapse of the eye-cup. The
cornea, iris and lens were removed, followed by vitrectomy. The
resulting eye-cup was filled with Krebs carbonate ringer solution.
A solution of ringer containing [ H]-choline was placed in the
eye-cup for 30 minutes and then the retina was continuously irrigated
for one hour with medium containing eserine sulphate. The medium in
the cup was replaced every five minutes and the total radioactivity
in the removed medium was measured. During this period, the retina
was exposed to light flashes (3 Hz, 25Z duty cycle, 800 lux). The
129electroretinogram (ERG) was recorded
The compounds under test, a series of amino phosphono acids (36), 
(n - 0 to n - 4), were dissolved in the medium and their effects were 
plotted to obtain the concentration of compound needed to produce a re­
duction in the release of ACh or the amplitude of the b-wave by 50Z
(EC^q ). (Table 11).
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TABLE 11 The effect of u)-phosphono-2-aminocarboxylic acids
on the light-evoked release of ACh and on the ERG b-wave
Compound
EC5 0 (ym)
ACh
release
ERG
b-wave
(±) 2-amino-3-phosphonopmpionic acid NE NE
L-(+)-2-amino-4-phosphonobutyric acid 7.5 5.8
D-(-)-2-amino-4-phosphonobutyric acid 115 140
DL-(±)-2-amino-4-phosphonobutyric acid 16 11
L-(+)-2-amino-5-phosphonopentanoic acid 230 155
D-(-)-2-amino-5-phosphonopentanoic acid 660 680
(±)-2-amino-6-phosphonohexanoic acid NE NE
(±)-2-amino-7-phosphonoheptanoic acid NE NE
Each result was obtained from graphs of log concentration against 
effect using at least 3 drug concentrations. Each drug concentration 
was the mean of at least 4 separate experiments.
NE » no effect up to 1 mM.
(±)APB (200 jjm) reversibly blocked the ON-response of the ganglion 
cells, whilst the OFF-response was increased in size. The b-wave of 
the ERG was abolished. At a lower concentration (100 the ERG was 
reduced by 80Z and the ON-response by 75Z. (+)-L-APB was far more
potent th£m (-)-D-APB in blocking ON-responses. Both isomers reduced 
the light-evoked release of ACh and had no effect on the spontaneous 
resting release. The (+)-isomer was much more potent, the '^"5 0»
(+) and (-) isomers being 7.5 ym and 115 ym respectively. For the
racemate the ■ 16 ym.
APP also reduced the light evoked release of ACh and the b-wave 
of the ERG but it was less potent than APB. The (+)-isoiaer was most
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effective, the EC^qS for the (+) and (-)-isomers being 230 pm and 
660 pm respectively.
(±)2-amino-3-phosphonopropionic acid (9) (n »0), APHex and APR, 
at concentrations up to 1 mM, had no obvious effect on either the light 
evoked release of ACh or the ERG. i ■
2.4 Discussion
2.4.1 Microiontophoretic studies and suppression of seizures 
The results of the microiontophoretic experiments on rat cerebral 
cortex showed that APR and APP inhibited the excitatory action of NMDA 
and aspartate (Table 6 ) (IC^q method was probably the most accurate, 
being least affected by reuptake and other processes.)
APR was approximately 1.5 times as potent as APP against excitation
due to NMDA and perhaps rather more potent when assessed against
 ^  ^59,121a,154 aspartate
Experiments testing the anticonvulsant action of the amino phos- 
phono acids indicated that APR was approximately 10 times more potent 
than APP by both intracerebroventricular and intraperitoneal routes.
This constancy of relative effect suggested that the two compounds are 
closely similar in their pattern of absorption and their capacity to
enter the brain from the circulation.
The (-)-isomers of APP and APR were more potent than the (+)- 
isomers at suppressing sound-induced seizures. The proconvulsant 
(myoclonus-inducing) properties of (>)-APR suggested a partial agonist
action.
Evaluation of chemically-induced seizures in Swiss S mice showed
an increase in the potency ratio, APHiAPP, for suppression of tonic
seizures after the administration of 3MPA. Biochemical studies have
indicated that 3MPA owes its convulsant effect to a reduction in
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GABAergic transmission subsequent to inhibition of the enzyme syn­
thesising GABA (3) glutamic acid decarboxylase (GAD). It has recently 
been shown in preloaded rat brain slices that the release of ( H]-D-
aspartate is enhanced by 3MPA^^^. A special role for excitatory
46amino acid transmission in 3MPA seizures must be considered
The development of the successive stages of a seizure involves tKe 
progressive recruitment of different neural populations into a syn­
chronous firing pattern. Any factor which can reduce excitatory 
transmission will hamper this process of recruitment. The element 
of positive feedback in the recruitment process will enhance even a 
small difference in potency between two antagonists; which explains 
why the late tonic seizures after 3MPA, or the complex segmented 
elements of the sound-induced seizure response are more potently 
suppressed by APH (relative to APP) than would have been predicted 
solely on the basis of single unit responses.
Having shown that APP and APH potently block excitation due to 
NMDA and suppress epileptic responses in a genetically determined 
syndrome of reflexepilepsy (sound-induced seizures in DBA/2 mice) it 
was decided to investigate the effect of these compounds on the baboon, 
Papio papio, which exhibits a genetically determined syndrome of 
photosensitive epilepsy.
APH abolished myoclonic responses for 5 hours and APP whilst
giving less prolonged protection had toxic side effects. Thus, the
greater anticonvulsant potency of APH against APP was consistent with
1 2 1 aearlier observations •
The epileptic responses ^i f e a t e d  by Papio papio are blocked by 
anticonvulsant drugs, such as barbiturates, benzodiazepines and 
sodium valproate, which are effective against primary generalised 
seizures in man^^®. So the importance of certain amino phosphono 
acids which have such a marked effect on this photosensitive syndrome.
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a valuable model for testing novel anticonvulsant agents, cannot be 
stressed enough.
Convulsions induced by NMDA may be diie to a direct action of 
NMDA on a subgroup of excitatory receptors. Receptors of this type 
are prominent in the cerebral cortex but it cannot be assumed that 
this is the site of epileptogenesis.
The effectiveness of specific NMDA receptor antagonists, in each 
of the models studied, siq>port a major role for NMDA receptor- 
mediated excitation in the generation or propagation of epileptic 
neuronal hyperactivity within the CNS. The endogenous agonist or 
agonists acting at the NMDA receptor have not been identified but it 
is possible that both glutamate and aspartate are involved.
The regional site of anticonvulsant action of APP and APH is xin-
known. Although it is likely that reduction in excitatory transmission
in the cortex modifies seizure responses, anatomical and electrophysio-
logical evidence indicates that brain stem and mid-brain systems play
a major role in the development of audiogenic seizure and m  tonic 
1 2 1 aseizures
Testing of the possible clinical usefulness of this new class of 
anticonvulsant agent must await further studies of the anticonvulsant 
profile of these agents and of their acute and chronic toxicity in both 
rodents and primates.
2.4.2 ON- and OFF-channels in amacrine cells
APB has a relatively weak and non-selective antagonist action on 
NMDA; quisqxialate- and kainate-induced depolarisations, cosqpared to 
APP and APH^®^ and therefore the later compounds are used prefer­
entially in studies on brain. However, it has been found that APB is 
very useful, pharmacologically, in retina research.
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The retina is an integral part of the QiS, having an overall
173metabolic organisation resembling that in the brain . Retina can be 
isolated without much injury and kept for hours, in a viable con­
dition, responding to ligiht^ . Responses are monitored by recording 
the ERG or by intracellular recording. The retina is a very thin, 
layed structure, having very short diffusion pathways and the extra­
cellular fluid, therefore, can equilibrate rapidly with the bathing 
fluid,an obvious advantage in release studies. The absence of any 
barrier in diffusion pathways ensures that compoimds are applied to 
cellular elements in known concentrations. It is reasonable to asstane 
that retina utilises transmitter substances which occur in the rest of 
the CNS and therefore may provide clues to an \inderstanding of central 
synaptic mechanism in general.
In the outer retina, photoreceptors appear to communciate with a 
dark released agent which provides excitatory input at both the onset 
and termination of a light stimulus^^. Two post-synaptic elements, 
horizontal cells (HCs) and OFF-bipolars, are depolarised in the dark.
A third cell type, ON-bipolar, is hyperpolarised in the dark. A light 
stimulation which hyperpolarises the photoreceptors causes a reduction 
in the rate of transmitter release resulting in a depolarisation of ON- 
bipolars and a hyperpolarisation of HCs and OFF-bipolars.
Exogenously applied glutamate and aspartate on second order 
neurons mimic the photoreceptor transmitter^^^*^^®*^^^. In mudpuppy, 
Necturus maculosus, retina. Slaughter and Miller^^^ attempting to 
characterise the synaptic receptors of second order neurons found APB 
to be a highly selective agonist which appeared to interact with the 
synaptic receptors of ON-bipolars. In low concentrations APB action 
in the outer retina was restricted to ON-bipolars. In the inner 
retina ON responses or response components were eliminated but OFF 
responses persisted. The loss of ON-activity in the inner retina
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probably reflects the action of APB at the bipolar cell level. In 
fairly high concentrations (10-20 nM) APB acted as an antagonist to 
horizontal cells.
The results of these experiments investigating the role of ON- and
OFF-channels in amacrine cells indicated that the release of ACh from
amacrine cells is mediated mainly via the ON-channels. It has been
shown that exposure of the retina to chloride-free medium also selec-
122tively abolished responses mediated via the ON-channels . Chloride- 
free medium also abolished the light-evoked release of ACh and produced 
charges in the ERG similar to those produced by high concentrations of 
APB. However, unlike APB chloride-free meditim increased the spon­
taneous resting release of ACh approximately two—fold.
Thus, APB selectively abolishes ON—channels in the rabbit retina 
and there is a strong possiblity that the activity of the cholinergic
amacrine cells is determined mainly by the depolarising bipolar cells.
122The ON-channels appear to require the presence of chlorj.de ions
The mechanism by which APB blocks transmission of ON-channels in 
the rabbit retina is unknown although in the mudpuppy it appears to 
mimic the endogenous photoceptor transmitter , which may be glutamate 
and/or asparte^^^. Results of work carried out with APB and other 
amir>r> phosphono acids are consistent with this suggestion.
An alternative possibility that APP and APH are acting as antag­
onists of aspartate or glutamate is very unlikely because antagonistic 
activity is greater in the (-)-isomers, rather than in the (+)-isomers 
which were most potent in the retina experiments. Furthermore, the 
order of potency in blocking NMDA recr^uors in the brain is APH > APP >
APB148 again the reverse of these results.
22The binding of [^]-APB has recently been characterised . The 
L-(+)-isomer is shovm to be fifteen times more active than the D-(-)-
form in inhibiting the binding of DL-[^H]-APB. which is in close
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CHAPTER THREE
SYNTHESIS OF SOME QUINOLINIC ACID ANALOGUES
3.1 Introduction
Quinolinic acid (2,3-pyridine dicarboxylic acid) (44) is an
^  T V /ci\107,130endogenous metabolite of L-tryptophan (51)
The demonstration of a cerebral pathway for the synthesis of quino­
linic acid is incomplete, but the biosynthetic mechanisms for 3—hydroxy— 
anthranilic acid (5 7 ), its immediate metabolic precursor, in the brain
have been established. Quinolinic acid has been unequivocally
X8 6 £lidentified in both rat and human brain tissue
3.1.1 Biosynthesis
The biosynthesis of 3-hydroxyanthranilic acid (57) in brain, as in
186other organs, occxirs via the kynurenine pathway (Scheme 1) , which
constitutes a minor route of tryptophan catabolism in cerebral tissue. 
In peripheral organs, 3-hydroxyanthranilic acid is rapidly converted to 
quinolinic acid and further to nicotinic acid (60).
Tryptophan is oxidised to L-N-formylkynurenine (52) which is con­
verted to kynurenine (5 3 ) by a liver enzyme, kynurenine formylase. 
Kynurenine is hydroxylated at position 3 to form 3-hydroxykynurenine
(56) .
A pyridoxal phosphate requiring enzyme, kynureninase, catalyses 
cleavage of 3-hydroa^kyntirenine and kynurenine to 3-hydroaqranthranilic
(57) and anthranilic (59) acids, respectively. Alanine is the other 
reaction product in both instances. 3-hydroxykynurenine is split 
approximately twice as rapidly as kynur.enine. The latter also trans- 
aminates; the corresponding keto acid undergoes ring closure to yield 
kynurenic acid (54) which is dehydroxylated to quinaldic acid (55).
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Scheme 1 Metabolic relationships among tryptophan and its 
metabolites
(5 1 ) (5 2 )
(5 7 )
(5 4 )
(4 4 )
2C H ^ O C oA + C 02
[N A D : N ic o tin a m id e  adenine d inucleotidel
(a) tryptophan pyrtolase; (b) kynurenine formylaae; 
(c) kynureninase; (d) kynutenine >hydrorylase j 
(e) 3—hydroxyanthranilic acid oxidase.
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o-Ajoino-S-carboxymuconic-A-semialdehyde (58) is the oxidation 
product of 3-hydroxyanthranilic acid (57) . The semi-aldehyde (58) is 
a branch point in tryptophan degradation; it may be converted to quino­
linic acid (44) or follow a pathway to glutaric acid and thus to acetyl 
CoA.
3.1.2 Quinolinic acid; a potent endogenous excitant
. 168Quinolinic acid is a potent excitant of neurones in rat brain
80and in cat caudate nucleus
Stone and Perkins applied quinolinic acid (44), quisqualic acid 
(8), N-methyl-D-aspartic acid (NMDA) (6 ), 2-amino-5-phosphono-pentanoic 
acid (APP) (11) and glutamic acid diethyl ester (GDEE) (19), ionto- 
phoretically to rat brain. A comparison of ejecting currents indicated 
that quinolinate was about as potent as glutamate and aspartate, about 
one quarter as potent as NMDA and one tenth as potent as quisqualate.
Both antagonists, APP and GEEE, blocked quinolinate responses which 
suggests that quinolinate like L-glutamate, may activate both the NMDA 
and quisqualate type of receptor. However, APP exhibited a far greater 
ease of antagonism than GDEE, so it is possible that quinolinate may act
preferentially on the NMDA receptor.
Surprisingly, it has taken more than twenty years for the importance 
of quinolinic acid, a rigid aromatic analogue of NMDA, to be realised. 
In 1978, Watkins^®^ stated an a footnote) that quinolinic acid showed 
little or no activity on the frog spinal cord. Unfortunately it has since 
taken five years for the proposal that quinolinic acid should merit 
special attention as a potential neurotransmitter to appear to be valid.
A study of neuronal sensitivity of quinolinic acid in different 
regions of the CNS has shown that this acid is unique among 
amino acid-related excitants described to date, being excitatory in some
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areas of the CNS such as cortex and hippocan^>us and almost completely 
inactive in others such as spinal cord (Table 1)
TABLE 1 Relative sensitivity to cells in CNS regions to glutamate 
and quinolinate
Area Cellstested
Excited by 
glutamate
Excited by 
quinolinate
Glu:Quin current 
ratio for compar­
able responses
Neocortex 25 25 25 0.71 ± 0.05 (25)
Spinal cord 17 17 4 0.14 ± 0.014 (4)
Neocortex 29 29 29 0.75 ± 0.07 (29)
Eippocanq>us 23 23 23 0.47 ± 0.06 (23)
Neooortex 21 2 1 20 0 . 8 6 ± 0.08 (2 1 )
Cerebellum 36 36 1 2 0.15 ± 0.03 (12)
Ant striatum 31 31 31 0.75 ± 0.06 (31)
Post striatum 29 29 29 0.33 ± 0.04 (29)
± indicates mean error
Figures in parentheses are number of cells tested.
Kynurenic acid (54), a metabolite of tryptophan^®^,is a relatively 
powerful antagonist of quinolinic acid^^^. However, kynurenic acid also antag­
onises NMDA and quisqualic acid; this lack of preferential antagonism
suggests that the effect is not a specific antagonism at one of the
182proposed populations of excitatory amino acid receptors
The presence of an endogenous antagonist could have many impli
cations for the role of quinolinic acid in the control of neuronal
. , 168 excitability
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3.1.3 ln_giirQ. release of [^]-purines by quinolinic acid
L-glutamate and L-aspartate can evoke [^]-adenosine release from
89the rat cortical surface in vivo . Recently, it has been shown that 
quinolinate also produces a large increase in basal release of [ H]- 
purines. See Table 2
N-Tnethyl-DL-aspartate (NMDLA) and potassiiiim chloride produced 
large increases, while glutamate, quisqualate and kainate had lesser 
effects.
3TATtT.R 2 Effect of amino acids and KCl on [ H]-purine release
Concentrations
(mM)
Percentage increase in 
release above baseline
Potassium chloride 56 245 ± 48 (2 1 )
L-glutamate 5.0 89 ± 23 (8 )
Kainate 1 . 0 56 ± 7 (5)
0.5 40 ± 5 (5)
0 . 1 87 ± 9 (5)
0.05 40 ± 12 (5)
Quisqualate 0.5 51 ± 10 (5)
NMDLA 5.0 277 ±70 (5)
1 . 0 152 ± 19 (8 )
Quinolinate 5.0 291 ± 39 (1 1 )
1 . 0 257 ± 39 (1 1)
0.5 143 ± 18 (4)
0.3 64 11 (5) IF
Figures in parentheses are the number of observations.
2-amino-7-phosphonoheptanoic acid (APH) (13), the NMDA-preferring 
receptor antagonist, significantly reduced the release evoked by quin­
olinate and NMDLA but not that produced by the other agonists
(glutamate, quisqualate and kainate), this gives further support to the
 ^ 168postulate that qxxinolinate acts on NMDLA-preferring receptors
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3.2 Structure-activity Relationships
3.2.1 Effects of cyclic dicarboxylic acids on the CNS
Davies e t ^ ®  reported that (±)cis-2,3-piperidiue dicarboxylic acid
(cis-2,3-PDA) (21) was an antagonist at excitatory amino acid receptors '
13in the spinal cord. A study by Birley et al examined the actions of 
a series of cyclic dicarboxylic acids, including cis-2,3-PDA and quino­
linic acid C^ ^ ) 9 in the cerebral cortex (Table 3).
Cis-2,3-PDA exhibited antagonistic properties towards excitatory 
amino acids which were not shared by the cis-2,4-, 2,5- or 2 ,6—dicarboxy­
lic analogues; this antagonism appeared to be relatively selective for 
NMDA. Davies et al^^ found cis—2,3—PDA to be most effective in 
antagonising responses to quisqualate. (The disparity is possibly due 
to some subtle differences between the spinal cord and cerebral cortex 
receptors i.e. in cortex either quisqualate excitations are more resis­
tant or NMDA is more susceptible to blockade by cis-2,3-PDA.) Such
selectivity was only observed at lower currents, at higher currents non
selective antagonism was reported.
(±)Cis-2,3-PDA showed some selectivity against responses to NMDA, 
presumably, as it is a highly structured, semi-rigid analogue of NMDA. 
However, the failure of 2,3-piperazine dicarboxylic acid (63) to show 
any activity does imply that the electronic distribution in the ring is 
of importance for activity, and the three-dimensional structure is not
the only criterion.
Cis-2,3-PDA is also a partial agonist^® and caused a weak increase of 
firing of a small proportion of neurones.
Quinolinic acid (40), a fully rigid aromatic analogue of NMDA (6 ), 
is an effective excitant of cortical neurones.
^ ;,A c02H
(4 0 )
H O 2C
«CO2 H
H bC ^ N H
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3,2.2 Convulsant action of quinolinic acid
Quinolinic acid and L-kynurenine sulphate (69) induced seizures
102after intracerebroventricular (icv) injection in mice . Kynurenine 
(53) like quinolinic acid is an endogenous tryptophan metabolite (Scheme 
1). It is possible that a relationship exists between the chemical 
structures of these metabolites and their strong convulsant action.
Lapin^®^ administered quinolinic acid (44), L-kynurenine sulphate 
(69), and a series of other dicarboxylic acids (Table 4) intracerebro­
ventricular ly in mice, inducing clonic seizures. When administered 
intraperitoneally (ip) or orally they were reported to antagonise 
strychnine—induced seizures. The convulsant effect of L—kynurenine 
suXphate was observed only when the pH of the solution was 4.0 or lower, 
\Aile the actions of the other drugs were not dependent on pH, Control 
injections of sulphuric acid induced seizures in 25% of the mice.
As all the compounds administered (icv) induced seizures, the 
0«c-C-C-C*0 moiety, presumably was responsible for the convulsant 
actions of quinolinic acid and L-kynurenine sulphate. The greater con­
vulsant action of quinolinic acid could be related to the stability of 
its stereoconfiguration which provides a constant distance between the 
C-0 group (6.81 % between two oxygen atoms), whereas the side-chain of 
L-kynurenine is flexible and, thefore, this distance may not always be
optimal.
Although the role of pH was not clear, it was reported that the 
action of L-kynurenine sulphate consisted of effects of the cation of 
kynurenine (75-80Î) and of the anion (20-25Z). The action required a 
low pH in the medium therefore, the charges on L-kynurenine sulphate salt 
must affect its activity. At pH 2.0 -2.5, L-kynurenine, which exists 
mainly in two betaine forms. I and II. had maximum pharmacological 
activity. At pH 5.0 and above, L-kynurenine exists mainly in
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TABLE 4 Convulsant and anticonvulsant actions102
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»witter-ionic form III and its activity disappears. Consequently, if 
the charge on the molecule is functionally important, the greater the 
positive charge, the stronger the action.
.NH,
X-CHo-CH-COOH
^ 1
I NHo
©
X-CHo-CH-COO
B ^ 1
0  NHo
II
© X-CHo-CH-COO
II " I
0  NHo
©
©
III
Quinolinic acid, at pH 2.5, exists mainly as two canonical zwitter- 
ions, IV and V,
OH .©
r
© 0© ©
IV V
the proportions of which, together with the neutral form of the molecule,
change when the pH is increased.
Phthalic acid C65) is devoid of these charges and was much, less 
active than quinolinic acid, which suggested that the charges on quino­
linic acid are important for convulsant activity. The independence of 
the activity of quinolinic acid from pH may be due to the presence of 
adequate charges in spite of charges in zwitter-ions. Succinic acid
(without charges) was also less active than aspartic acid (with charges).
The effect of L-kynurenine sulphate could be reduced by taurine, 
inhibitory amino acids such as glycine and y-aminobutyric acid (GABA), 
and interestingly, the side chain of the kynurenine molecule includes 
the structure of glycine (-CH(HH2)COOH) . However, these amino acids
could not counteract the effects of quinolinic acid. Thus, inspite of
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the presence of the 0*C-C-C-C»0 moiety in the structure of quinolinic acid 
its mechanism of action appears to be dissimilar to that of L-*kynurenine.
Stone^^^ has proposed that the convulsant activity of quinolinic 
acid may be a reflection of the direct excitatory action of this compound 
on central neurones. A view which Stone points out is apparently contra­
dicted by Lapin's report that the icv injection of kynurenine induced 
seizures with a shorter latency than did quinolinic acid. However, Lapin 
has also stated that quinolinic acid is 25 times more potent than kynur­
enine at inducing seizures in mice and conceivably the relatively large 
dose of kynurenine needed could be disrupting other pathways.
3 . 3  Quinolinic Acid: a Neurotoxic Amino Acid
3 .3 . 1  Toxic effects of excitatory amino acids
137Injection of an exogenous 'excitotoxin* into the brains of experi­
mental animals produces effects that have been considered as models of 
human degenerative disorders. Thus, striatal lesions caused by these 
agents are thought to closely resemble the neurochemical and neuropatho-
logical changes observed in Huntington's disease . The intraventricular,
6 125 190intrahippocampal or systemic administration of kainate * * results in
seizures and nerve cell changes characteristic of temporal lobe epilepsy in man.
The structural resemblance of exogenous amino acids such as kainic 
and ibotenic acids, to endogenous excitatory amino acids, e.g. glutamic 
and aspartic acids, has led to the hypothesis that hyperfunction of the 
body's own 'excitotoxins' may be related to neuronal damage in certain 
neuropsychiatrie diseases^®. Endogenous excitatory amino acids have been 
shown to exhibit only mr-.inal neurotoxic potency in the mature nervous 
system when compared to the experimental neurotoxins, as they would have 
to be transported across the blood brain barrier.
It has been reported’^ ®^ that quinolinic acid can produce axon-
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sparing neuronal lesions after intracerebral injection in rats. Neuro-
chemical, neuropathological and gross behavioural analyses show that
quinolinic acid mimics some of the effects of kainic acid and ibotenic
acid in both character and intensity.
The unilateral intrastriatal application of quinolinic acid (>150 nmol)
resulted in tonic-clonic movements of the contralateral forelimb which
lasted approximately five hours. This behaviour was dose dependent and was
usually accompanied by episodic barrel-like rotations, which have also
112been observed with kainate and ibotenate treatments . No abnormal
behaviour was reported to be displayed after the operation.
The general appearance of the striatum, with the exception of neuronal
degeneration, was unchanged. The number of glial cells were not reduced.
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'Distant' nerve cell loss, as observed with striatal kainate lesions , 
were not seen, and with the administration of nicotinic acid (60) (800 
nmol) the decarboxylated product from quinolinic acid, healthy neurones
were plentiful close to the injection site.
Ultrastructural analysis of the striatum four days after the 
injection of quinolinic acid (60 nmol) revealed disturbance of neuropil 
and nerve cells. The number of synaptic complexes was decreased and
dendritic swelling was evident. Axons were well preserved.
Neurochemical measurements’-^  ^ confirmed the axon-sparing qualities 
of striatal quinolinic acid lesions. Ascompared to the contralateral 
side, the activities of striatal glutamic acid decarboxylase (GAD) and 
choline acetyltransferase, marker enzymes for intrinsic GABAergic and 
cholinergic neurones, decreased in dose-dependent fashion with increasing 
amounts of quinolinic acid. Tyrosine hydroxylase activity, an indicator 
of the presenceorf the dopaminergic terminal network originating from cell 
bodies in the substantia nigra’"^ ,^ remained unchanged (Table 5).
Intrahippocampal injections of quinolinic acid (> 500 nmol) results 
in generalised convulsions, characterised by intermittent jumping, 
running fits, ipsilateral turning and pronounced exophthalmos, lasting
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TABLE 3 Effects of intrastriatal quinolinic and nicotinic acid 
on local neurotransmitter related enzymes
Injected
Glutamic acid 
decarboxylase
Choline
acetyltransferase
Tyrosine
hydroxylase
amino
acid
(nmol)
Percent of 
contra­
lateral 
Activity striatum Activity
Percent of 
contra­
lateral 
striatum
Percent of 
contra­
lateral 
Activity striatum
QUINOLINIC ACID
60 307 ± 15 96 797 ± 40 96 2.5 ± 0.1 1 0 2
150 158 ± 13 55 557 ± 62 78 2.6 ± 0.3 92
300 85 ± 17 26 424 ± 56 50 3.0 ± 0.1 1 1 2
600 44 ± 14 14 116 ± 31 14 2.9 ± 0.1 8 6
NICOTINIC ACID
800 298 ± 4 96 790 ± 45 95 2.5 ± 0.1 94
for two to four hours^^^. Histological examination showed lesions of 
the dorsal hippocampus and underlying thalamic nuclei; pyramidal cells 
were preferentially damaged over granule cells* (Nicotinic acid did
not damage the hippocampal formation.)
The absence of distant lesions, the production of circumscribed 
lesions and the lack of pronounced convulsant properties indicate an 
ibotenate-like activity’’^ ^; whilst the selective vulnerability of 
pyramidal cells and the absence of neurotoxic effects in seven-day old 
stiTLAtd or liippocsinpi mdicät© sl lcÄHiÄt6“lilcß ticurotoxxcity •
Since kainic and ibotenic acids provide an animal model for 
Huntington’s disease, it is possible that quinolinic acid has a role in 
the etiology of this disorder. A metabolic defect in the brain or 
increased transport from the periphery could provide an excess of 
quinolinic acid sufficient to induce neuronal degradation of the type 
seen experimentally •
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3.3.3 Summary of pharmacology
Evidence to support the* suggestion that quinolinic acid may act
preferentially at NMDA receptors has been provided by the results of
168iontophoretic studies on rat brain (APP blocked quinolinate*s
3action more easily than GDEE) and also by the assessment of [ H]-purine 
release evoked by quinolinic acid^^^ (APH reduced the release evoked 
by quinolinate and NMDLA but not ttxat due to the other agonists, e.g. 
glutamate and quisqualate).
Quinolinic acid exhibits neuronal sensitivity in different regions
of the CNS i.e. it is excitatory in the cortex and hippocampus but it
147is inactive in the spinal cord .
Intracerebral injection of quinolinic acid produced axon-sparing 
neuronal lesions^^^. Neurochemical, neuropathological and gross 
behavioural analyses showed quinolinic acid to be both kainate-like
and ibotenate—like in its actions.
Quinolinic acid induced convulsant action after intracerebro- 
ventricular injection in mice^°^; structurally-related compounds 
were also examined and the results suggested that the presence of the 
C« 0  moiety may be necessary for the induction of this action. 
Stone^^^ suggested that quinolinic acid's convulsant action may be a 
result of its direct excitatory action on central neurones.
As a result of the various reports of the tremendous activity of 
quinolinic acid it was decided to develop analogues of quinolinic acid 
(some of which, it was hoped, would be specific antagonists of NMDA) 
which could be submitted for pharmacological testing.
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3.4 Synthesis of Some Quinolinic Acid Analog^es
3.4.1 Introduction
From the foregoing introduction, quinolonic acid is seen to be 
pharmacologically interesting, for example, it causes neuronal 
excitation * * induces seizures in mice and produces axon­
sparing lesions^^^. However, if the full significance of quinolinic 
acid's activity is to be realised, especially with respect to the 
identification of an excitatory amino acid receptor, extensive studies 
(e.g. structure activity relationships) need to be carried out. It 
was thought that examination of the biological effects of analogues 
having the general structures shown below would enhance the quinolinic
acid 'field*;
( 7 5 q ) X =(CH2)niY -  C02H (108) Z =-NH(CH2)n-Y 
( 7 5 b )  X = (C H 2 )n iY  = PO3H 
(7 5  c) X =(CH2)ni Y = SO3H
As with the straight chain acidic amino acids (see 2.1.1) the 
length of the alkyl chain could be increased and the acid group (Y) 
could be either a carboxylic, phosphonic or sulphonic acid group. The 
acid (7 5a) would afford a relatively rigid glutamic acid (1 ) analogue.
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H- O 2H
H
(1)
e x * " '^ ^ C 0 2 H
X =  CH2 
Y =  CO 2H
(7 5 q )s (45)
Peptide analogues could also be synthesised (e.g. (108)). Hence, 
a diverse choice of synthetic possibilities exists and therefore it was 
decided to undertake syntheses of the following compounds: the acids 
(45) and (46) and the peptide (47).
C O 2 H • N H ^ ^ 0 2 H  
•C02H
( 4 5 ) (46) (47)
The acid (45) is a known compound  ^and its preparation would allow 
us to explore the chemistry of difunctional pyridine compounds and would 
provide an analogue for pharmacological testing. The diacid (46) is 
not a known compound but our knowledge gained from synthesising acid
(4 5 ) would benefit its preparation.
The glycyl peptide analogue (47) is the first member of the series
(and nay be biologically active). Once the methodology had been 
devised, the phosphonic and sulphonic compounds could be derived by
the ame route.
3 4^ , 2 Preparation of 8~homoquinolinic acid (45)
Quinolinic acid (44) was an obvious starting materiali homolo­
gation, in principle, would only require the insertion of a methylene
group (Scheme 2). 79
Scheme 2
S , A co2H
(45)
+  CHa
< ^ C 0 2 H
(44)
Several methods exist for increasing the length of a carbon chain 
by one carbon^ . The best general method is the Axndt-Eistert syn­
thesis^^ which converts an acyl halide to homologous carboxylic acid.
In the first step the acyl halide is converted to a diazoketone in 
the presence of excess diazomethane. The actual rearrangement (Wolff 
rearrangement®^ occurs in the second step (Scheme 3). If an alcohol,
R*OH, is used instead of water, the ester, RCH2COOR' is isolated.
Scheme 3
R - C - C l  +  C H îN i  II 
O
H 2 O
R -C -C H N 2  —
^  A g j O
R - C H 2 - C O 2 H
A literature search revealed that a patent issued in 1946 reported 
the preparation of a decarboxylated derivative of B-homoquinolinic acid, 
pyridine-3-acetic acid (45b), which employed the Amdt-Eistert homolo­
gation of quinolinic acid (Scheme 4).
Scheme 4
^ Y | - C 0 2 H
^^A c02H
(44) (45a)
(45b)
R = CH3
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3.4.2.1 Synthesis of the diazoketone (73)
The anhydride (70) was synthesised in good yield, 67Z after re­
crystallisation, by stirring a solution of quinolinic acid (44) in 
acetic anhydride with the slow addition of hydrochloric acid. The 
anhydride's infrared spectrum had absorptions at 1630 and 1690 cm 
indicative of an anhydride. (Typically at 1710 cm ^.)
Selective esterification of the anhydride in methanol afforded 
the 2-carbomethoxy acid (71) in 60Z yield (melting point 122-125*C, 
literature melting point 125-126®C^^). The methoxy protons appeared 
as a singlet (6 4.48) in the NMR spectrum of the monoester (71). 
Infrared absorptions at 3540 (broad stretch) and at 1620 and 1730 cm 
indicated the presence of carboxylic acid and ester groups.
The monoester (71) was then heated under reflux with thionyl 
chloride to prepare the acyl chloride (72); the progress of the 
reaction being followed by TLC and infrared. The acid chloride has 
a characteristic absorption at 1785 cm” .^ The crude acid chloride 
(72) was isolated in 98Z yield on evaporation of solvent (Scheme 5).
-1
Scheme 5
A c jO /H ®
r  M ----- ----- »•
C O 2 H
(44)
*<5:j^ C 0 2 C H 3
(72)
S O C I.
(71)
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The acyl chloride (72) in dichloromethane was carefully added to
2 63a solution of diazomethane * in diethyl ether, at 0**C (Scheme 6 ).
The progress of the reaction was again followed by TLC and infrared 
spectroscopy (absorptions at 2100 cm  ^ (CHN2 ) and 1620 cm ^ (COCHN^))« 
Excess diazomethane was destroyed with acetic acid and after the 
evaporation of solvent the diazoketone (73) was isolated. It was 
found to be stable at 0®C; there being no evidence (TLC) of decompo­
sition within 12 hours at 0®C or 60 hours at -10*C.
Scheme 6
•COCI C H 2 N 2
O ’ C
(72 )
.COCHN2
CO2CH3 Et20/CH2Cl2 ^ ^ C 0 2 C H 3
(73)
2.4.2.2 Conversion of diazoketone (73) to diester (74)
The diazoketone (73), stirred as a solution in methanol at 50*C, 
was treated with two equivalents of silver (1 ) oxide over a period of 
2 hours. When the evolution of nitrogen ceased the reaction mixture 
was carefully filtered, several times, to remove all traces of silver 
(1) oxide. The residue had to be immediately purified by chromato­
graphy on silica as the crude residue readily decomposed at room 
temperature and 0**C.
Despite the difficulty in handling the reaction mixture, (with
care), the diester (7 4 ) could be isolated as a pale yellow oil in good
yield (72i). An accurate mass spectrum of the diester (74) established
the molecular formula as (molecular ion at m/e 209.071).
Confirmation of its structure came from the NMR spectra: methylene
proton resonances at i 4.61 and methoxy protons at S 3.71 (CH^CO^CHj)
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13and 6 3.96 (CO^CH^); C absorptions were at 6 38.73 (CT2CO2CH2 ),
6 52.06 (CH2C02CH^), 6 52.22 (002^^).
Scheme 7
C^0CHN2
C^02CH3
(73)
A g j O a H 2C0 2 C H 3 
0 2 C H 3  
(74)
As silver (1) oxide is a relatively expensive material, it was
decided to examine the use of a cheaper alternative: copper(i) iodide
is a less expensive catalyst and has been reported to catalyse the
187Wolff rearrangement successfully.
Copper(I) iodide in acetonitrile/methanol, at 65®C, successfully 
catalysed the conversion of diazoketone (73) to diester (74) (TLC 
evidence). However, the work-up of the reaction mixture was much more 
difficult and required more filtrations than with silver oxide. The 
diester was isolated in low yield (152). Silver (1) oaide, therefore, 
was a more suitable catalyst than copper iodide.
3.4.3.3 Hydrolysis of diester (74)
The diester (74) was smoothly hydrolysed by treatment with two 
equivalents of sodium hydroxide for 4 hours, The reaction mixture 
was acidified and B-homoquinolinic acid (45) isolated after ion 
exchange (Dowex 50, H*) column chromatography and recrystallisation, 
in good yield (781) (Scheme 8 ). On larger scales the reaction mixture 
had to be purified by silica column chromatography due to the presence 
of impurities (a possible result of decarboxylation) before recrystal-
isation of the acid (45).
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Scheme 8
I.N qOH.A
^ ( ^ C 0 2 C H 3 2 . H ®
(7í^)
l<ii\^H2C02H
S f^ C 02H
(45)
Elemental analysis of 8—homoquinolinic acid confirmed the 
molecular formula as CgH^NO^. Its C NMR spectrum showed singlets 
due to carboxy groups at 6 164.09 (CO2H) and 6 174.71 (CH2CO2H) and its 
mass spectrum showed a molecular ion at m/e 181.
Quinolinic acid, therefore, could be homologated using the 
Amdt-Eistert methodology. Silver oxide was found to be essential for 
the rearrangement of the intermediate diazoketone (73) and although 
on larger scales longer purification procedures were required it was 
still possible to prepare relatively large amounts of 8-homoquinolinic
acid.
3 , 4 , 3  Approaches to the synthesis of Z-carboxy-S 
(-2-carboxyethyl) pyridine (46)
3.4.3.1 Introduction: synthetic considerations 
B-HomoquinoUnic acid (45) could in theory be converted to the 
next higher homologue (46) using, once again, the Amdt-Eistert method 
(Route A). However, this would result in a lengthy route. Also, 
although the conversion of individual steps was efficient, the overall 
yield from quinolinic acid (twelve steps) would be very low. Therefore, 
since we could always revert to this route, alternative approaches were 
examined to achieve better conversion of quinolinic acid.
84
One possible avenue (Route B) required that the carboxylic acid 
group (3-position) be "converted" to a halomethyl moiety (CH2-X, where 
X is a leaving group (e.g. halogen or Otosy]) which could be derived from 
an alcohol) which would then be reacted with a two carbon homologating 
nucleophile (e.g. diethyl potassio malonate or ethyl lithio acetate). 
(Scheme 9).
Scheme 9
•CO2H Routes
•COiH
(46)
^ A c 02CH3
(45)
/  CH2CO2R 
'X
•t
RouteA
(CH2N2 .Me OH)
V
< i j ; ^ C 0 2 H
(44)
Initially, we attempted to synthesise, selectively, the alcohol 
(76), hoping to convert the hydroxyl to either X or Otosyl.
3.4.3.2 Synthesis of 2—carbomethoxy—3— 
hydroxymethyl pyridine (76)
The diester (74) could not be used as it lacked selectivity, 
therefore. 3-carboxy-2-carbomethoxy pyridine (71). easily available.
had to be used.
The selective reduction of a carboxylic acid to the corresponding 
primary alcohol, in the presence of an ester or other substituents, by
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20 21 188 189borane in tetrahydrofuran (THF) has been well docuioented ’ * * .
Lithium aluminium hydride or sodium borohydride are non-selective, and 
would give 2,3-dihydroxymethyl pyridine.
Using borane in dry THF (Scheme 10) the acid (71) smoothly afforded 
the alcohol (76) in good yield, 65Z after ion exchange column chroma­
tography and recrystallisation. The alcohol’s (76) H NMR spectrum 
showed a singlet at 6 7.92- 8.83 due to pyridyl protons. Its mass 
spectrum exhibited molecular ions at m/e 167 (m) and 149 (M-H2O) which 
confirmed its structure.
Scheme 10
•CO2CH3
(71)
O C ^ ^ C 02CH3
(76)
All attempts to synthesise the bromo (77) or tosyl (78) derivatives 
of the alcohol (76) were unsuccessful. A variety of conditions and 
reagents were used (e.g. PBrj or CBr^/PPhj or TsCl/py), but to no avail. 
The reactions were difficult to follow by TLC and there was a possibility 
of deleterious reaction of the products due to acidic by-products.
a C H 2 Br 
,, C02CH3
(77)
a C H i O T s  
„ CO2CH3 
(78)
As the alcohol (76) could not, under the conditions used, be con­
verted to the bromide or tosylate an alternative approach to the syn­
thesis of 2-carboxy-3-(2-carboryethyl) pyridine (46) had to be sought
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3.4.3.3 Attempted C-3 metallation of 2 ,3-lutidene 
Since we could not obtain a methylene group activated toward 
nucleophilic displacement (i.e. pyridine (78)) it was decided to 
explore the possibility of achieving the desired homologation via the 
opposite strategy. if we could obtain a synthon for pyridine (80), 
then the reaction between it and, for example, ethyl bromoacetate ought 
to furnish the desired product. None of the intermediates prepared 
thus far could serve this purpose. A new starting material had to be 
sought. (Scheme 11).
Scheme 11
C O 2 R
‘CO2R
(80)
•N"
(79)
J 3  ® 
M
C O 2R
(81)
123
Since radical ethoxycarboxylation of 3-picoline (79) , m
particular (and of pyridines in general) is possible in very low yield, 
we turned our attention to achieving the preparation of 'anion' (81) 
(and hence (80)). which could then be alkylated to afford the desired
product (46a).
Although 3-picoline had been metalated and subsequent products
. . . rA^^A Vaiaer^^ has shown that it can be metalatedobtained in poor yield, Kaiser
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Q'i 1 2*5 179  ».Similar work is well documented * * * . As a result of these
facts the readily available 2 ,3-lutidine (8 6 ) was used as starting 
material for the proposed synthesis of the acid (46). If the 2-methyl 
group, due to its greater acidity, could be selectively converted to a 
carboxy function, then subsequent selective metallation would achieve 
preparation of synthon (80).
3.4.3.3.1 Preparation of alcohol (87)
2,3-Lutidine (8 6 ) was treated with one equivalent of butyl lithium 
-20"C; the resulting anion smoothly underwent condensation with 
benzaldehyde at 0®C (Scheme 14). The alcohol (87) was isolated in 
very good yield, 85Z after column chromatography. The NMR spectrum of 
the alcohol (87) with a methylene singlet (3 protons) at 6 2.20 showed 
that only one methyl ’group’ was still present; resonances due to the 
methylene protons appeared as a multiplet (6 3.05); absorptions of the 
side chain methine proton at 6 5.28 and benzyl (and pyridyi) protons in 
the region, 6 7.10-8.38 indicated that benzaldehyde had reacted with 
only one methyl group. The presence of a strong hydroxyl group 
absorption at 3400 cm"’’, in the infrared spectrum of the alcohol (87) 
and its mass spectrum with a molecular ion at m/e 214 (m'") confirmed 
the structure of the alcohol; analysis confirmed its molecular formula
as
Scheme 14
1. BuLi.THF.-20 C
2. PhCHO
I®-------3. ■Ph
( 66 ) (8 7 )
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3.4.3.3.2 Dehydration of alcohol (87)
Alcohol (87) was heated under reflux with toluene and one equiva­
lent of para-toluenesulphonic acid over night (Scheme 15). The 
dehydration product, the alkene (8 8 )., a yellow oil, was afforded in good 
yield, 98Z after column chromatography.
Analysis and an accurate mass spectrum of the alkene (8 8 ) estab­
lished the molecular formula aa (molecular ion at m/e 195.104).
Absence of any absorption assignable to a hydroxyl group in the infrared 
spectrum of the alkene and the absence of the me thine proton resonance 
(at 6 5.28), together with the presence of olefinic protons at 6 6.9 
and the benzyl and pyridyl resonances (6 7.05-8.46) confirmed its
structure.
Scheme 15
OH tosicQcid
Ph
(87)
toluene/A •Ph
( 8 6 )
3.4.3.3.3 Synthesis of the carboxylic acid (89) 
Pyridyl compounds containing a vinyl substituent have been con­
verted to the carboxylic acid and/or aldehyde, by ozonolysis^’^ °®. The 
carboxylic acid (89) was. thus, synthesised by passing ozone through a 
methanol solution of the alkene (8 8 ) at room temperature (Scheme 16).
It was isolated in good yield (65Z after recrystallisation), melting 
point 110-C (literature melting point llO'C^l“). The NMR spectrum of 
the acid (89), which did not show absorptions due to the benzylidine 
moiety (^Ph) l.e. no olefinic or phenyl protons, did have a methylene
singlet at « 2.71 and pyridyl resonances (three protons) in the 6 7.95 - 8.52.
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Scheme 15
OH
•Ph
(87)
tosic acid
toluene/A •Ph
( 86 )
3.4.3.3.3 Synthesis of the carboxylic acid (89) 
Pyridyl compounds containing a vinyl substituent have been con- 
verted to the carboxylic acid and/or aldehyde, by ozonolysis . The
carbo:cylic acid (89) was. thus, synthesised by passing ozone through a 
s«thanol solution of the alkene (8 8 ) at room temperature (Scheme 16).
It was isolated in good yield (651 after recrystallisation); melting 
point 110-C (literature melting point 110 «C^'“). The hMk spectrum of 
the acid (89). which did not show absorptions due to the benzylidine 
moiety (^Ph) i.e. no olefinic or phenyl protons, did have a methylene
singlet at 6 2.71 and pyridyl resonances (three protons) in the 6 7.95 - 8.52.
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3.4.3.3.4 Esterification of acid (89)
The acid (89) was not soluble in protic solvent e.g. THF or hexa- 
methylphosphoramide (HMPA), which would be used in the subsequent 
metallation reactions, and was, therefore, converted to the methyl ester 
(90) using dicyclohexylcarbodiimide (DCC), methanol and pyridine 
(Scheme 18). Other methods, for example treatment with methanolic 
hydrochloric acid gave markedly lower yields (15-25Z).
Scheme 18
■CO 2 H
DCC .MeOH 
DMAP. Py , RT •CO2CH3
(89) ( 9 0 )
The ester (90) was isolated in 80Z yield after colum chroma­
tography. Proton resonances in its NMR spectrum were due to the C-3 
methyl, a singlet at i 2.60; the ester methyl, a singlet at i 3.98 
and pyridyl protons in the region 5 7.35-8.56.
3.4.3.3.5 Attempted metallations of ester (90) 
Ester (90) was added to a solution of freshly prepared lithium di-
isopropylamideihexamethylphosphoramide (1 :1 ) complex in tetrahydrofuran 
at O’C (Kaiser's conditions): methylbromoacetate (the electrophile) 
was added and after work-up a product was isolated in lOZ yield after 
column chromatography. Its 4' NMR spectrum indicated that the expected 
product (96) had not been isolated i.e. the C-3 methyl singlet (at 6 
2.57) was still present. An extra absorption due to methylene protons 
appeared at S 3.8 (2H, multiplet) but as there were still three ring 
(pyridyl) protons the methylene group had to be attached to the C-2 
functionality. An absorption at 1730 cm'^ indicated an ester was still
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present and an accurate mass spectrum established the molecular formula 
as ^3 o^^11^^3 193.603) and a peak at m/e 92 (M-
C0CH2C0 2Me) confirmed the structure of the product as 6-keto-pyridyl 
ester (98).
*
CO2CH3
(96) (98)
Alkylation at the 3-methyl group presumably had not occurred as 
neither of the two possible products; the alkylated pyridine (96) nor 
the acylated pyridine (97) had been in evidence. Pyridine (97) would 
arise from attack by anion (95) at the bromoacetate carbonyl.
e ®
Li
(95)
•Br
O
•CO2CH3
(97)
All attempts to carry out the reaction using modified reaction 
conditions e.g. solvent, time of reaction, temperature, more equivalents 
of base (for generating "anion") were equally unsuccessful.
The initial reaction was repeated using the same conditions but a 
•simpler model*, mono- rather than difunctional alkylating agent, in 
order to determine whether failure to obtain the desired product was 
due to failure to metallate or due to some untoward reaction of the di­
functional electrophile. Benzyl bromide was used instead of methyl
bromoacetate.
column chromatography afforded a product in 50Z yield. However.
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as with methyl bromoacetate its NMR spectmm showed C-3 methyl resonances 
(6 2.55). Benzyl protons appeared as 6 5.44 and phenyl protons (and 
pyridyl) at 6 7.3 -8.54 (8H). Its infrared spectrum showed ester 
absoiT)tion at 1730 cm  ^and mass spectrxim, with molecular ions at m/e 
228 and 1 2 1 (M*^-OCH2Ph), were consistent with the product having
the structure of benzyl ester (1 0 0 ) and not the expected alkylated 
pyridine structure (99).
Ph
^ > ^ C 0 2 C H 3
(99)
.Ph ^ , - ^ C O iCH3
( 1 0 1 )
It was now clear that reaction was preferentially occurring at 
the ester carbonyl. To determine whether any "anion" (95) was being 
generated, phenylselenyl chloride, a very reactive carbanion-trapping 
agent^^® , was used as the electrophilic species (under conditions 
employed above). The carbanion derived product (101) was not obtained
(starting material 'v* 60Z was recovered).
Therefore, under conditions required to metallate the methyl 
group the ester group reacted preferentially. Work is in progress to 
determine under what conditions, if any, the C-3 methyl of 2 ,3-lutidxne 
can be selectively metallated.
3.4.3.4 Attempted metallation of alkene (8 8 )
Using the same conditions as above, metallation of alkene (8 8 ) 
was attempted, but no reaction occurred at -78*C, O'C or higher 
temperatures.
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3.4.4 Alternative approach to preparation of acid (46)
3.4.4.1 Selective functionalisation of the 3-methyl 
group in 2,3-lutidine (8 6 )
Attempts to functionalise the ester (90) at the 3-methyl group had 
not succeeded due to preferential reaction at the ester carbonyl, under 
the reaction conditions employed. Therefore, a strategy was sought, 
whereby the 3-methyl moiety could be homologated initially and the 2- 
methyl group oxidised to a carboxy function (Scheme 20) (using the 
methodology developed previously (Scheme 19) thereafter:
Scheme 19
( 8 6 )
■ Ph
( 88)
■COiR
(89) R=H
(9 0 ) R=CH3
(80)
R = C H 3
Scheme 20
•COjR
‘C O 2 R • ^ ^ P h
O 2 R
= ^ L ! l
( 1 0 7 c ) ( 1 0 7 b )
( 1 0 7 a )
• ^
e  0 
M ,
0  0
— ^H or QX N'^
( 8 2 ) (82 a)
(86)
R = H , C H 3
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A method had to be found, therefore, to convert the less reactive
3-position in 2,3-lutidine (8 6 ) into an electrophilic centre (i.e.,
(82a)) (since the converse approach had failed). A literature search
,67arevealed that 3-bromomethyl-2-methyl pyridine (105) had been prepared 
by two methods, though it had not been rigorously characterised. It 
was decided to prepare this intermediate:
Reduction of the readily available ethyl ester (103) with lithium 
aluminium hydride (three equivalents) furnished the alcohol (lOA) in 
92Z yield, after chromatography (Scheme 21).
Scheme 21
LiAlH<..Et20,
( 1 0 3 )  ( 1 0 ^ 1
Treatment of an ethereal solution of the alcohol (104) with one 
equivalent of phosphorus tribromide, led to the total disappearance of 
starting material (TLC) and the appearance of a single, less polar, 
product. After standard extractive work-up this single spot was still 
apparent. However, all attempts to isolate the product were unsuccess­
ful (Scheme 22). Evaporation of the solvent (diethyl ether), even at
Scheme 22
P B r,.Eh O  _ 
L  J i ,  0 *C. «  mins. or-
■ (105)
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Reaction of 2,3-lutidine (8 6 ) with N-bromosuccinimide (NBS) in 
the presence of azobisisobutyronitrile (AIBN), with lamp irradiation, 
for 90 minutes, resulted in the disappearance (TLC) of starting 
material. A single, less polar reaction product, identical to that 
observed from the bromination of alcohol (104) appeared as the amount 
of starting material decreased. After concentration of the reaction 
mixture, the solution was added dropwise to a refluxing solution of 
potassiodiethyl malonate in dry THF. After 2i hours no bromide was 
apparent (TLC) . Standard extractive work up gave a 56Z yield of the
malonate adduct (106).
The selective C-3 bromination of 2 ,3-lutidine is extremely 
surprising in view of the fact that 2-picoline was found to be much more 
reactive than 3-picoline toward radical bromination . No explan­
ation has been put forward to account for this anomalous reaction.
A NMR spectrum of the malonate adduct (106) exhibited peaks due 
to the 2-methyl group (6 2.58) and the three pyridyl protons (C5 proton 
6 7.05), C4 proton 6 7.5 and C6 proton 6 8.4). In addition to these 
absorptions and those o£ the ethyl groups of the ester (« 1.2 and 6 4.2), 
the methine proton shift was observed at 6 3.5 and that of the "nalonate" 
methylene group at 6 3.24. The adduct was further characterised by
elemental (C,H,N) analysis.
Scheme 24
'ih.
C O 2 C2 H 5 2 .H
( 1 0 6 )
.CO 2 H
( 1 0 7 )
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The adduct (106) was then successfully hydrolysed and decarboxylated 
to the acid (107), obtained* in 8 8 Z yield after ion exchange chromatog­
raphy and recrystallisation. The 3 methylene protons exhibited 
absorptions at 6 2,55, in the NMR spectrum of acid (107), and the a 
methylene protons at 6 3.05. A methyl singlet (6 2.74) and three 
pyridyl proton multiplets (C5H: 6 7.7; C4H and C6H; 6 8,3) confirmed 
the presence of the 2-methyl pyridyl moiety. Once again, the acid was
further characterised by C,H,N analysis.
Having successfully functionalised and homologated 2,3-lutidine at 
the C—3 position it should now be possible to oxidise the 2-methyl 
group of the acid (107) (presumably via an ester derivative) to a car­
boxyl function using the approach employed previously. The pKa of 
model systems^^^^ would tend to lend support to this expectation:
,CH3
R-CH2-CO2R
PKq 2 4 -2 5 pKa ~  9 -10
Work is now in progress to achieve this end.
3 .4 . 5  Synthesis of some peptide analogues of quinolinic acid
3 .4 .5.1 Synthesis of »glycine» analogue (47).
3 .4.5.1.1 Introduction
From scheme 25 an obvious disconnection indicates that the obvious 
starting «terial is quinolinic acid . But C-2 needs protection 
and therefore the C-2 ester of quinolinic acid. (71). prepared before, 
ought to be used. An activated acid is required and glycine (109) 
needs to be protected and therefore the ethyl ester was used.
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Scheme 25
^ , ^ C 02H
[ 1 * 1 ) R=CH3
Z= activated 
carbonyl
(108)
+ NH2CH2CO2R
R = C 2 H s
( 1 0 9 )
3.4.5.1.2 Preparation of peptide acid (47) 
Initially, the ester (71) and glycine ethyl ester hydrochloride 
(1 1 0 ) were stirred at room temperature in dichloromethane, in the 
presence of one equivalent of dicyclohexylcarbodiimide (DCC) and three 
equivalents of pyridine. After work up and column chromatography, 
two products were isolated. The less polar product(6750 was identified 
as the anhydride (70) on the basis of its mp (136®C) and by TLC com­
parison of an authentic sample. The other product was characterised 
as the diester-amide (111) (24%) (Scheme 26).
An NMR spectrum of the amide (111) exhibited characteristic peaks 
due to the ethyl (three proton triplet at 6 1.32 and a methylene 
quartet at 6 4.20), and methyl esters (singlet at 6 4.0). In addition, 
a two proton singlet at 6 4.27 confirmed the presence of the methylene 
of the glycine residue. The structural assignment was further con­
firmed by mass spectroscopy (molecular ion at m/e 251).
Formation of the anhydride (70), no doubt, arises from intra­
molecular nucleophilic attack by the ester oxygen on the intermediate, 
activated ester (112). The fact that this is an intramolecular
process accounts for the relatively high yield.
It was found that when the reaction was carried out at lower 
temperature (O’C) the yield of peptide (lU) iucreased to (44Z) but the
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Scheme 27 o
o
r o
CO2H
SOCI2 ,
0•CO2CH3 ^
(7 0 )
(71 ) (7 2 )
O
•NH^C02C2Hs
Base hydrolysis of peptide (111) followed by ion exchange column 
chromatography afforded the acid (47) in good yield (8 6 Z). Elemental 
analysis of the acid (4 7 ) established the molecular formula as CgHgNOj 
and its mass spectrum exhibited a molecular ion at m/e 224. Absence 
of any absorptions, in the (MR spectrum of the acid (47) due to 
methyl or ethyl esters together with the presence of a methylene 
singlet at i 4.24 and pyridyl resonances at 6 7.78- 8.99 confirmed its
Structure.
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The diphenylphosphoao-peptide (113) was prepared by the method
developed previously £or the carbon analogue (111). Reaction of the
acid chloride (72), at O^C, with the diphenylaminomethylphosphonate
hydrobromide (119) afforded a 56Z yield of the diester-amide (113),
after column chromatography. Some anhydride (70) (20Z) was again
isolated. Base hydrolysis of the peptide (113), followed by ion
exchange chromatography, gave the phosphonic acid (114) in 78Z yield.
31The presence of phosphorus was confirmed by P spectroscopy (singlet 
at 6 10.8 relative to phosphoric acid (H^PO^)).
3.4.6 Conclusion
Homoquinolinic acid (45) was successfully synthesised and 
although the higher homologue, the acid (46) was difficult to make due 
to the problem of dicarbonyl selectivity, this has been largely overcome. 
The way is now open for the preparation of more carboxylic analogues.
The peptide derivatives (47) and (114) were easier to make and 
therefore this series of analogues can be easily extended.
Preliminary studies by T. Stone^^^^ of St. George's Hospital, 
London, have found e-homoquinolinic acid (45) to be at least twelve 
times more potent than quinolinic acid as a neurotoxin. Further 
pharmacological testing of acid (45) is in progress. Also, the 
effect of the amido (NH-^ ) «oiety on the potency of the quinolinic 
derivatives (47) and (114) is currently being examined.
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CHAPTER FOUR
APPROACHES TO THE SYNTHESIS OF TRICHOLOMIC ACID
4.1 Introduction
4.1.1 Isolation and purification
Takemoto^^^*^^^, in the 1960s, investigated the fly-killing com­
ponent of Tricholoma muscarium, a tasty mushroom which is widely 
distributed in Japan. The ready passage of the fly-killing component 
through cellophane membranes and its solubility properties suggested 
that it had a relatively low molecular weight, while its behaviour 
toward cation exchange resins, on paper electrophoresis and its 
reaction with ninhydrin suggested it was an acidic amino acid.
Chromatography of an aqueous extract of the mushroom (80 g of 
pulverised mycelium) on ion-exchange resin columns yielded a fraction 
(10 mg) which gave a positive ninhydrin test and had fly-killing 
activity. Recrystallisation of the fraction gave colourless prisms 
melting at 207*C (with decomposition) and an optical rotation of [o Id 
+80.0® (c, 0.2, H^O). The composition corresponded to a formula of
C H O N .  The new substance was named tricholomic acid after the 
5 8 4 2
mushroom from which it was obtained.
4.1.2 Structure elucidation
The structure of tricholomic acid »as proposed as a-amino-3-oxo- 
5-isoxazolidine acetic acid. It rapidly decolourised aqueous 
potassium permanganate or bromine, indicating some unsaturation in the 
molecule. On hydrogenation over PtO^, amide (121) was isolated which 
when hydrolysed gave the o-amino acid (122) (Scheme 1). The 
degradation product (122) was identified as esrthro-3-hydroxy-L-
,  ^ . ..170,172.glutamic acid
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Scheme 1
X O 2 H
H  r H  
NH?
HjN-
N H 2
O  OH
•CO 2 H
(121)
NH2
H O 2 C'' Y  ^ 0 2 H
OH (122)
NMR spectroscopy had indicated the presence of a moiety,
therefore, the only possible structures to fit the evidence were the 
er^thro— and threo~isoxalidines, (50) and (120) respectively.
HI :0 2 H
H
X O 2 H
H
ER.YTHR0
(50)
THREO
( 120)
The postulated structure was confirmed by ultraviolet spectra and by the 
treatment of tricholomic acid with 6M HCl. The products of the hydro­
lysis were y-hydroxyglutamic acid (123). succinic acid (6 6 ). hydroxyl-
amine and ammonia (Scheme 2)*
The D-erythro- and D- and L-threg-isomers of tricholomic acid, 
unlike the L-erythro-isomer are not biologically active«^ as excitants/ 
waste enhancers.
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Scheme 2
HN.
(50)
•CO2H
’H
NH,
6M HCl.105°C
OH NH2
O 2H + NH2OH + NH3
( 66 ) (123)
4.1.3 Biosynthesis
Apart from tricholomic acid (50) only a few other compounds con­
taining modified isoxazole rings have been isolated. Ihotenic acid 
(26), muscimol (125) and muscazone (126) have been isolated from the 
mushroom. Amanita. The structural similarity between tricholomic acid 
and ibotenic acid (except for the oxidation state) prompted the proposal
of a cornnon mode of biogenesis (Scheme 3).
B-Hydroxyglutamic acid (122) is thought to be converted to the 
hydroxylamine (124) which is then cylised to tricholomic acid. Sub­
sequent loss of a proton and a hydride ion gives ibotenic acid which can 
be decarboxylated to muscimol or be transformed in a nuBier of step
to muscazone.
Recent Japanese studies^^®* suggest that tricholomic acid is a 
very potent neuroexcitant of the quisqualate/ glutamate receptor. 
Tricholomic acid (50) can be thought of as a conformationally
restricted analogue of glutamic acid (1 )•
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HO.
;o 2 H
HO
•CO2 H
( 26)
Ibotenic acid (26), an unsaturated analogue of tricholomic acid, 
is also a glutamic acid analogue, which has a strong neuroexcitant 
and neurotoxicant action®^’^ *-^ ’^®^. Although ibotenate has been dis­
cussed theoretically as a selective agonist for receptors showing a
92 . . .preference for glutamate, (in an 'extended' conformation) , it is in 
fact a preferential NMDA agonist®^’'’'^ *^'^ ®^ . Ibotenic acid's effective 
interaction with a NMDA-receptor is thought to be a function of its 
carboxyl groups being less than maximally separated.
lontophoretic application of ibotenic acid to cat spinal neurons 
In vivo produces a biphasic action on neuronal excitability, i.e. an 
initial excitation followed by a long lasting inhibition . This 
inhibition is antagonised by bicucalline (a known antagonist of mus­
cimol (125) and y-aminobutyric acid GABA (3)” ), which suggests that 
this unusual effect, not seen with glutamic acid or other related 
analogues is the result of ibotenic acid forming its decarboxylated 
derivative, muscimol. This decarboxylation easily occurs i n  vitro.
(US, 5S)^-Amino-3-chloro-4,S-dihydrO-5-iso*azole acetic acid (127)
sometimes leferred to as AT-125, is another structural analogue of 
tricholomic acid, though again in a different oxidation state.
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As the related compoimds, ibotenic acid and AT-125 exhibit such 
marked biological activity it seems highly probable that tricholomic 
acid too is an 'active' compound. Thus, it was decided to subject 
tricholomic acid to pharmacological testing. However, a total lack 
of availability of the acid prompted us to undertake a literature 
search to determine whether tricholomic acid could be obtained by 
synthetic methods.
4.2 Review of Previous Approaches to the 
Syntheses of Tricholomic Acid
4,2.1 General approaches to isoxazole ring formation 
Generally the methodology employed for the construction of the 
isoxazole ring system falls into one of two categories. The first 
involves ring closure of a (&-aminoxy) amino acid derivative (Route 1) 
and the second, the cyclisation of an appropriate 0-hydroxamic acid 
(Route 2) (Scheme 4).
Scheme 4
'NH2
RO \  /  —
H2N—o 
(12a)
•NH2
/  \   ^
HN
I
HO
(129)
•NH2
(130)
111

Scheme 5
H55Q2^
OH 0  0
,1.BrucineADH/H
2 h®
H
1. ZC I.N qHCOb
2. BzBr,E1-3N.DMF 
3.0CA,H*
OH DCC.CH3H
2.MsCl,py
;
EtjN
Z = OCH2Ph DC C = (CtHiiN)2C
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The syntheses of racemic tricholomic acid described by Kamiya and
Iwasaki were lengthy and low yielding and so too was the resolution 
87procedure . The separation of the D~ and L-isomers utilised ethyl 
thiofluoroacetate, ammonia and quinine; total recovery of both isomers 
was pnly 13Z.
In the fifteen years that have elapsed since these publications 
no reports of syntheses of tricholomic acid, using either Kamiya's 
unverified methods or similar routes have appeared. For this reason 
and the others mentioned above, it was decided that a synthetic route 
to tricholomic acid would have to be designed, which overcame these 
problems.
4.3 Synthesis of Tricholomic Acid
4.3.1 Retrosynthetic analysis
The simplest way to obtain tricholomic acid would be by the 
attempted hydrogenation of its unsaturated analogue, ibotenic acid (26). 
Itowever, Takemoto has reported that hydrogenation of ibotenic acid gave 
an unstable product, due to ring opening, which could not be satisfac­
torily isolated^’®. Thus, it was decided to design a short, simple 
and flexible route to tricholomic acid which would require readily
available starting materials and reagents (Scheme 9).
Coupling of the »-protected hydtoxylamine (137a) and the di-
protected glutamate (136a) would give the hydroxamic acid (136).
Cyclisation of the hydroxamic acid to the triprotected isoxazolidine
(135) (via an intramolecular Michael addition) is then followed by
deprotections to give tricbolomic acid. Such a triprotected trUho-
. . u j Koon nreoared by Baldwin et al in theirlomic acid derivative had been prepar y
elegant synthesis of AT“125.
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Scheme 9
R -N v , -CO z R’
NHR
( 1 3 5 )
m
^  R
( 1 3 6 )
NHR
C O 2 R
r ’ - N - O H  
^  ( 1 3 7 )
R ^ - N - O H
( 1 3 7 q )
U 9 ••
R + N H 2 O H
( 1 3 7 b )  ( 1 3 8 )
( 1 3 6 Q )
X O 2 R
‘NHR^
( 1 3 6 b  )
c inmle starting materials, another attrac- Apart from the use of simple starring
• if a flexibility with respect to the ti/e quality of this route is its flexible y
1 2 3protecting groups, R > R ^ *
or  ^fi,« isoxazolidine ring is
Kelly^^ has shown the nitrogen o « ^ jof the sensitive N-0 bond
selectivity deprotected, without any cleavage 
of the ring (Scheme 10) .
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Scheme 10
I.H i/Pd  
y  9  e  
2.02=N=N
Z = ^ O C H 2 P h
O
Pht
Baldwin et al also showed that several different groups could be
4used to protect the isoxazolidine structure .
Thus, it was decided that the carboxylic acid would be protected 
as a benzyl ester (R^ which could be easily removed with aluminium 
amalgam^*. The two nitrogens would be protected with benzyloxy- 
carbonyl groups, deprotection would be simultaneously affected by
dehydr ogenat ion.
From the retrosynthetic scheme, the starting materials required 
are hydroxylamine (137) and a glutamic acid derivative d 3 6a),^^the 
derivative can be easily prepared from the lactone acid (136b) .
4,3.2 Preparation of acid (144)
a-Ketoglutarate (5) and benzyl carbamate (1*1). prepared in high 
yield (85X) from amK>nia and benzyl chloroformate, were heated under
vacuum to give the lactone acid (1*2) (70Z)^“’ . which was converted to
, u triethylamine (75Z) (Scheme 11)the ester (143) with benzyl bromide and tr y
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4,3.3 Preparation of hydroxylamine (146)
It has been shown that the presence of a substituent on nitrogen
24facilitates the cyclisation of the hydroxamic acid . The difference 
between N-protected and unprotected hydroxamic acids has been 
attributed to the unsubstituted hydroxamic acid possessing several 
nucleophilic sites, whereas there is only one nucleophilic site in N- 
substituted hydroxamic acid.
Hydroxylamines are kinetically acylated on oxygen and in order 
to avoid 0 -acylation the hydroxylamine would have to be 0-protected.
See Scheme 13.
Scheme 13
B z O .^ ^ C l+  NHgOH +
Bz = -CHjPh
It was necessary, therefore, to N-protect hydroxylasnne. with a 
bensyloxycarbonyl group, as the subsequent deprotection could be 
achieved by mild, facile hydrogenation over palladium . The acylate 
(146) was easily prepared, in overall 681 yield, by initial reaction 
with benzyl chloroformate and hydroxylamine (138) and then with t ^ -  
butyldimethylsilyl chloride (TBDMS-Cl). (Scheme 14).
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Scheme 14
Ph NH,OHHCl
NaHCOa
O
(138 ) (145)
+ ^ - C l
DMF.
H
t
P h / ^ C r ^ N H
^ 4 -
(146)
j «1 -irio of v^ Y^ 7"ovylamine (146)^4.3.4 Attempted coupling ot -------------------
with acid (1441
1 • riAfil with the acid (144) wasCoupling of acylated hydroxyUmxne
 ^ • N-hvdroxysuccinimida (NOHS). DCC and dimathylamnoattempted using N-hydroxysuccim 26,82,83
pyridine (DMAP). DMAP was used to facilitate acylation 
(Scheme 15) .
T.e .n.ydroxylamide" could not be coupled with the acid;
increasing reaction time and the addition of pyridi-e (to ensure e-
 ^ , .j\ also had no effc^ t^*protonation of the acid)
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The amide (149) was isolated (55Z yield, after column chromatog­
raphy) and its NMR spectrum showed the presence of both the hydroxamic 
acid moiety (i.e., olefinic proton at 5 6.83-6.9 and benzylic protons 
at 6 5.13-5.19) and significantly the characteristic doublet of the 
methyl protons. (6 1 .2 2 ) of the isopropylamine moiety.
The fact that the hindered amine could be coupled with the acid 
suggested that the methodology i.e. technique and reagents, was not at 
fault. Presumably, the very weak nucleophilicity of amidic nitrogen, 
as exists in the acylated hydroxylamine was important. It was thought, 
therefore, that the coupling of the acylate (146) with a more active
ester might be more successful.
Thus, it was decided to convert the acid (144) into an acyl 
chloride (150), where the chloride, a good leaving group, should 
facilitate the coupling reaction.
4.3.5 Acyl chloride (150)
initially, even though the acid (144) was reacted with thionyl 
chloride in dichloromethane at RT or heated under reflua at 50-80«C, 
the acyl chloride (150), could not be isolated. The reaction con­
ditions eng,loyed were possibly too harsh. The mild reagent, 1-chloro- 
N,N-2-trimethylpropenylamine5‘ >”  ,„.ble to chlorinate the acid
However, it was found that the unstable acyl chloride (150) could be
e fhp acid in toluene and DMF (aprepared by stirring a solution of the acio in
1 at 0*C. TLC showed that nocatalytic amount) with thiony
starting material remained after one hour.
j .«1 -ina of Vivdroxvlamine (146)4.3.6 Attempted nyaro^------------
with acyl chlorl^^ (150)_
a-fiona (as previously described for coupling Using the same conditions (as p
•a il46) still could not be coupled with the acyl reactions), the amide (146)
chloride (150).
Diisopropylamlne (148) was successfully coupled with the acyl 
chloride; the product (149) was isolated in a yield of 25Z (Scheme 17). 
It was the same as that isolated with the acid (144) (Scheme 16).
Scheme 17
(148)
O
.CO 2B Z
NHZ
(150)
NOHS.DCC
A
i O z B z
NHZ
(149)
The reduction in yield may have been due to competition between 
decomposition of the acyl chloride (150) and reaction of the amine (148).
It is probable that the amide (146) being much less nucleophilic 
than the amine (148) and, therefore, reacting much mote slowly, was 
unable to couple with the acyl chloride (150) before the latter had
fully decomposed.
4.3.7 W-Allvl-P’~"tecting group
• . .he reactivity of the acid (144), by conversion to As increasing the reactiviuy
facilitate the coupling of the the acyl chloride (150) , did not facilitât
j ' AnA rhat the hydroxylamine moiety rather than acylate (146) it was decided that the nya
the acid should be modified.
nitroeen is important in the acylation The nucleophilic character of nitrogen i«P
V 1 M-f>rotecting group would have to be replaced and so the benzyloxycarbonyl N ptotecti g g
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by a group which would have '.little effect on the nitrogen's basicity.
Such a group, was the acid- and base-stable, allyl groupé®
Generally, the protection method involves reaction of an amine (151) 
with an allylic compound to give an N-allyl derivative (152). Deallylation, 
under neutral aprotic conditions, is catalysed by various transition 
metal complexes e.g. tris(triphenyl phosphine)rhodium chloride 
(RhCl (PPh^) ^) . The resulting enamine (152a) then undergoes facile
hydrolysis to give the product (152b) (Scheme 18).
Scheme 18
R-N H ,
H
MX: ROM
H 2O
R-NH2
( 1 5 1 ) ( 1 5 2 ) ( 1 5 2 a ) ( 15 2 b )
27The N-allyl hydroxylamine (154) was synthesised . However, it 
and its precursor, oxime (153). although stable in dilute solution, 
polymerised on attempted isolation, making them very difficult to purify
(Scheme 19).
Scheme 19
rH
NH2OH
( 1 5 3 )
. • iu our hands, was extremely difficult to handleAs the alkyl oxime, m  our nanus,
an alternative N-protecting group was sought.
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4.3.8 Alternative approaches towards N-protection 
of hydroxylamine
4.3.8.1 The ortho-nitrobenzyl protecting group
Ortho-Nitrobenzyl groups have been widely and successfully used
24as N’-protecting groups . A facile deprotection of this group can be 
achieved using aluminium amalgam or ultra violet radiation.
The silylated N-(ortho-nitrobenzyl)-hydroxylamine (158) was readily 
synthesised from ortho-nitrobenzaldehyde (155) in 79Z overall yield 
(Scheme 20) .
Scheme 20
N O 2
H
(155)
N O 2
(158) •
N H j O H ^  
NqOAc '
-|-SiC(
Et3N,DMF
N O 2
(156)
1. NaCNBHs/H®
2. EtOAc,pH~ 7
(¡102
¿ r r
OH
( 15 7 )
V . • ^ the available aldehyde, was reducedThe oxime (156), derived from the avaiiao
A -Ac The work-up of the reaction mixturewith sodium cyanoborohydride.
oH 7; pH greater than 7 lowered had to be carried out at approximately P
the yield of the hydroxylamine (157). Silylation was effected hy 
t^-hutyldimethyisilyl chloride under basic conditions.
The silylated hydroxylamine (158) «as smoothly coupled to the acx
(144) using DCC and NOHS.
127
4.3.8 .1.1 Structure and deprotection 
of coupled product (159)
NO2 o o
_ " - O ^ P h
o
(159)
Examination of the tMR spectrum of the coupled product (159) 
confirmed the presence of the 0-tert-hutyl-dimethylsilyl group (singlet 
absorptions at 6 0.038 and 0.87) and the o8 unsaturated glutamyl 
moiety (olefinic proton multiplet atÍ 6.3- 6.9, and a methylene multi­
plet at 6 3.6). The methylene protons of the unsubstituted acid (144) 
resonate at Í 3.3. In the benzylic methylene region (5.0-5.30), 
however, the NMR spectrum indicated the presence of three, not two, 
benzyl groups. This was confirmed by reference to the aromatic 
region (6 7.25 - 7 .3 5) which again indicated the presence of four extra 
protons (due to the ortho-nitrobenzyl aromatic protons).
The widespread nature of the olefinic multiplet (6 6.3-6.9) 
perhaps deserves some comment. Some hydroxamic acids have been 
shown”  to exist as an Z/E equilibrium mixture of rotamers. the Z 
(çis) rotamer being capable of participating in intramolecular H-
Kot-qf-nents enhance the tendency for such bonding. Bulky nitrogen substituen
D — H
trans(E)
cr
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acids to exist as two different rotamers. In our case, presumably, 
the olefinicproton experiences two very differing electronic environ­
ments in each rotamer. Hence, the widespread nature of its chemical 
shift.
The silylated hydroxamic acid (159) was treated with p-toluene- 
sulphonic acid in methanol at room temperature and hydroxamic acid 
(160) was afforded in good yield, 74% after colunn chromatography.
NMR assignments for the hydroxamic acid (160) showed that the terlt- 
butyldimethylsilyl group had been removed (i.e. gross spectrum same as 
above but no absorptions at 0 - 0 . 1 region due to protecting group).
N O 2
O H
X O 2B 2
NHZ
( 160 )
B z = - C H 2Ph
Z = Y 'O CH 2Ph
4 .3 .8 .1 . 2  Attempted cvclisation of 
hydroxamic acid (160)
Hydtoxamic acid (160) could not be cyclised in sodium bicarbonate 
or sodium hydroxide. Other reaction conditions were used; e.g. 
sodium bicarbonate and tetrahydrofuran (THF); triethylamine in a 
solution of THFiwater (10:1): excess triethylamine or potassium 
hydroxide in methanol: longer reaction times; without success. In 
all cases the starting material was recovered in greater than 90Z yield, 
This failure to cyclise the acid (160) under any of the conditions 
employed may be caused by the electron-withdrawing effect of the nitro 
group in increasing the acidity of the aromatic protons of the o-nitro-
benzyl protecting group.
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In neither case would the acid exist as its anion; hence the 
hydroxamic oxygen would not be an.' a'vailable nucleophile. The fact 
that starting material was recovered in high yield would tend to 
support this postulate, only internal salt formation, no other 
reactions had occurred. Neither of the two possible intermediates 
(163) or (164) would undergo internal Michael reactions as formation 
of the six-membered conformer (in basic media) would be easier and 
therefore more favourable than cylisation to the hydroxamic acid.
4.3.8 .2 The 2 ,4 -dimethoxybenzyl group 
N-protection of an ortho-nitrobenzyl group had thus proved un­
suitable and an alternative protecting group had to be employed. A 
2,4-dimethoxybenzyl group would be used to N-protect hydroxylamine 
(138). Methoxybenzyl groups can be readily and efficiently removed
with 2 ,3-dichloro-5 ,6-dicyanobenzoquinone (DDQ) ; other methods
e.g. treatment with trifluoroacetic acid, and sodium in liquid
ammonia are much more harsh, yet still effective.
Hydroxylamine (167) was isolated, after colomn chromatography, in 
72Z yield. The pH of the ’work-up* conditions was not critical.
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Singlets in the NMR spectrxm of hydroxylamine (167) for. the 
methoxy protons were at 6 3.78. The silylated hydroxy lamine' s (168) 
NMR spectrum also exhibited similar resonances for methoxy protons at
I
6 3 . 7 9 and the tert-butyldimethylsilyl group's methyl singlets at 6 
0.09 and 0.92 (Scheme 22).
Scheme 22
H 3 CO' ‘OCH3
N H 2O H . H C 1
Nq O A c
(165)
, 1
H 3 C O ' " ^ = = : i ' ^ C H 3
( 166 )
I.NaCNBHj/H® 
ZEtOAc
t
OH
j O CH , C O ' ^ = i ^ O C H 3
(167)
H3CO' ^  'OCH3 
( 168)
The silylated hydroxylamine (168) was successfully coupled (as 
before) with the acid (144) and the tert-butyldimethylsilyl group 
removed with tosic acid/methanol at room temperature. Column chroma­
tography afforded a mixture of products, however, whose NMR spectrum 
indicated that a number of hydroxamic acids had been isolated. 
Presumably, the „-protecting group of the hydroxylamine moiety had 
either two methoxy groups (169), two hydroxy groups (161) or one methoxy 
and one hydroxy group (162). Separation of each of these compounds 
from the mixture, would be tedious and very difficult since all products 
were separated by an Rf of about 0 .1 , likewise, the alternative step of
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treating the mixture with base would have yielded a mixture of all six 
possible diastereoisomers of cyclised products which would again require 
separation.
H,CO-
N-
1
OH
.CO2B Z
NHZ HO'
.C0 2 B 2
NHZ
H3CO' 'OH
T
OH
.CO2BZ
NHZ
(162)
Bz -  -C H 2Ph 
Z =
O
4.3.8 .3 The para-tnethoxybenzyl protecting group
It was thought that a para-methoxybenzyl group would be mire
easily handled. Para-methoxybenzyl groups, as with the dimethoxy-
----  . 131a
benzyl groups, can be easily re«.ved with DDQ under mild conditions .
A para-methoxybenzyl group had been used for N-protection in Baldwin’s
synthesis of AT-125 (127)* (although, there, it had served to activate
the triprotected tricholomic acid toward imino chloride formation).
Hydroxylamine (172), prepared from £ara-methoxybenzaldehyde (170).
in good yield (82Z. after column chromatography) was smoothly silylated
(Scheme 24).
The protons of the tert-butyldimethylsilyl group in the NMR 
spectrum of the silylated hydroxylamine (173) , exhibited absorptions
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6 0.05 and 0.92 and the tnethoxy protons at 6 3.78. The aromatic 
protons appeared as a multiplet at 6 6.79 - 7.29.
Coupling of the silylated hydroxylamine (173) and the acid (144) 
afforded a mixture of products, in low yield (24%). NMR resonances
of this mixture (methylene protons at 6 3.55-3.66; benzylic protons 
at 6 5.03- 5.19; olefinic protons at 6 7.32; methoxy group singlet at 
6 3.78 was not equivalent to three protons) indicated that the coupling 
reaction had produced two hydroxamic acids: one with the para-methoxy- 
benzyl group intact and the other with a N-benzyl group, (174) and 
(175), respectively (in a 1:3 ratio) (Scheme 24).
As an efficient separation of this mixture was very difficult it 
was decided to revert to a simpler system i.e. an N-benzyl protecting 
group. Use of a benzyl group for N-protection had previously been 
avoided as it was thought to be more difficult to deprotect the end 
product. However, at this stage it was most important to show that a 
route based on an intramolecular Michael reaction was a viable approach 
and therefore a hydroxamic acid had to be cyclised (subsequent depro­
tections being of lesser importance). Also, once a cyclised product 
had been isolated it had to be shown that the diastereoisomers could be
separated.
4.3,8 .4 The benzyl protecting group 
N-Benzylhydroxamic acid (175) was prepared from the coupling of 
acid (144) and a silylated hydrorylamine (179) using methods employed 
for the other substituted bensyl protected hydroxamic acids.
The ^  NMR spectrum of the hydroxamic acid (175) had absorptions 
for the methylene protons at Í 3.26-3.35 and benzylic protons at Í 
5.09-5.2: resonances for the olefinic proton occurred as a multiplet
in the region 6 6 . 7 5 -6.9 and the aromatic protons at 6 7.35.
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Scheme 24
(170) (171)
I.NqCNBHb/h^ ^
lE t O A c
H »CO '
(172)
;iCl
DMF,
•NH
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O H  NHZ 
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•N'
O H
.CO 2 BZ
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The hydroxamic acid (175) was smoothly cyclised to the isoxa- 
zolidine (181) in sodium bicarbonate, which was isolated in 84Z yield
(Scheme 25).
Scheme 25
[H®]
Bz— N ^ C 0 2 Bz
< y ^  NHZ 
(175)
B z = - C H 2 Ph ; Z =  V '
O
NaHCOj
B z -fk _ ^ /C 0 2 B z
H T ' H
NHZ
(181)
O C H 2 Ph
The (MR spectrum of the product (and TLC) indicated the disappear­
ance of starting hydroxamic acid. No olefinic resonances were apparent 
and the methylene multiplet (6 3.26- 3.35) had disappeared, to be 
replaced by a similar 2-proton multiplet at 6 2.9. This was assigned 
to the isoxazolidine ring methylenes. The three benzyl groups (three 
methylenes at « 5.0-5.38 and fifteen aromatic protons at « 7.25-7.3) 
were still present. However, the presence of a two-proton multiplet 
in the region 6 4.40-4.88 was the most significant feature of the 
spectrum. The starting acid (175) exhibits no absorptions in this 
region. On the other hand, the diastereomeric methines (H^ and H,,) 
would, by analogy with previously known compounds ’ (e.g. isoxa-
zolidine (182)), have their chemical shifts in this region. TLC 
«»lysis confirmed the presence of two very closely differentiated
spots (R, 0.56 and 0.59 in ether/petrol 7:5).
The isoxazolidine (182) synthesised by Cha^* was not deprotected 
or purified (an analytical sample was prepared for its characterisation).
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(182)
so far. attempts to separate the erythro- and tl^-diastereo- 
isomers have proved difficult using conventional column chromatography, 
The triprotected tricholomic acid (181) decomposes on silica (lOZ 
recovery) and alumina (no recovery). Pre-elution or washing and 
drying of the silica with triethylamine or methylamine or precoating 
with silver nitrate has had no beneficial effect. Neither has 
use of alumina in its basic, neutral or acidic forms. However, work 
is in progress to surmount this problem: high performance I ' q  
chromatography studies are currently being undertaken to attempt the 
separation of the erythro-and threo-tricholomic acids.
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CHAPTER FIVE
EXPERIMENTAL
Melting points were determined on an Electrochemical melting point 
apparatus. and ^^P NMR spectra were measured with a Jeol FX
90 Q Fourier Transform spectrometer; the reported chemical shifts are 
relative to TMS (^H and and H 3P0 ^ (^^P) as external standards * IR
spectra were recorded on a Perkin-Elmer 298 spectrometer and mass 
spectra on a JMS DX 300 spectrometer . Optical rotations were 
obtained on a NPL Automatic Polarimeter 143D.
Column chromatography with Kieselgel 60 (70 - 230 mesh) silica gel 
or Dowex 50 (h ”^) ion-exchange resin (BDH) was used for the purification.
For reactions, diethyl ether, dichloromethane, chloroform, toluene 
and benzene were dried and distilled iron phosphorus pentoxide: methanol 
and ethanol frommagnesium. letrahydrofuran (THF) was dried and dis­
tilled from sodium benzophenone ketyl and N,N-dimethyl£ormamide (DMF) 
was stirred over calcium hydride before being decanted and distilled
under reduced pressure.
Lithium diisopropylamine (LDA) was prepared, in IM concentration,
150according to the method of Reich ct al
(DCC “ N,N'-Dicyclohexylcarbodiimide)
* 6-values are expressed in parts per million (ppm)
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5.1 Amino Phosphono acids
Diethyl-2-acetamido-2-[diethyl-2-phosphonoethyl3-malonate (40)
To a solution of sodium (0.9 g, 0.94 mol) in ethanol (20 mis) was 
added diethyl acetamido malonate (8.5 g, 0.04 mol). Solvent was 
evaporated, in vacuo, and the residue washed with toluene (3 x 15 ml), 
to give diethyl sodiomalonate (9.6 g, 0.04 mol) which was suspended in 
toluene (40 ml) and diethyl carbonate (40 ml). Diethyl-2-bromoethyl 
phosphonate (3 7 ) (1 0 . 8 g, 0.04 mol) was added, the mixture heated under 
reflux overnight, filtered hot, and the solvent evaporated, in vac^, 
to give a dark yellow oil (15.8 g). Chromatography on silica gel (500 g) 
using diethyl ether/chloroform 1 : 1 as eluant afforded acetamido adduct 
(40) (7.72 g, 51Z) as a viscous yellow oil.
(¿)-2-»Amino-4-phosphonobutanoic acid (APB) (10)
A solution of the acetamido adduct (40) (7.72 g, 0.02 mol) in 
6M HCl (100 ml) was heated under reflux for 12 hours. The solution 
was evaporated, in vacuo, and the residue dissolved in methanol.
Propylene oxide was added until no further precipitate formation was 
apparent. Filtration and recrystallisation from water-ethanol gave 
(±)-APB (10) (2.5 g, 6 8 Z) as white crystals: mp 225»c (with decompo­
sition) (lit. mp 225«C^^); NMR (H^O) 6 20.04 and 26.17 (d, J -
138 Hz, POT2 ), 24.38 (d„ J - 3.1 Hz, PCH2 CT2 ), 53.31 and 54.12 (d,
J - 18.3 Hz. CHNH^). 172.11 (s. CO^H) i «MR (H^O) i 26.65 (s).
Anal, calcd for C^H q^NOjP: C, 26.23! H, 5.50! N. 7.65! P.16.92.
Found: C, 26.08; H, 5.48; N, 7.37; P, 16.87.
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Resolution of (t)-2~Amino-4-pho8phonobutanoic acid (APB) (10)
A solution of L-lysine (1.46 g, 0.01 mol) and (±)-APB (10) (183 g, 
0.01 mol) in water (10 ml) was heated gently (60*C) for 15 minutes; 
methanol was added until the initial appearance of a flocculent precip­
itate. The “mixture was cooled, diethyl ether added until the onset of 
a slight cloudiness and left at -10*C overnight. The precipitate was 
filtered to give the (-)-APB-lysine salt (1.48 g, 45Z) which was 
dissolved in 2M pyridine and poured onto an ion-exchange resin column 
(Dowex 50, pyridinium form). The column was eluted with 2M pyridine, 
all ninhydrin positive fractions were combined, evaporated, in__vacuo, 
the residue washed with methanol and solvent evaporated, in vacuo, to
give (-)-APB (7.70 mg): [ « 5 4 5 1 “ “14.8" (c - 2.7, H 2O).
The mother-liquor from the above filtration was poured onto an 
ion-exchange resin column (Dowex 50, pyridinium form) and (+)-APB 
(620 mg) was isolated as above: - +11.3* (c - 6 .2 , H2O).
Diethyl-3-bromopropyl phosphonate (38)^
Sodium (4.14 g, 0.18 mol) was added to a solution of diethyl 
phosphite (22.84 g. 0.18 mol) and diethyl ether (20 ml). The resulting 
solution was added dropwise to a stirred solution of 1 .3-dibromopropane 
(55 g. 0.27 mol) in diethyl ether (25 ml) at 0»C. The mixture was 
allowed to warm to room temperature, left overnight, heated under reflux 
for three hours, cooled and then filtered. The solvent was evaporated. 
in vacuo, and the residue chromatographed on silica gel (500 g) using 
ethyl acetate eluart to give bromopropyl phosphonate (38) (17.82 g. 38Z) 
as a colourless oil: “ c NMR (neat) 6 16.79 and 17.06 (d. J - 6 Ha. 
OCH^GHj). 21.51 and 27.74 (d. J - 140 Hz. PCH^) . 26.92 and 27.09 (d.
J - 3.7 HZ. CH^Br). 34.45 and 35.27 (d. J - 18.3 Hz. PCH^CH^). 61.6 and
61.9 (d. J - 6 Hz. OCH^); 1®®
139
Diethyl~2-acetamido-2 -[diethyl-3~pho8phonopropyl ]-nnalonate (41)
To a solution of sodium (1.6 g, 0.07 mol) in ethanol (35 ml) was 
added diethyl acetamido maionate (14.9 g, 0.07 mol). Solvent was 
evaporated» in vacuo, and the residue washed with toluene (3 x 20 ml), 
to give diethyl sodiomalonate (16.9 g, 0.07 mol) which was suspended 
in toluene (60 ml) and diethyl carbonate (60 ml). Bromopropyl phos­
phonate (38) (17.8 g, 0.07 mol) was added, the mixture heated under 
reflux overnight, filtered hot, and solvent evaporated, in vacuo, to 
give a dark yellow oil (29 g). The acetamido adduct (41) was isolated 
as a viscous yellow oil (13.9 g, 50Z) after column chromatography on 
silica gel ( 5 9 9 g) using diethyl ether/ethyl acetate 1 : 1 as eluant.
(t)-2-Amino-5-phosphonopentanoic acid (APP) (Hj
A solution of the acetamido adduct (41) (13.9 g, 0.035 mol) in 
6M HCl (100 ml) was heated under reflux for 12 hours. Solvent was 
evaporated, in vacuo, and the residue taken up in methanol; propylene 
oxide was added until no further precipitate formation was apparent. 
Filtration and recrystallisation from water-ethanol afforded (±)-APP 
(11) (6.24 g. 90%) as white crystals: mp 230»C (with decomposition) 
(lit. mp 250*C^®); NMR (H^O) 6 18.55 and 18.74 (d, J = 4.3 Hz,
CH^CHira^). 23-16 a«» 29-2° W ,  J - 136 Hz. PCH^). 30.66 and 31.39 (d.
J . 16.5 Hz, PCH^Ol^). 53.17 (s. CHNH^). 172.30 (s. CO^H); ^^P NMR 
(HjO) « 29.95 (s). Anal, calcd for C5Hj^ 2 *^ OjP: C, 30.46, H, 6.14,
N. 7.10; P. 15.71. Found: C. 30.09; H, 6.14; N. 6.81; P. 15.62.
Resolution of (tl-2 -amino-5 -phosohonopentanoic acid (llj
A solution of L-lysine (2.92 g. 0.02 mol) and (±)-APP (ID (3.94 g, 
0.02 mol) in water (20 ml) was heated gently (60"C) for 15 minutes and 
methanol was added until the initial appearance of a flocculent precip-
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itate. The mixture was cooled, diethyl ether added until the onset of 
a slight turbidity and left at -10*C overnight. The precipitate was 
filtered to give the (-)-APP-.lysine salt (3.3 g, A8Z) which was then taken 
up in 2M pyridine and poured onto an ion-exchange resin column (Dowex 
50, pyridinium form). The column was eluted with 2M pyridine, all nin- 
hydrin positive fractions were combined, evaporated, in vacuo, the 
residue washed with methanol and the solvent evaporated, in vacuo, to
afford (-)-APP (1.71 g): *
The mother-liquor from the above filtration was poured onto an
ion-exchange resin column (Dowex 50, pyridinium form) and (+)-APP 
(1.65 g) was isolated as above: H2O).
Diethyl-5-bromopentvl phosphonate (39)_
To a solution of diethyl phosphite (20.64 g, 0.16 mol) in diethyl 
ether (20 ml) was added sodium (3.68 g, 0.16 mol). The resulting 
solution was added dropwise to a stirred solution of 1 ,5 -dibromopentane 
(76.5 g, 0.33 mol) in diethyl ether (35 ml) at Q-C. The mixture was 
allowed to warm to room temperature, left overnight, heated under 
reflux for three hours, cooled and then filtered. The solvent was 
evaporated, in vacuo, and chromatography of the residue on silica gel 
(400 g) using petroleum ether (30-40«C)/diethyl ether 9:1 eluant yielded 
bromopentyl phosphonate (39) (15.59 g, 34%) as a colourless oil:
NMR (neat) 6 16.96 and 17.23 (d, J - 6 Hz, 0 CH2^ 3 ), 22.32 and 22.54 
(d, J - 4.9 Hz, PCH2CH2OT2 ), 22.81 and 29.04 (d, J - 140 Hz, PCT^), 
29.15 and 29.85 (d, J - 16 Hz, PCH2OT2 ), 32.99 (s, CH2 CH2Br), 34.56 
(s, OT2Br), 61.33 and 61.60 (d, J - 6 Hz, OOT2 ); ? ^  (neat)
6 30.69 (s).
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Die.thyl-2~acetamido-2- [dlethyl~5-phosphonopentyl 1-malonate (42)
Diethyl acetamido maionate (10.7 g, 0.05 mol) was added to a 
solution of sodium (1.2 g, 0.05 mol) in ethanol (20 ml). The solvent 
was evaporated, in vacuo, and the residue washed with toluene (3 x 20 ml) 
to give diethyl sodiomalonate (13 g, 0.05 mol) which was suspended in 
toluene (40 ml) and diethyl carbonate (40 ml). Bromopentyl phosphonate 
(3 9 ) (15.59 g> 0.05 mol) was added, the mixture heated under reflux 
overnight, filtered hot, and solvent evaporated, in vacuo, to give a 
dark yellow oil (25 g). Chromatography on silica gel (400 g) using 
ethyl acetate/diethyl ether 4 : 1 0  eluant afforded the acetamido adduct 
(42) (12 g, 52Z) as a viscous yellow oil.
(¿)-2-Amino~7-phosphonoheptanoic acid (APH) (13)
A solution of the acetamido adduct (42) (12 g, 0.03 mol) in 6M HCl 
(100 ml) was heated under reflux for 12 hours. The solvent was 
evaporated, in vacuo, and the residue dissolved in methanol. Propylene 
oxide was added until no further precipitate formation was apparent. 
Filtration and tecrystallisation from water-ethanol yielded (±)-APH (13) 
(4.5 g, 70Z) as white crystals: mp 213»C (with decomposition! lit. mp 
228°C^®); NMR (H^O) « 22.05 and 22.27 (d, J - 4.9 Hz, PCH^CH^CH^),
23.46 (s, P(CH2)3£H2), 24.16 and 30.12 (d. J - 134 Hz, PCH^) , 29.20 and 
30.12 (d. J . 20.8 HZ. PCHjCHj). 30.12 (s. CH^CHNH^) . 53.63 U  . CHHH^). 
172.87 (s. CO^H); « 31.77 (s). Anal, calcd. for C^H^^NOjPi
C. 37.33i H. 7.16; N. 6.22, P. 13.76. Found: C. 37.13, H, 7.29,
N, 6.11; P, 13.76.
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Resolution of (±)-2-amino-7-pho8phonoheptanoic acid (13)
A solution of L-lysine (3.21 g, 0.022 mol) and (±)-APH (13) (5 g, 
0.022 mol) in water (22 mis) was heated gently (60®C) for 15 minutes 
and methanol was added until the initial appearance of a flocculent 
precipitate. The mixture was cooled, diethyl ether added until the 
onset of a slight cloudiness and left at -10®C overnight. The precip­
itate was filtered to give the (-)-APH-lysine salt (3.80 g, 46Z) which 
was taken up in 2M pyridine and poured onto an ion-exchange resin 
column (Dowex 50, pyridinium form). The column was eluted with 2M 
pyridine, all ninhydrin positive fractions were combined, evaporated, 
in vacuo, the residue washed with methanol and the solvent evaporated, 
in vacuo. to afford (-)-APH (2.1 g): [o“ gl - -7* (c - 10, H^O).
The mother liquor from the above filtration was poured onto an 
ion-exchange resin column (Dowex 50, pyridinium form) and (+)-APH 
(1.88 g) was isolated as above: * +7.5* (c - 5, H 2O).
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5 .2 Quinolinic Acid Analogues
2.3“Pyridinecarbo3cylic anhydride (70)17
Concentrated HCl (8 ml) was added to a stirred solution of quinolinic 
acid (4 4) (50 g, 0 . 3 mol) in acetic anhydride ( 1 1 0 ml); over two hours at 
65®C. The mixture was then poured into carbon tetrachloride (1 1) and 
the precipitated solid was crystallised from ethylacetate-hexane to 
give the anhydride (70) (29.7 g, 67Z): mp 136®C (lit. mp 136-138®C^^); 
IR (nujol) 3400, 3150, 1690, 1630, 1580, 760 cm
172-Carbomethoxy-3“carboxypyridine (71)
A solution of anhydride (70) (21.74 g, 0.15 mol) in methanol (115 ml) 
was heated under reflux overnight, solvent was evaporated, in vacuo, and 
the oily residue dissolved in hot water. On cooling to O'C, ester (71) 
precipitated and recrystallisation from water and then ethyl acetate 
gave ester (71) (15.84 g, 60Z): mp 122-125'“C (lit. mp 125-126*0 ):
IR (nujol) 3540, 1730, 1620, 1580, 1300, 1210, 1160, 1090, 900, 760 cm'^ 
NMR (DjO) 6 4.48 (s, 3H, CO^CHj)» 8.25 (dd, J ■■ 5.13 Hz and 8 Hz, 1 , 
C5H), 8.81 (dd, J ■ 1.6 Hz and 8 Hz, IH, C4H), 9.19 (dd, J ■ 1.6 Hz and 
5.13 Hz, C6H); NMR (H^O) 6 154.34 (CO^CHj), 127.47 (05), 129.86 (03),
139.77 (04), 147.25 (02), 150.66 (06), 167.72 (CO^OHj), 169.99 (CO^H).
2-0arbomethoxv-3-[l'-chloro-l'-o%o-methyl1-pyridine (72)_
A solution of ester (71)(6 g, 0.033mol) in redistilled thionyl chloride 
(70 ml) was heated under reflux for five hours. The solvent was 
evaporated, in vacuo, to give the acyl chloride (72) (6.5 g, 98Z): IR 
(liq. film) 2950, 1785, 1750, 1560, 1300, 1200, 1140, 1100, 880, 710
cm-1
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2-Carbomethoxy~3-[2*~dia20-l*-oxo-ethyl]-pyridine (73)^^
A solution of the acyl chloride (72) (6.5 g, 0.033 mol) in dich-
2loromethane (20 ml) was added drop-wise to a solution of diazomethane 
(1.5 g, 0.036 mol) in ether (180 ml), with stirring at 0*C. Solvent 
was evaporated, in vacuo, to give the diazoketone (73) (6.7 g, lOOZ) as 
a dark brown oil: IR (Uq. film) 3600, 3400, 3100, 2950, 2100, 1740,
1620, 1360, 1210, 1140, 880, 710 cm’ .^
2-Carbonwthoxy-3-[2'-^trboiiethoxy-ethyl]-i>yridiTie (74)
A paste of silver (1) oxide (15 g, 0.065 mol) in methanol was 
added, portion-wise, to a solution of diasoketone (73) (6.7 g, 0.033 mol) 
in methanol (120 ml) with stirring at 50*C. VIhen evolution of nitrogen 
ceased, the mixture was filtered with Celite (3 times) and solvent evaporated, 
in vacuo. The residue was chromatographed on silica gel (100 g) using 
ethyl acetate as eluant to afford the diester (74) (4.99 g, 72Z) as a 
pale yellow oil: IR (Uq- 2940, 1730, 1560, 1430, 1300, 1 2 0 0 ,
1170, 1090, 1000, 720 cm*^ Si NMR (CCl^) 6 3.71 (s, 3H, CH^CO^CHj), 
3.96 (s, 3H, CO^CHj), 4.4 (s, 2H, CH^CO^CHj), 7.38 (m, IH. C5 H), 7.58 
(m, IH, C6 H), 7.62 (m. IH, C4 H); NMR (CCl^) 6 38.73 (OT^CO^CHj),
52.06 (CH^COjCHj), 52.22 (CO^GHj), 125.79 (C5), 131.64 (C3), 139.7 
(C4), 148.06 (C6 ), 148.44 (C2), 166.31 (CO^CHj), 170.17 (CHjCO^CHj), 
mess spectrum, m/e 209 (M*), 150 (M - 0 0 ,0 8 3 ), 92 (M*-2(0 0 ,0 8 3 )) , calcd. 
for O3 0 8 3 3 NO4 209.206, found 209.0712. Anal, calcd. for 0 ,0 8 ,3 8 0^:
0, 57.41; 8 , 5.3; N, 6.69. Found: 0, 57.21; 8 , 5.28; N, 6.44.
of diester (7 4 ) u-lnf, cupper (D iodide
Oopper (I) iodide (3.43 g, 18 mmol) was added to a solution of the 
diazoketone (73) (1.87 g, 9 mmol) in dry acetonitrile/methanol 5:1 
(100 ml) heated at 65 - 70°0 for four hours. The mixture was
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cooled, filtered and the solvent evaporated, in vacuo, to give a dark 
brown residue. Chromatography using ethyl acetate eluant on silica 
gel (30 g) afforded the diester (74) (260 mg, 15Z) as a yellow oil, which 
was characterised as above.
2»(^rboxy*3 ~ [ 2 *-carboxy-ethyl]-pyridine (45) [Homoquinolinic acid]
A solution of the diester (74) (300 mg, 1.4 mmol) in sodixim 
hydroxide (O.IM, 14 ml) was heated under reflux for four hours. The 
mixture was allowed to cool to room temperature, hydrochloric acid 
(O.IM, 15 ml) added and the solution poured onto an ion-exchange resin 
column (Dowex 50 (h "^ )). The resin was eluted with water, the solvent 
evaporated, in vacuo, and the residue recrystallised from water-ethanol 
to yield the acid (45) (190 mg, 73Z) as tan crystals: mp 186-187‘’C (lit. 
mp 187«C^^); IR (nujol) 3450, 1710, 1640, 1600, 1335, 1240, 1210, 1180, 
1160, 1100, 935, 800, 710 cm“S  fMR (D^O) 6 4.26 (s, 2H, CH^CO^H), 
8.04 (dd, J ■ 5.6 Hz and 8 Hz, IH, C5H), 8.51 (dd, J “ 1«5 Hz and 8 ,
IH. C4H), 8.67 (dd, J - 1.6 Hz and 5.6 Hz. C6H) : (H^O) 6 38.68
(OT^COzH). 128.01 (C5). 134.68 (C3). 139.99 (C4). 145.62 (C2). 150.39 
(C6 ). 164.09 (CO^H). 174.71 (CH^O^H) i mass spectrum, m/e 181 (M),
163 (M-H^O), 137 (M-CO,) 91 (M-CH^CO^H and CO^H) . Anal, calcd. for
CAH0,.H,0: C. 48.24, H. 4.55, N. 7.11. Found: C. 48.44, H.
8 7 4 2
4.25; N, 7.11.
2-Carbomethoxy-3-hydroxymethyl pyri<^ ^^ g—(762_
TO a stirred solution of the ester (71) (1.6 g. 9 mmol) in THF
(40 ml), borane-tetrahydrofuran complex (IM. 12 ml) was added, under 
nitrogen at 0«C. After 30 minutes the solution was allowed to warm to 
room temperature and left overnight. The mixture was diluted with 
water (40 ml), basified with sodium bicarbonate and evaporated, in
„ . u .  » .  »  .. « »  • »
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(50 ml) and the ethylacetate layer discarded. The aqueous layer was 
acidified with concentrated HCl, poured onto an ion-exchange resin 
column (Dowex 50 (H*)), eluted with water and the eluate evaporated, 
in vacuo. Recrystallisation from water-ethanol gave the alcohol (76) 
(0.97 g, 65%) as white crystals: NMR-(D2O) 6 3.96 (s, 3H, CO2CH2 ),
7.92 (dd, J - 5.13 Hz and 7.8 Hz, IH, C5H), 8.47 (dd, J * 1.5 Hz and 
7.8 Hz, IH, C4H), 8.83 (dd, J - 1.5 Hz and 5.13 Hz, IH, C6H): mass 
spectrum, m/e 167 (M), 149 (M-H^O), 123 (M-CO^), 105 (M-CO^CHj and
H.O) , 77 (M-CH^OH and CO^CHj) .
2— [2*-hvdroxy-2'-phenyl-ethyl 1-3-methyl-pyridine (87)
n-Butyllithium (55 lal, 93 mnol) was slowly added to a stirred 
solution of 2,3-lutidine (10 g, 93 mmol) in THF (50 ml) under nitrogen 
at -20°C. The mixture was allowed to warm to room temperature, after 
30 minutes, benzaldehyde (15 ml, 93 mmol) was added dropwise at 0»C.
The mixture was again allowed to warm to room temperature. The 
colourless mixture was poured into ethyl acetate (60 ml) and water 
(45 ml) and IM HCl (45 ml) added. The aqueous layer was basified with 
.880 ammonium hydroxide and the organic layer was separated. The 
aqueous phase was extracted with mote ethyl acetate (3 x 100 ml). The 
combined extracts were dried (Na^SO^), filtered and solvent evaporated, 
in vacuo, to afford a yellow oil. Chromatography on silica gel (260 g) 
using diethyl ether as eluant gave the pure alcohol (87) (17 g, 85%) as 
white crystals: mp 63«C; IR (CH^Cl^) 3A0O, 3070, 3040, 2930, 2870, 
1725, 1690, 1630, 1590, 1565, 1455, 1275, 1210, 1110, 1080, 1045, 1030, 
740, 700 cm"^: ^  «MR (oicij) 6 2.20 (s, 3H, CHj) , 3.05 (m, 2H,
CH^CHPh), 5.28 (dd, J - 4.64 Hz and 7.56 Hz, IH, CHPh), 7.10 (dd, J - 
4.64 HZ and 7.57 Hz, IH, C5H) , 7.36 (m, 6H, CHPh and C4H), 8.38 (dd,
J - 1.2 Hz and 4.64 Hz, IH, C6H); mass spectrum, m/e 214 (M ), 196
(M*_H20), 170 (M-CHOHPh), 92 (M^-CH^CHOPh). Anal, calcd. for C^^H^gNO:
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C, 78,84; H, 7.09; N, 6.57. Found: C, 78.81; H, 7.2; N, 6.42.
3-Methy1~2[-2 *-phenyl-ethenyl]-pyridine (8 8 )
A 100 ml round bottomed flask fitted with a condenser and a Dean 
and Stark trap, was charged with the alcohol (87) (300 mg, 1.41 mmol), 
tosic acid (600 mg, 3.15 mmol) and toluene (15 ml). The mixture was 
heated under reflux overnight. On cooling, the mixture was poured 
into ethyl acetate (15 ml) and water (15 ml) ; the aqueous layer was 
basified with .880 ammonium hydroxide and the organic layer separated. 
The aqueous phase was extracted with more ethyl acetate (3 x 20 ml).
The combined ethyl acetate extracts were dried (Na2S0 ^), filtered and 
solvent evaporated, in vacuo. Chromatography on silica gel (8 g) 
using hexane/diethyl ether 5:1 eluant afforded the alkene (8 8 ) (270 mg, 
98Z) as a yellow oil; IR ( l i q .  film) 3060, 3030, 2980, 2930, 2860, 
1690, 1635, 1590, 1580, 1560, 1490, 1450, 1420, 1380, 1330, 1275, 1220, 
1100, 1075, 1030, 970, 770, 740, 690 cm“^; NMR (CDCl^) 6 2.43 (s, 
3H, CH3 ),* 7.05 (dd, J - 4.76 Hz and 8 Hz, IH, C5H), 7.40 (m, 6H, Clffh 
and C4H), 8.46 (dd, J - 1.5 Hz and 4.64 Hz, IH, C6H); mass spectrum, 
m/e 195 (M), 117 (M*-Ph), 105 (M*-CHPh), 91 (M-CHCHPh), caled, for 
^4^13^ 195.265, found 195.1041 . Anal, caled, for C, 86.12;
H, 6.71; N, 7.17. Found: C, 86.03; H, 6 .6 8 ; N, 6.89.
* 6.9 (m, 2H, HC-CH)
2-Carboxy"3-methylpyridine (89)_
Ozone was passed through a stirred solution of the alkene (8 8 ) 
(9 . 3 3  g. 0.05 mol) in methanol at room temperature, until the solution 
became colourless. The solvent was evaporated. inj«cuo. and recrys­
tallisation from dichloromethane-hezane yielded the acid (89) (A.3 g. 
65X) as white crystals; mp llO'C (lit. mp 1H*C ); 4  NMR (CDClj)
5 2.71 (s. 3H. CHj). 7.95 (dd. J - 5.66 Hz and 8.3 Hz. IH. C5H) . 8.52
(m, 2H, C4H and C6H). 148
C, 78,84; H, 7.09; N, 6.57. Found: C, 78.81; H, 7.2; N, 6.42.
3-Methy 1-2 [-2 * -phenyl-etheny 1 ] -pyridine (8 8 )
A 100 ml round bottomed flask fitted with a condenser and a Dean 
anti Stark trap, was charged with the alcohol (87) (300 mg, 1.41 mmol), 
tosic acid (600 mg, 3.15 nmol) and toluene (15 ml). The mixture was 
heated under reflux overnight. On cooling, the mixture was poured 
into ethyl acetate (15 ml) and water (15 ml) ; the aqueous layer was 
basified with .880 ammonium hydroxide and the organic layer separated. 
The aqueous phase was extracted with more ethyl acetate (3 x 20 ml).
The combined ethyl acetate extracts were dried (Na2S0 ^), filtered and 
solvent evaporated, in vacuo. Chromatography on silica gel (8 g) 
using hexane/diethyl ether 5:1 eluant afforded the alkene (8 8 ) (270 mg, 
98Z) as a yellow oil; IR (liq. film) 3060, 3030, 2980, 2930, 2860, 
1690, 1635, 1590, 1580, 1560, 1490, 1450, 1420, 1380, 1330, 1275, 1220,
1100, 1075, 1030, 970, 770, 740, 690 cm 
*
-1 NMR (CDClj) 6 2.43 (s.
3H. CH3),* 7.05 (dd, J - 4.76 Hz and 8 Hz, IH, C5H), 7.40 (m, 6H, c m  
and C4H), 8.46 (dd, J - 1.5 Hz and 4.64 Hz, IH, C6H), m s s  spectrum, 
m/e 195 (M), 117 (M*-Ph), 105 (M*-CHPh), 91 (M-CHCHPh), caled, for 
C1 4 H1 3N 195.265, found 195.1041. Anal, caled, for C3 4H3 3N: 0,86.12;
H, 6.71; N, 7.17. Found: C, 86.03; H, 6 .6 8 ; N, 6.89.
* 6.9 (m, 2H, HC-CH)
2-Carboxy-3-methylp7ridine (89^
ozone was passed through a stirred solution of the alkene (8 8 ) 
(9 . 3 3  g, 0.05 mol) in methanol at room temperature, until the solution 
became colourless. The solvent was evaporated, inj«cuo, and recrys­
tallisation from dichloromethane-hexane yielded the acid (89) (4.3 g, 
65Z) as white crystals, mp llO'C (lit. mp lll'C ^^“); ^  «DCI 3)
5 2.71 (s, 3H, CH3), 7.95 (dd, J - 5.66 Hz and 8.3 Hz, IH, C5H), 8.52
(m, 2H, C4H and C6H).
2-Carbomethoxy-3-methylpyridine (90)
Dicyclohexylcarbodiimide (721 ng, 3.5innol), dimethylaminopyiridine 
(3,8 mg» 0.004 nmol) and a solution of methanol/dichloromethane (3ml) 
vere added to a suspension of the acid (89) (480 mg» 3,5 mmol) in 
pyridine (7 ml) with stirring for 12 hours at room temperature. The 
mixture was then filtered to remove dicyclohexyl urea. After the 
solvent had been evaporated» in vacuo» the residue was taken up xn a 
volume of dichloromethane» the solution cooled at -10°C for a 
few hours to precipitate any residual urea and filtered. The solvent 
was evaporated» in vacuo» and the residue chromatographed on silica gel 
(10 g) using hexane/ethyl acetate 1:1 eluant to give the ester (90)
2 1a,
(424 mg» 80Z) as a colourless oil: bplOS'C (lit. bp 102-103”C 15 mmHg ); 
IR (liq. film) 2960-2860» 1730» 1675» 1570» 1440» 1385» 1300» 1230» 1200» 
1140» 1100» 790» 710 cm"^: HMR (CDCI3) « 2.60 (s» 3H» CH3) » 3.98
(S» 3H» CO3CH3)» 7.35 (dd» J -4Hz and 7.8 Hz» 1H» C5H)» 7.63 (dd» J -
1.5 Hz and 7.8 Hz» 1H» C4H) » 8.56 (dd» J - 1.5 Hz and 4.4 Hz» 1H» C6H).
3-Methvl-2-r3'-carbomethoxv-l'-oxo-propyl1-pyii<iine (98)_
Hexamethylphosphoramide (HMPA) (0.085 ml» 0.44 nmol) was added to
a stirred solution of LDA (0.44 ml» 0.44 nmol) in THF (2 ml) under
nitrogen at -10»C. A solution of the ester (90) (60 mg» 0.4 mmol) in
THF (1 ml) was added dropwise to the mixture. After 30 minutes the
mixture was allowed to warm to 0“C» methylbromoacetate (0.05 ml» 0.6
nmol) was added» the mixture allowed to warm to room temperature and
left overnight. The solvent was evaporated» inj^cuo» to give a dark
brown oil (480 mg). Chromatography on silica gel (8 g) using diethyl
ether/hexane 2:1 eluant afforded the ester (98) (10 mg» 122) as a brown
oil: ^H NMR (0 X ^ 3 ) 6 1.01 (s» 3H» OCH3)» 2.57 (s» 3H» . 3.8 (m»
2H» OT,)» 7.31 (dd» J - 4.6 Hz and 7.8 Hz» IH» C5H)» 7.60 (dd» J
1.7 Hz and 7.8 Hz» IH» C4H)» 8.55 (dd» J » 1-7 Hz and 4.6 Hz» IH» C6H):
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mass spectrum, ta/e 193 (M) , 92 (M-COCH^CO^CHj), calcd. for 
193,205, found 193.603.
3-Methylpyridine“2~carboxylic acid, benzyl ester (100)
To a stirred solution of LDA (0.36 ml of IM solution) in THF (3 ml). 
HMPA (0.07 ml, 0.36 mmol) was added under nitrogen at -10°C. A solution 
of the ester (90) (50 mg. 0.33 mmol) in THF (2 ml) was added and after 
50 minutes the solution was allowed to warm to 0»C. The mixture was 
recooled, benzyl bromide (0.1 ml, 0.72 mmol) added and after 2 hours 
allowed to warm to room temperature and stirred overnight. The solvent 
was evaporated, in vacuo, and the residue chromatographed on silica gel 
(5 g) using hexane/diethyl ether 2 : 1 eluant to give the benzyl ester 
(100) (40 mg. 50Z): IR (Uq- fü") 30” . 2980-2860, 1730. 1540, 1500, 
1450. 1375, 1300. 1230. 1200. 1140, 1100. 790, 740. 700 cm'S NMR 
(CDCI3 ) « 2.55 (s. 3H. Œ 3 ). 5.44 (s. 2H. OT^Ph). 7.3 ,(m. 7H. CH^Pb.
C4H and C5H), 8.54 (dd. J - 1.7 Hz and 4.6 Hz. IH. C6H); mass spectrum, 
m/e 228 (M*), 121 (M^-OCH^Ph), 93 (M^-CO^CH^Ph).
3-HvdroxYmethvl-2-methvl pyridine (104)
To a stirred suspension of lithium aluminium hydride (1.38 g,
38 mmol) in dry diethyl ether (200 ml) was added dropwise. at 0"C, a- 
solution of the ester (103) (8 g, 48 mmol) in ether (100 ml). After 
the addition, the mixture was allowed to warm to room temperature over 
a period of 45 minutes, before being heated under reflux for 30 minutes. 
Water (5 ml) was cautiously added to the cooled solution and the 
resulting precipitate filtered and washed with more diethyl ether (2 x 
100 ml). Drying (Na^SO^). filtration and evaporation, invacuo. of 
the filtrate afforded a pungent oil (8.3 g). Chromatography on silica 
gel (80 g) using diethyl ether as eluant gave the alcohol (104) (4.9 g.
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92Z) as a white solid: NMR (CDCl^) 6 2.50 (s, 3H, CH^), 3.56
(broads, IH, OH), 4.7. (s, 2H, CH^OH), 7.13 (dd, J - 4.9 Hz and 7.8 
Hz, IH, C5 H), 7.74 (dd, J - 1.7 Hz and 7.8 Hz, IH, C4H), 8.32 (dd, J - 
1.7 Hz and 4.9 Hz,* IH, C6 H).
Reaction of alcohol (104) with phosphorus tribromide
To a stirred solution of the alcohol (104) (369 xng» 3 mmol) in 
dry diethyl ether (12 ml) was added dropwise phosphorus tribromide 
(810 mg, 0.28 ml, 3 nmol), under nitrogen, at 0*C. The mixture was 
stirred for 4 5 minutes when no more starting material was apparent 
(TLC). The mixture was poured onto ice (10 g) and the whole extracted 
with diethyl ether (5 x 30 ml). The extracts were washed with 
aqueous sodium bicarbonate (2 x 20 ml) , water (2 x 25 ml), dried 
(Na2 S0 ^) and filtered. Evaporation of the solvent, in vacuo, led to 
a red solid. TLC analysis of the reaction mixture, before and after 
work-up, had shown a spot (R^ 0 . 8 in diethyl ether; starting material 
0 . 3 5 in diethyl ether) which was not in evidence on evaporation of
solvent.
3-r2'.2'-DWrbethoxyethYl1-2-nethyl pyridine (106)
A mixture of 2 ,3-lutidine (8 6 ) (2.14 g, 20 tnol) and N-bromo- 
succinimide (4.27 g. 2 2 m »!) in carbon tetrachloride (80 ml) containing 
a trace of azobisisobutyronitrile (660 mg. 4 mmol) was heated under 
reflux, with lamp irradiation for 90 minutes. The mixture was then 
concentrated to about 2/3 volume and added, dropwise. to a refluxing 
solution of diethyl potassiomalonate (prepared from potassium t-butoxide 
(6.72 g. 60 nmol) and diethyl malonate (9.6 g. 60 mm.D) in THF (150 ml), 
under nitrogen. The resulting mixture was stirred and heated under 
reflux for another 2J hours. The solvent was evaporated, inj^acuo. to
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give the malonate adduct (106) (2.98 g, 56Z) as a yellow oil: H
NMR (CDCl^) 6 1 . 2 (t, J - 7 Hz, 6H, 2 X OCH2CH^j), 2.58 (s, 3H, CH^) ,
3.24 (d, J - 8 Hz, 2H, CH2CH(C0 2Et)2 ), 3.58 (m, IH, (^^(»(CO^Et)^),
4.20 (q, J - 7 Hz, 4H, 2 x OCH^ 2^H3), 7.05 (m, IH, C5 H), 7.50 (m, IH,
C4 H), 8.4 (m, IH, C6 H). Anal, calcd. for C^4Hi9N0 4 i C, 59.72;
H, 7.94; N, 5.80. Fotmd: C, 59.68; H, 8.21; N, 5.92.
A sample ('x* 250 mg) was chromatographed on silica gel (5 g) using 
diethyl ether/hexahe (1 :3 ) eluant, but the bulk of the adduct (106) was 
used in the next reaction without further purification.
3 - [ 2 *~Carboxyethyl]•“2-methyl pyridine (107)
The oalonate adduct (106) (2.6 g, 9.8 nmol) and concentrated 
hydrochloric acid (50 ml) were heated under reflux for 18 hours. The 
mixture was evaporated to dryness, the residue dissolved in water (25 rf) 
and chromatographed on ion exchange resin (Dowex 50 [H*] using water as 
eluant. All UV (254 nm) active fractions were combined and evaporated. 
in vacuo, to afford a solid. Recrystallisation from water/ethanol 
gave the pure acid (107) (1.42 g. 882): NMR (D^O) 6 2.55 (t, J -
7.5 Hz, 2H, CHjCHjCO^H), 2.74 (s, 3H, CH^) , 3.05 (t, J - 7.5 Hz,
N r«; H') 8 3 (m. 2H, C4 H and C6 H). Anal.CH2CH2CO2H), 7.7 (m, IH, C5 h ;, o.J V ,
« u ft 71* N 8.48. Found; C, 65.29;calcd. for 65.43; H, 6.71, N,
H, 6.77; N, 8.61.
,-r.rHnrnethoxv-3-frM-2’-carfaethoxy-ethyl)amidol pyridine ( 1 ^
Glycine ethyl ester hydrochloride (2.09 g. 15 » o D . dicyclohexyl- 
carbodiimide (4.12 g, 20 mmol) and dimethylaminopyridine (0.18 g. 1.5 
«„,1 ) were added to a stirred solution of the ester (22) (2.86 g. 15 
mmol) in dichloromethane (60 ml) and pyridine (5 ml). The 
was stirred overnight at room temperature. The solvent was evaporated.
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vacuo, the residue taken, up in a minimum volume of dichloromethane 
and the solution cooled at -10*C for a few hours to precipitate dicyclo­
hexyl urea and filtered. The solvent was evaporated, in vacuo, and 
the residue chromatographed on silica gel (20 g). Initially using 
diethyl ether/ethyl acetate 2:1 eluant afforded the anhydride (70)
(1.26 g): mp 136®C. Diethyl ether/ethyl acetate 1:2 as eluant gave 
the ester (111) (900 mg, 24Z): IR (liq. film) 3300, 3040, 2960, 2925, 
1740, 1650, 1300, 1200, 1170, 1130, 1020 , 990 , 710 cm"^; SMR (CDCI3) 
« 1.32 (t, 3H, CHjCHj), 3.99 (s, 3H, CO^CHj), 4.27 (m, 9H, CH3CH3 and 
CH,C0,Et), 6.69 (broads, IH, HH), 7.52 (dd, J - 4.6 Hz and 7.8 Hz, IH,
C5 H), 7.97 (dd, J - 1.7 Hz and 7.8 Hz, IH, C4 H), 8.77 (dd, J - 1.7 Hz 
and 4.6 Hz, IH, C6 H) j mass spectrum, m/e 251 (M) , 233 (M-H^O), 161
(M-CO^CjHj), 106 (M-CONHCH3CO3C2H5).
2-Carboxv-3-f(H-2 '-carbozyethyl)amido]pyridine (47)
A solution of the ester (111) (800 g, 3.6 mmol) in 4M sodium 
hydroxide (3 ml) was stirred overnight at 60«C. The mixture was 
allowed to cool to room temperature, poured onto an ion exchange resin 
column (Dowex 50 [H*]) which was then eluted with water. Acidic 
fractions were corf.ined, evaporated, in vacuo, and recrystallised from 
water-ethanol to give the acid (47) (690 mg, 8 6 Z) as white crystals: 
mp 203»C; IR (nujol) 3600, 3400, 1940, 1720, 1640-1560, 1230, 1160, 
950, 825, 720 cm'S (MR (D^O) 6 4.24 (s, 2H, CH^CO^H), 7.78-8.99 
(m, 3H, C4 H, C5 H and C6 H); HMR (H^O) 6 42.0 (CH^), 128.3 (C5),
133.3 (Cl), 145.2 (C4), 145.6 (C2), 147.6 (C6 ), 169.8 (CONH), 172.0 
(CO^H) ; mass spectrum, m/e 224 (M\ 207 (M-H^CHl), 161 (.a-CO^H and 
-H3O), 105 (M-CO^H and -NHCH^CO^H), 78 (M-CO^H and -COHHCH^CO^H).
Anal, calcd. for CgH^NOj: C, 41.52: H, 4.65: N, 10.77. Found:
C, 41.37; H, 4.57; N, 10.6
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5.3 Tricholomic acid
Benzyl carbamate (141)
Benzyl chlorofonate (15 ml, 0.11 mol) was added slowly to 0.880 
ammonium hydroxide (60 ml) at O’C, with vigorous stirring. The mixture 
was allowed to warm to room temperature, left for 30 minutes, filtered, 
the solid washed with water and dried, in vacuo, to give benzyl car­
bamate (141) (14.13 g, 85Z) as white crystals: mp 86° (lit.-mp 86°c:^ ;
IR (nujol) 3400 , 3320 , 3260, 1690, 1610, 1400, 1070 , 730 cm H NMR 
(CDClj) 6 5.08 (s, 4H, NH^CO^CH^Ph), 7.34 (s, 5H, CH2 2 1 ) •
w-::.„,,1nxy.arbonvl-2-aminotetrahvdro-5-oxo-2-furan carboxylic acid (1422
A 250 ml, two-necked flask equipped with a thermometer and a conden­
ser was charged with finely powdered benzyl carbamate (141) (16 g, 0.11 
mol) and 2-keto-glutaric acid (22 g, 0.15 mol) . The mixture was 
vigorously stirred and heated, at 85-90°C, under reduced pressure (10- 
15 mmHg) for two hours. The solid residue was recrystallised from
ethyl acetate to give the lactone acid (142) (20.7 g, 70Z) as white
109crystals: rap 175*C (lit. rap 176*C ).
-N-benzv1 nxvcarbonYl-2-aminotetrahydro-5-oxo-2-furan
carboxylate (143)
TO a stirred solution of lactone acid (142) (8.37 g, 30 ™.l) in
ethyl acetate (50 ml), triethylamine (6.9 ml, 50 mmol) was added drop-
wise at 60°C. Benzyl bromide (3.9 ml, 33 mmol) was added after 10
minutes. The mixture was heated under reflux for 3 hours, filtered
and the solvent evaporated, i n ^ -  The resulting oil was triturated
j « ,.«rrvatallised from dichlororaethane-hexane to give with hexane and then recrystaiiisea itum
a. fa 3 2 75%) as white crystals: rap 117-118*C;the lactone ester (143) g» *
icznn 715 cm“^; H NMR (CDCl,,)IR (nujol) 3260, 1745. 1710, 1500, 1130, 715 era 3
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6 2.73 (m, 4H, CH^OTj) , 5 . U  (s, 2H, CCO^CH^Ph), 5.24 (d, J - 3 Hz, 2H, 
CNHCO.CH^Ph), 6.51 (broad s,lH, CNHOT2‘'H2^ ^ ' ^ •'CO^CH^Ph 
and CNHCO-CH^Ph)
H-BenzYlo3cycarbonYl-l-benzyl-(Z)-2.3-dehydroglutainate (144)
To a solution of the lactone ester (143) (4.74 g, 13 nmol) in dry 
THF (20 ml) cooled to 0*C and under nitrogen, 1,5- diazabicyclo 15:4.0] 
undec-5-ene (DBO) (4 ml, 26 mmol) was added dropwise and the resulting 
solution stirred for 30 minutes. The mixture was allowed to warm to 
room temperature, diluted with water/ethyl acetate 1:1 (300 ml), the 
aqueous layer was acidified with IM HCl and the ethyl acetate layer 
separated. The aqueous phase was extracted with mote ethyl acetate 
(3 X 30 ml). The combined extracts were dried (NaSO^), filtered and 
solYent evaporated, in vacuo, to give a pale yellow oil. Crystallis­
ation from dichloromethane-hexane yielded the dehydroglutamate (144) 
(3.3 g, 71Z) as slightly-yellow crystals: mp 115-116«C (lit. mp 115- 
117*C^Si IR (nujol) 3400 , 3260, 1720, 1680, 1060 , 730 cm‘S  NMR
(CDCI3) 6 3.3 (d, J = 7 HZ, 2H, CH^CO^H), 5.11 (s, 2H, CO^CH^Ph), 5.17 
(s. 2H, NHC0 2 CH2 Ph), 6.78 (t, IH, CH^CH), 6 . 8 6 (broad s, IH, NH), 7.32 
(s, lOH, 2xSi) 10.05 (s, IH, CO^H). Anal, calcd. for C^QH^jHOg: C,
65.03; H, 5.18; N, 3.79. Found: C, 64.92; H, 5.16; N, 3.79.
TO a vigorously stirred suspension of benzyl chloroformate (17.05 g, 
0 . 1 mol) in ethyl acetate (80 ml) and water (80 ml) was added hydroxyl- 
amine hydrochloride (8.34 g, 0.12 mol), at 0«C. Sodium bicarbonate 
(25.44 g, 0.24 mol was slowly added, the mixture allowed to warm to
room temperature and was left overnight. The aqueous layer was
a. A uri and the ethyl acetate layer separated, acidified with concentrated HCl and the y
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The aqueous phase was extracted with mote ethyl acetate (3 x 100 ml). 
The combined extracts were washed with brine (60 ml) , dried (Na2S0 ^) > 
filtered and the solvent evaporated, in vacuo, to yield a colourless 
oil which solidified on standing. Recrystallisation from hexane- 
diethyl ether afforded the hydroxylamine (145) (10 g, 50Z).
N-BenzYloxycarbonvl-O-t-butvldimethylsilyl hydroxvlamine (146)
t-Butyldimethylsilyl chloride (2.89 g, 19.2 mmol) and imidazole 
(3.92 g, 5 7 . 6 ranol) were added to a stirred solution of the hydroxyl­
amine (145) (3.7 8 . 19.2 mnol) in dimethylformamide (50 mis), at room 
temperature, under nitrogen. The mixture was left for 24 hours, 
diluted with ethyl acetate (30 ml) and water (15 ml) and the ethyl 
acetate layer was separated. The aqueous phase was extracted with 
more ethyl acetate (3 x 30 ml). The combined ethyl acetate extracts 
were dried (Na^SO^), filtered, and the solvent evaporated, i° vacuo. 
Chromatography on silica gel (80 g) using hexane/diethyl ether 3:1 
eluant gave the silylated hydroxylamine (146) (3.54 g, 6 8Z) as a
yellow oil.
N-Benzy loyvcarbony l-l-benzyl- (Z) -2,3-dehydro-^
NeH-diisopropylamido glutamate (149)^
A solution of dehydroglutamate (144) (55 mg, 0.15 mmol), N-hydroxy- 
succinislide (17 mg, 0.15 sm»l) and OCC (31 mg, 0.15 » o D  in dichloro- 
methane (3 ml) was stirred for 30 minutes under nitrogen at room 
temperature. Oiisopropylamine (148) (0.033 ml, 0.24 sm.ol) was then 
added, the mixture left overnight, filtered and solvent evaporated, in
the solution cooled at -10«C for a few hours, filtered and the solvent
evaporated, in vacuo. The residue was chromatographed on silica gel
(5 g) using hexane/diethyl ether 2:1 eluant to give the amide (149)
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The aqueous phase was extracted with more ethyl acetate (3 x 100 ml). 
The comhined extracts were washed with brine (60 ml) , dried (Ha^SO^) , 
filtered and the solvent evaporated, in vacuo, to yield a colourless 
oil which solidified on standing. Recrystallisation from hexane- 
diethyl ether afforded the hydroxylamine (145) (10 g, 601).
N-Beozvloxycarbonvl-0-t-butvldimethvlsilyl hydroxvlamine (146)
t-Butyldimethylsilyl chloride (2.89 g, 19.2 mmol) and imidazole 
(3.92 g, 5 7 . 6 mnol) were added to a stirred solution of the hydroxyl- 
amine (145) (3.2 g, 19.2 mmol) in dimethylformamide (50 mis), at room 
temperature, under nitrogen. The mixture was left for 24 hours, 
diluted with ethyl acetate (30 ml) and water (15 ml) and the ethyl 
acetate layer was separated. The aqueous phase was extracted with 
more ethyl acetate (3 x 30 ml). The combined ethyl acetate extracts 
were dried (Na^SO^), filtered, and the solvent evaporated, in_vacuo. 
Chromatography on silica gel (80 g) using hexane/diethyl ether 3:1 
eluant gave the silylated hydroxylamine (146) (3.54 g, 6 8Z) as a
yellow oil.
N-Benzyloxvcarbony 1-1-benzyl- (Z) -2,3-dehydro-5^
NeN-diisopropylamido j^ lutamate (1^ ?_).
A solution of dehydroglutamate (144) (55 mg. 0.15 mmol). N-hydroxy-
succinimide (17 mg. 0.15 » o D  and DCC (31 mg. 0.15 mnol) in dichloro-
methane (3 ml) was stirred for 30 minutes under nitrogen at room
temperature. Diisopropylamine (148) (0.033 ml. 0.24 mol) was then
added, the mixture left overnight, filtered and solvent evaporated, in
Che solution cooled at -10»C for a few hours, filtered and the solvent
evaporated, in vacuo. The residue was chromatographed on siUca gel
(5 g) using hexane/diethyl ether 2:1 eluant to give the amide (149)
156
(35 mg, 54Z): NMR (CDCl^) 6 1.22 (dd, J - 4.88 Hz and 9.52 Hz, 6H,
N(CH3 )2>, 3.22 (d, J - 4.84 Hz, 2H, COCH^), 3.2 - 3.9 (m, 2H, NCH), 
5.13 - 5.19 (m, 4H, CO^CH^Ph and NHCO^CH^Ph) , 6.83 - 6.9 (m, 2H, CH2CH 
and NH), 7.34 (s, lOH, 23^).
Isolation of amide (149) via acyl chloride (150)_
To a stirred solution of dehydroglutamate (144) (40 mg, 0.11 mmol) 
in toluene (3 ml) and DMF (0.2 ml), a solution of thionyl chloride 
(10 *j1, 0.11 mmol) in toluene (0.1 ml) was added at 0*C, under nitrogen. 
After 1 hour the mixture was allowed to warm to room temperature, 
diisopropylamine (148) (18 gl, 0.13 mmol) added and left overnight. The 
resulting solution was diluted with water (5 ml) and ethyl acetate (10 ml), 
the aqueous layer was acidified with concentrated HCl and the ethyl 
acetate layer separated. The aqueous phase was extracted with mote 
ethyl acetate (4 x 20 ml) . Ethyl acetate extracts were combined, dried 
(NSjSO^), filtered, the solvent evaporated, 1° vacuo, to give an oily 
residue. Chromatography on silica gel (5 g) using hexane/diethyl 
ether 1:1 eluant gave the amide (149) (13 mg, 252).
2 -Nitrobenzaldoxime (156)
To a solution of 2-nitrobenzaldehyde (155) (9.02 g, 60 mmol) in 
ethanol (95 mis) was added hydtoxylamine hydrochloride (6 g. 90 mmol) 
and sodium acetate (6.56 g. 80 mmol) . The mixture was heated under 
reflux for 2 hours and the solvent evaporated, inj^cuo. to give the 
oxime (156). (9 g, 902) as white crystals; 4  NMR (ClKllj) 6 4.29 (s.
IH, CHPh), 7.52 - 8.05 (m, 4H, CHPh).
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N-(2 -Nitrobenzyphydroxylamine (157)
To a stirred solution of the oxime (156) (10 g, 60 nmol) and 
sodium cyanoborohydride (3.8 g, 60 mmol) in methanol (90 ml), a trace 
of methyl orange was added. A solution of 2M methanolic-HCl was 
added to maintain the red colour. The mixture was left overnight, the 
solvent evaporated, in vacuo, the residue taken up in water (40 ml) and 
ethyl acetate (40 ml) and the organic layer separated. The aqueous 
layer was raised to pH 7.5-8 with sodium hydroxide pellets, extracted 
with ethyl acetate (4 x 35 ml), the extracts combined, dried (Na2S0^), 
filtered and solvent evaporated, in vacuo. Chromatography on silica 
gel (50 g) using diethyl ether/hexane 2 : 1 eluant gave the hydroxylamine 
(157) (5.7 g, 57X) as white crystals: ^  NMR (CDaj) i 4.33 (s. 2H, 
CH,), 5 (broad s, IH, NH), 7.41-8.04 (m, 4H, Ph).
t-ButTldlmethYlsilYl-«-(2-Pitrobenzyl)-hydroaylasiine (158)
t-Butyldimethylsilyl chloride (0.97 g. 6.4 omol) was added to a 
stirred solution of the hydroxylamine (157) (1.08 g, 6.4 mnoD and 
triethylamine (1.2 ml. 8.5 mmol) in DMF (6 mis) under nitrogen at room 
temperature and left overnight. The mixture was diluted with water 
(10 ml) and ethyl acetate (20 ml). The aqueous layer was acidified 
with concentrated HCl and the ethyl acetate layer was separated. The
aqueous phase was extracted with more ethyl acetate (3 x 40 ml). The
extracts were combined, dried (Na^SO^) . filtered and the solvent 
evaporated, in vacuo. The residue was chromatographed, using hexane/ 
diethyl ether 1 : 1 eluant, on silica gel ( 2 0 g) to afford the silylated 
hydroxylamine (158) (1.63 g. 90Z) as a yellow oil: NMR (01X ^ 3 ) 6
0.03 (s. 6H. OSKCHj)^). 0.87 (s. 9H. 0 8 1 (0 8 3 )3 (0 8 3 )3 . 4.26 (broad s.
IH, NH) , 5.16 (m, 2H, CH^) , 7.51 (m, 4H, Ph) .
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N-BePzyloxycarbonyl“l-benzyl-(Z)-2,3-dehydroglutamic
-5-N“ (2-aitrobenzyl) hydroxamic acid (160)
A stirred solution of the dehydroglutamate (144) (590 mg, 1.6 mmol), 
H-hydroxysuccinimide (310 mg, 2.77 mmol) and dimethylaminopyridine (20 
ml, 0.16 mmol) in dichlotomethane Gml) under nitrogen at room temper­
ature was left for 15 minutes and DCC (550 mg, 2.7 mmol) was added.
After a further 15 minutes a solution of the silyUted hydroxylamine 
(158) (756 mg, 2.7 nmol) in dichlotomethane (3 ml) was added. The 
mixture left for two days. The mixture was filtered, the solvent 
evaporated, in vacuo, the residue taken up in a minimum volume of 
dichloromethane and the solution cooled at -lO’C for a few hours to 
precipitate residual dicylohexyl urea and filtered. The solvent was 
evaporated, in vacuo, and the residue diluted with water (15 ml) and 
ethyl acetate (20 ml): the aqueous layer was acidified with IM HCl and 
the organic layer was separated. The aqeuous phase was extracted with 
more ethyl acetate (3 x 2 0  ml), the extracts were combined, dried 
(Na^SO^), filtered and solvent evaporated, in vacuo, to afford the 
silylated hydroxamic acid (159) (820 mg, 82Z) : NMR (CDCI3) 6 0.032
(s, 6H, 0 Si(CH3 ),), 0.87 (s, 9H, 0 8 1 (0 8 3 )3 (0 8 3 )3); 3.56-3.66 (m, 28,
OOOB3), 5.04-5.30 (m, 78, OxOB^Ph and 8 8 ), 6.29 -6.87 (m, 18, OB3OB),
7.26- 7.32 (m, 14H, 3Ph) .
TO a stirred solution of the silylated hydroxylamine (159) (820 mg,
1- If 1; WAS added tosic acid (250 mg,1.3 mmol) in ethyl aceHte-methanoK 5 ml) was added
U 3  trmol) at room temperature. After 30 minutes, solvent was evapor-
ated. in vacuo, and the residue chromatographed on silica gel (5g)
• ilvdToxamic acxd (160) (497 mg,using diethyl ether eluant to gtve the hydroxamic
74X), as a tan foam; mp 9 5 - 1 0 0 *0 ; IR (nujol) 1785, 1730-1690, 1280,
715 cm-S ^ 8  NMR (OOOI3) 5 3-56 -3.66 (m, 28, OOOH3), 5.04-5.30 (m,
i. ( 1H CH CH) 7.26 — 7.35 (jn, 14H, 3x1^) 7H, SxCH^Ph and NH) , 6 .29- 6.87 (m, , 2 -  *
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N~BePzyloxycarbonyl~l~benzyl~(Z)—2,3~dehydroglutamic
-5-N-(2-aitroben2yl) hydroxamic acid (160)
A stirred solution of the dehydroglutamate (144) (590 mg, 1.6 mmol), 
N”hydro3cysuccinimide (310 mg, 2.77 mmol) and dimethylaminopyridine (20 
ml, 0.16 mmol) in dichloromethane 0 ml) under nitrogen at room temper­
ature was left for 15 minutes and DCC (550 mg, 2.7 mmol) was added.
After a further 15 minutes a solution of the silylated hydroxylamine 
(158) (756 mg, 2.7 mmol) in dichloromethane (3 ml) was added. The 
mixture left for two days. The mixture was filtered, the solvent 
evaporated, in vacuo, the residue taken up in a minimum volume of 
dichloromethane and the solution cooled at -10*C for a few hours to 
precipitate residual dicylohexyl urea and filtered. The solvent was 
evaporated, in vacuo, and the residue diluted with water (15 ml) and 
ethyl acetate (20 ml): the aqueous layer was acidified with IM HCl and 
the organic layer was separated. The aqeuous phase was extracted with 
more ethyl acetate (3 x 2 0 ml), the extracts were combined, dried 
(Na^SO^), filtered and solvent evaporated, in_vacuo, to afford the 
silylated hydroxamic acid (159) (820 mg, S 2 Z ) : NMR (CDCI3) 6 0.032
(s, 6H, 0 Si(CH3 )2 ), 0.87 (s, 9H, 0 8 1 ( ^ 3)2 (0 1 3 )3); 3.56- 3.66 (m, 2H,
COCH2 ), 5.04 -5.30 (m, 7H, 3xCH2Ph and NH), 6.29 -6.87 (m, IH, CH2CH),
7.26- 7.32 (m, 14H, 3Ph).
To a stirred solution of the silylated hydroxylamine (159) (820 mg,
1.3 mmol) in ethyl acetate-methanol ( 5 ml) was added tosic acid (250 mg,
1.3 ™ol) at room temperature. After 30 minutes, solvent was evapor­
ated, in vacuo, and the residue chromatographed on silica gel (5g) 
using diethyl ether eluant to give the hydroxamic acid (160) (497 mg, 
74Z), as a tan foam: mp 95-100»C; IR (nujol) 1785, 1730-1690, 1280, 
715 cm-S "h  NMR (CDCI3) 6 3.56-3.66 (m, 2H, COCH^), 5.04-5.30 (m,
7H, 3xC^Ph and NH) , 6 .29 - 6.87 (m, IH, CH^CH) , 7.26-7.35 (m. 14H, 3xPh) .
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N-(2,4 -dimethoxy)benzaldoxime (166)
To a solution of 2 ,4 -dimethoxybenzaldehyde (165) (lOg, 60 nmol), 
in ethanol ( 1 0 0 ml) was added hydroxylamine hydrochloride (6.26 g,
90 nmol) and sodium acetate (7.38 g. 90 mmol). The mixture was heated 
under reflux for 2 hours and the solvent evaporated, invacuo, to give 
the oxime (166) (9.3 g, 85Z) as white crystals s mp 106-7*0.
N-2 ,4-Dimethoxybenzylhydroxylamine (167)
To a stirred solution of the oxime (166) (9 g, 50 nmol) and 
sodium cyanoborohydride (3.14 g. 50 mmol) in methanol (90 ml), a trace 
of methyl orange was added. 2M methanolic HCl was added to maintain 
the red colour. The mixture was stirred overnight, solvent evaporated.
vacuo, the residue diluted with water (40 ml) and ethyl acetate 
(40 ml) and the ethyl acetate layer separated. The aqueous layer was 
then basified to pH > 9 with sodium hydroxide pellets and extracted 
with ethyl acetate (4 x 35 ml). The ethyl acetate extracts were 
combined, dried (Na^SO^). filtered and the solvent evaporated, in 
vacuo. Chromatography on silica gel (50 g) using diethyl ether/ 
hexane 2:1 eluant yielded the hydroxylamine (167) (6.5 g. 72%) as white 
crystals: "h  NMR (CDCI3) « 3.78 (s. 6H. 2XOCH3). 3.96 (s. 2H. CH^Ph) .
6.00 (broad s, 2H, N H O W , 6.35- 7.26 (m, 3H, ^ ) .
u-.-«..tvldime^>'rl .Uvl-N(-2 .4 -dimethoxybensyl)hvdroxylamine (IW
To a stirred solution of the hydroxylamine (167) (1.3 g, 7 nmol) 
in DMF V/ ml), t-butyldimethylsilylchloride (1.05 g. 7 mmol) and imidasole 
(0.48 g. 7 « o D  were added, at room temperature, under nitrogen. The 
mixture was stirred overnight, taken up in water (12 ml) and ethyl 
acetate (25 ml), the ethyl acetate layer was separated. The aqueous 
Phase was extracted with more ethyl acetate (3 x 50 ml). The extracts
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were combined, dried (Na^SO^) , filtered and the solvent evaporated, 
in vacuo. The residue was chromatographed on silica gel (50 g) using 
hexane/diethyl ether 5 : 2  eluant to afford the silylated hydroxylamine 
(168) (1.9 g, 90Z) as a yellow oil: NMR (CDCl^) 6 0.09 (s, 6H,
OSKCHj)^), 0.92 (s, 9H, OSi(CHj)2 (CH3)3 ), 3.79 (s, 6H, 2XOCH3 ), 3.96 
(s, 2H, CH^Ph), 5.34 (broad S,1H, MH), 6.36-7.26 (m, 3H, ^ ) .
Attempted synthesis of H-benzvloxycarbonyl-l-benzyl-(Z)- 
2.3-dehydroffi"tsmic-S-N-(2.4-dimethoxvbenzvl)hydroxamic acid (169)
A stirred solution of the dehydroglutamate (144) (600 mg, 1.63 mmolX 
N-hydroxysuccinimide (187 mg, 0.63 o»ol) and dimethylaminopyridine (20 
Bg, 0.16 mmol) in dichloromethane (3 ml) under nitrogen, at room temper­
ature, was left for 15 minutes and DCC (336 mg, 1.63 snwl) was added. 
After 15 minutes a solution of the silylated hydroxylamine (168) (484 mg, 
1.63 mmol) in dichloromethane (3ml) was added; the resulting solution 
was stirred for 2 days, filtered to remove dicyclohexyl urea and the 
solvent evaproated, inj»=u=. The residue was taken up in a minimum 
volume of dichloromethane, left at -10"C for a few hours to precipitate 
any residual urea and the solvent evaporated, in vacuo. The residue 
was diluted with water (20 ml) and ethyl acetate (25 ml), the aqueous 
layer was acidified with IM HCl and the ethyl acetate layer was 
separated. The aqueous phase was extracted with more ethyl acetate 
(3 X 25 ml), the extracts were combined, dried (Na^SO,), filtered and 
the solvent evaporated, i n «cuo, the residue was chromatographed on 
silica gel ( 1 0 g) using hexane/diethyl ether 2 : 1 as eluant to afford 
the silylated hydroxamic acid (169*) (370 mg, 3':.; as an oil: H NMR
((3)0 1 3 ) 6 0.035 (s, 0 8 1 (0 8 3 )3), 0.87 (s, 0 8 1 (0 8 3 )3 (0 8 3 )3 , 3 .4 4 - 3 . 6 6  
(m, 0 0(^3), 3.75-3.82 (m, OO8 3 ), 5.03-5.24 (m, 0 8 3 8 8 ), 6.27-6.86 
(m, CH2CH and NH^ ), 7.30- 7.32 (m, Ph).
161
4~Methoxyben2aldoxime (171)
, Hydroxylamine hydrochloride (7 g, 100 mmol) vas added to a stirred 
solution of 4 -methoxybenzaldehyde (170) (9 ml, 74 mmol) in ethanol 
(20 ml) at room temperature. After 10 minutes the solution was cooled 
to 0*C. left for 2 hours and filtered. The white crystals were sus­
pended in saturated aqueous sodium bicarbonate and extracted with ethyl 
acetate (3 x 20 ml). The ethyl acetate extracts were combined, dried 
(Na.SO,), filtered and the solvent evaporated, in vacuo. Recrystal­
lisation from benzene-hexane gave the oxime (171) (8 g, 722) as whtte
24cryst&ls» tap 64*C (lit tup 63 C )•
N-(4-Methoxvbenzyl)hydroxylamine (172)
TO a stirred solution of the oxime (171) (8 g, 53 mmkl) and sodium 
cyanoborohydride (3.33 g, 53 mmol) in methanol (55 ml), a trace of 
methyl orange was added. 2M methanolic HCl was added to maintain the 
red colour, the mixture stirred overnight and solvent evaporated, in 
„acuo. The residue was washed with diethyl ether, diluted with water 
(50 ml), raised to pH 8 with sodium hydroxide pellets and extracted 
with ethyl acetate (4 x 60 ml). The extracts were combined, dried 
(Na,S0,), filtered and solvent evaporated, i n j ^ .  Recrystallisation 
from ethyl acetate-hexane gave the hydroxylamine (172) (6.62 g, 822) as 
white crystals; mp 76”C (lit mp 75.7°C ).
>-v..>yis;..ethvlsilvl-H-(4-methoxvbenzyl)hydroxylamine (173)
t-Butyldimethyl»ilyl chloride (1.17 g, 7.78 mmol) and imidazole 
(2 . 1 2 g, 31 mmol) were added to a stirred solution of hydroxylamine 
(172) (1.19 g, 7.78 mmol) in dimethylformamide (9 mis) at room temper­
ature, under nitrogen and the solution was left overnight. The 
solvent was evaporated, in vacuo, to give a yellow oil which was
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distilled, in vacuo, to afford the silylated hydroxylamine (173) (1.18 g, 
54Z) as a colourless oil: bp 104®C/15 mmHg; H NMR (CDCl^) 8 0.05 
(s, 6H, OSKCHj)^, 0.92 (s, 9H, 0 8 1 (0 8 2 )2 (0 8 3 )3), 3.78 (s, 3 8,0 0 8 3 ),
3.93 (s, 28, CB^Ph), 4.75 (broad s, 18, NBCB^Ph), 6.79- 7.29 (m, 48,
08,^).
Att— «-pthesis of H-benzylox7carbonyl-l-bentyl-(Z)-2,3- 
dehYdroglutamic-5-N-(4-methoxybenzYl)hYdroxamic acid (174).
A stirred solution of the dehydroglutanate (144) (427 mg, 1.16 
mmol). N-hydromysuccininide (133 mg. 1.16 ».oD and dimethylamino- 
pyridine (15 mg. 0.012 mmol) in dichloromethane (3 ml) under nitrogen, 
at room temperature, was left for 15 minutes and DCO (240 mg, 1.16 mmol) 
was added. After 15 minutes a solution of the silylated hydroxylamine 
(173) (310 mg. 1.16 mmol) in dichloromethane (3 ml) was added and the 
mixture was left stirring for 2 days. The resulting mixture was 
filtered, the solwent eYaporated. in Yacuo. the residue taken up in a 
minimum Yolume of dichloromethane. left at -10«C for a few hours to 
precipitate any residual dicyclohexyl urea, filtered and the solYent 
eYaporated. in Yacuo. The residue was diluted with water (15 ml) and 
ethyl acetate (20 ml). the aqueous layer was acidified with IM BCl and 
the ethyl acetate layer was separated. The aqueous phase was extracted 
with more ethyl acetate (3 x 25 ml). The combined extracts were dried  ^
(Na^so^). filtered and solYent eYaporated. in_Yacuo. to yield the 
silylated hydroxamic acid (180) (500 mg. 70Z) as an oil: 8  NMR
(CDCI3) 6 0-.035 (s. 6 8 . 0 8 1 (0 8 3 )3). 0.86 (s. 98. 0 8 1 (0 8 3 )3 (0 8 3 )3 ).
3.42 (d. J - 6.84 8 Z. 28. OOOB3). 3.76 (s. 38. OOH3 ). 4.7 (broad s. 18. 
NB), 5.08-5.29 (m, 6 8 . 3CB3Ph). 6 . 6 8  - 6.84(m. 18. OB3OB). 7.34 (s,
14H, 3^).
TO a stirred solution of the silylated hydroxylamine (180) (500 mg.
0.97 mol) in ethylacetate/methanol 1:1 (8 ml), tosic acid (184 mg.
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0.97 mmol) was added at room temperature and left for 30 minutes. The 
solvent was evaporated, in vacuo, and the residue chromatographed on 
silica gel (8 g) , using ethyl acetate eluant, afforded N-(4-methoxy- 
benzyDhydroxamic acid (174) and N-(benzyl)hydroxaiaic acid (175) (90 mg): 
NMR (CDCl.) i 3.55-3.66 (m, COCHj), 3.76 (s, OCHj) , 5.03-5.19 
(m, CHjPh), 5.50 (broad s, C-OH) 6.28-6.85 (m, CH^CH^), 7.32 - 8.04 (m, Fh^ ).
o.vcarbonyl-2-ben2Vl-(Z) - 2 .3-dehydroglutainic 
-4-H-(benzyl)bydroxamic acid (175)
To a stirred solution, under nitrogen, of the dehydroglutamate 
(144) (5.54 g> 15 nnol) ^  N-hydroxysuccinimide (1.73 g. 15 mnoD m  
dry dichloromethane (60 ml) was added DCC (3.09 g. 15 mmol) and the 
mixture stirred at room temperature for 25 minutes. The silylated 
hydroxylamine (179)”  (3.91 g. 16.5 ™aol) in dichloromethane (5 ml) was 
then added and the resulting mixture stirred for a further 48 hours at 
room temperature. After cooling to 0«C. ethyl acetate (75 ml) was 
added, the mixture filtered and the filtrate eyaporated. injjacuo. to 
giye a red oil which was dissolyed in a minimum of dichloromethane and 
kept at -10 *C oyemight. Filtration of the precipitated dicyclohexyl 
urea, eyaporation of the solyent followed by chromatography of the 
residual oil. on silica gel (60 g) using ethyl acetate/hexane 3:2 
eluant afforded the hydroxamic acid (175) (3.6 g. 50Z): Rf 0.52 (ethyl 
acetate/hexane 3:2); 'h  NMR (CDCI3) 5 3.26- 3.35 (d. J - 7.3 Hz. 2H. 
COCH,). 5.09-5.2 (m. 6H. NCH,Fh. C0 ,CH,Ph. HHC0,CH,Ph). 6.75 - 6.9 
(m. IH. COCH3CH). 7.35 (m. 15H. NCH,Ph. CO^CH^Ph. NHCXD.CH^Ph).
............,-nT.-N-benzy: oxycarbonyl-^-"<<"°-3-be°CT^-~3-
oxo-5-isoxazolidine acetic acid benzyl ester (18U
To a solution of the hydroxamic acid (175) (237 mg. 0.5 mnoD m  
THF/water (10:1) (5 ml) was added saturated aqueous sodium bicarbonate
164
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